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Post-transplant lymphoproliferative disease (PTLD) is an Epstein-Barr virus (EBV)-
associated disease, which occurs in up to 10% of transplant patients and can be fatal
in up to 70% of cases. PTLD has been successfully treated with cellular adoptive
immunotherapy using EBV-specific cytotoxic T-cell lines (CTLs). However, little is
known about the development of these CTLs. This project therefore sought to
establish how the CTLs developed in terms of their growth, phenotype and T-cell
receptor (TCR) repertoire diversity. It also sought to establish which cytolytic
molecules were present in the CTLs and which pathways they employed to effect
their cytotoxic potential.
The phenotype and the cytolytic proteins of the CTLs were investigated by
fluorescence activated cell sorting and western blotting. The TCR repertoire diversity
was established by spectratyping analysis of the complementarity determining region
3 of the variable P chain of the TCR. Cytotoxic activity and pathways were assessed
using chromium release assays.
The results show that the CTLs developed phenotypically into mature T-cells within
the first four weeks of culture, with an increase in CD45RO and CD69 expression
and a decrease in CD45RA, CD62L, CD27 and CD28 expression. The CTLs also
expanded most during that period and had viability in excess of 60%. The growth
and viability of the polyclonal CTLs decreased continuously after four weeks of
culture. The TCR repertoire of the CTLs remained diverse during the course of
culture. Granzyme B, perforin and Fas ligand (FasL) were all detected in the CTLs.
There was significantly more granzyme B in CD8+ T-cells than in CD4+ T-cells
(p=0.0016) and there was also a significantly greater proportion of CD8+ T-cells
expressing granzyme B than CD4+ T-cells (p=0.0023). There was no significant
difference in the proportion of CD4+ T-cells and CD8+ T-cells expressing FasL or
perforin, or in the amounts of FasL or perforin found in the respective cell types.
Granulysin was detected in 33% of the CTLs tested. Cytotoxicity was significantly
iii
inhibited by concanamycin A (p=0.0007) and ethylene glycol-bis tetraacetic acid
(pO.OOOl) indicating that the principal cytotoxic pathway employed by the CTLs
was a calcium and perforin-mediated exocytosis pathway leading to the release of
granzyme B.
These findings suggest that CTLs develop into mature CTLs in the early stages of
culture without a reduction in TCR repertoire diversity. These findings also suggest
that both CD4+ T-cells and CD8+ T-cells contribute to the overall cytotoxicity of the
CTLs using a perforin-mediated cytotoxic granule exocytosis pathway. It is hoped
that this basic characterisation of CTLs will reveal features that can potentially
enhance the clinical effects ofCTLs.
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BART Bam A rightward transcripts
BFA Brefeldin A
BL Burkitt's lymphoma
BMLF Bam M leftward open reading frame
BMT Bone marrow transplant
bp Base pair
Bq Becquerel
BSA Bovine serum albumin
BrdU Bromodeoxyuridine
Ca Calcium
CD Cluster of differentiation
cDNA Complementary deoxyribonucleic acid






CTL Cytotoxic T-cell line
Da Dalton
dATP Deoxyadenosine 5' triphosphate
DC Dendritic cell
dCTP Deoxycytosine 5' triphosphate
dGTP Deoxyguanine 5' triphosphate
dH20 Distilled water
DMEM Dulbecco's minimum essential medium
DMSO Dimethyl sulphomethoxasol
DNA Deoxyribonucleic acid
dNTP Deoxynucleotide 5' triphosphate
dTTP Deoxythymidine 5' triphosphate
DTT Dithiothreitol
EBER Epstein-Barr virus encoded small RNAs
EBNA Epstein-Barr virus nuclear antigen
EBV Epstein-Barr virus
EDTA Ethylene diamine-tetraacetic acid
EGTA Ethylene glycol-bis (P-aminoethylether)-N,N,N',N'-tetraacetic acid
E:T Effectontarget ratio











GM-CSF Granulocyte macrophage-colony stimulating factor
gP Glycoprotein
GrB Granzyme B
GVHD Graft versus host disease




HHV Human herpes virus
HIV Human immunodeficiency virus
HL Hodgkin's lymphoma
HLA Human leucocyte antigen






KSHV Kaposi sarcoma associated herpes virus
1 Litre
LCL Lymphoblastoid cell line
L-Glut L-Glutamine





MFI Mean fluorescence intensity
Mg Magnesium
MHC Major histocompatibility complex
min Minute
ml Millilitre
MOI Multiplicity of infection




NBF Normal buffered formaline





OHL Oral hairy leucoplakia
ORF Open reading frame
p Pico (10~12)
PBMC Peripheral blood mononuclear cell
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PE Phycoerythrin
PECy5 Phycoerythrin Cyanin 5
Per Perforin
P/S Pencillin/Steptomycin
PTLD Post-transplant lymphoproliferative disease
RNA Ribonucleic acid
RPMI Rosewell Park Memorial Institute
RT-PCR Reverse transcriptase-polymerase chain reaction
s Second
S Weekly stimulation with LCL
SAP Signalling lymphocytic-activation molecule (SLAM) associated
protein
SCID Severe combined immunodeficiency
SDS Sodium dodecyl sulphate
SLAM Signalling lymphocytic-activation molecule
SNBTS Scottish National Blood Transfusion Services
SPBS Sterile phosphate buffered saline
TBE Tris borate EDTA
TCR T-cell receptor
Th T helper
TNF Tumour necrosis factor
Tris Tris(hydroxymethyl)aminomethane
UI International unit/ Unite internationale
V|3 Variable (3 chain
VHAS Virus-associated haemophagocytic syndrom
VCA Viral capsid antigen
v/v Volume/volume
VZV Varicella zoster virus
w/v Weight/volume




























Herpes viruses are the most widely disseminated viruses, with over 130 known
herpes viruses infecting mammals and birds, but also reptiles such as turtles and
invertebrates such as oysters (Farley et al, 1972; Pass, 2003). Herpes viruses are
divided into three subfamilies -Alpha-, Beta- and Gammaherpesvirinae. These three
subfamilies are thought to have arisen between 220 to 180 millions years ago and
that sublineages or genera, within these subfamilies in turn arose 80 to 60 millions
years ago (McGeoch et al, 1995). A new class of herpesviruses was recently
identified in Pacific oysters (Davison et al, 2005).
1.1.1 Herpes virus structure
Herpes viruses are double-stranded enveloped DNA viruses with co-linear genomes
ranging in size from 125 to 230 kilobase pairs (kbp) and encoding between 70 to 200
genes (Roizmann et al, 1992). Herpes viruses contain a toroid-shaped protein core
surrounded by DNA and an icosadeltahedral nucleocapsid with 162 capsomeres in a
T=16 arrangement (Kieff and Rickinson, 2001). The diameter of the nucleocapsid
ranges from 100 to 110 nm (Cleator and Klapper, 2000). There is an amorphous
protein tegument between the nucleocapsid and the glycoprotein-bearing envelope
(Kieff and Rickinson, 2001). Typically, the diameter of human herpes virus (HHV)
virions ranges between llOnm and 300nm (Roizman and Baines, 1991). Figure 1.1
diagrammatically represents the structure of human cytomegalovirus (HCMV) and










Figure 1.1: Human cytomegalovirus. A) Diagram of the virus. B). Virtual 3-
dimensional model showing viral component (gB: glycoprotein B and gH:
glycoprotein H) (Gandhi and Khanna, 2004). A) Reprinted from Virology, Volume
260, Chen DH, Jiang H, Lee M, Liu F and Zhou ZH, Three-dimensional
visualisation of tegument/capsid interaction in the intact human
cytomegalovirus, page no 10-16, Copyright (1999), with permission from
Elsevier. B) Reproduced with permission from Marko Reschke,
www.biografix.de.
1.1.2 Human Herpes Viruses
Eight HHVs have been identified to date, HHV-8 being the last HHV to have been
identified by Chang et al in 1994 (Chang et al, 1994), and these are listed in table
1.1. The genus that each HHV belongs to is also given in table 1.1. The
Cercopithecine herpesvirus 1, a herpes virus of Old World monkeys, can infect and
be fatal to humans following bites from an infected animal (Whitley, 2001). This
virus is not listed in table 1.1, as its natural host is Old World monkeys and it is
therefore not a true HHV. Cercopithecine herpesvirus 1 was fully sequenced recently
by Tyler et al (Tyler et al, 2005).
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HHV-1 Alpha- Simplex- Herpes Simplex-1
(HSV-1)
HHV-2 Alpha- Simplex- Herpes Simplex-2
(HSV-2)
HHV-3 Alpha- Varicello- Varicella Zoster Virus
(VZV)
HHV-4 Gamma- Lymphocrypto- Epstein-Barr Virus
(EBV)
HHV-5 Beta- Cytomegalo- Human
Cytomegalovirus
(HCMV)
HHV-6 Beta- Roseolo- Human Herpesvirus-6
(HHV-6)
HHV-7 Beta- Roseolo- Human Herpesvirus-7
(HHV-7)
HHV-8 Gamma- Rhadino- Kaposi's Sarcoma-
associated Herpes Virus
(KSHV)
Table 1.1: Known human herpes viruses - compiled using information from Cleator
and Klapper (2000) and (Anonymous, 2001).
HHVs are categorised into the alpha-, beta- and gawma-herpesviruses subfamilies
according to their biological properties, and they are further classified into genera by
deoxyribonucleic acid (DNA) sequence homology and genome arrangement, as well
as homology between major viral proteins (Roizman and Baines, 1991). The four
principal biological properties of herpes viruses are summarised below (Roizmann et




1. Herpes viruses encode genes for enzymes involved in nucleic acid metabolism and
DNA synthesis. Enzymes involved in protein processing are also sometimes
encoded. The number and nature of these enzymes varies depending on the herpes
virus in question.
2. Viral DNA synthesis and capsid assembly occurs in the nucleus and the capsid is
enveloped as it transits through the nuclear membrane.
3. Progeny virus production is always associated with cell death during lytic
replication.
4. Known herpes viruses are all able to remain latent in their natural host. During
latency the viral genome circularises into an episome. The expression of viral genes
in latently infected cells is restricted thus enabling the virus to persist.
Biological properties
Subfamily Genus (-virus) Growth
cycle




Short Cytolytic Sensory gangliaNeurons

















Dennis Burkitt, a British surgeon, while working in East Africa recognised and
defined a previously unknown childhood tumour in 1958, which is now known as
Burkitt's lymphoma (BL) (Burkitt, 1958). The unusual epidemiology of BL across
equatorial Africa, where malaria is endemic, led Burkitt to postulate that the tumour
he recognised was of infectious aetiology and that mosquitoes were the carriers of
this infectious agent (Burkitt, 1962). In 1961, Anthony Epstein met Dennis Burkitt
following a talk by the British surgeon on BL and it was agreed that tumour material
would be shipped from East Africa to the Middlesex Hospital in London where
Epstein's laboratory was established. Initial work using electron microscopy and
standard virological methods was unsuccessful but the generation and the
examination by electron microscopy of the first in vitro BL cell line yielded positive
results with the detection of herpes virus-like particles (Epstein, 1979; Epstein et al,
1964; Epstein and Barr, 1964). The biological and immunological properties of these
particles were assessed and confirmed that the particles were a new herpes virus
known as EBV (Epstein et al, 1965). EBV is now known to infect B-cells, T-cells
and epithelial cell types, as well as other cells, both in vitro and in vivo. It is now also
known to be associated with a number of diseases, such as infectious mononucleosis,
all of which will be presented in section 1.3.2. The molecular biology of EBV is
discussed in this section and its epidemiology is discussed in section 1.3.
1.2.1 EBV genome, proteins and latency programmes
1.2.1.1 EBV genome
The genome of the EBV B95-8 prototype laboratory strain was first sequenced and
cloned in 1984 (Baer et al, 1984). It is 172 kb in length and contains 84 open reading
frames (ORFs). EBV was sequenced from an EBV DNA BamHl fragment cloned
library and therefore ORFs, genes or sites for transcription of ribonucleic acid are
often referred to as specific BamHl DNA fragments. So, the gene encoding EBV
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DNA polymerase is referred to as BALF3 - BamHl fragment A, third leftward ORF
(Kieff and Rickinson, 2001). The B95-8 prototype laboratory strain of EBV was first
isolated by Miller et al in 1973 (Miller et al, 1973). A Bamlil digest of the EBV
B95-8 genome is shown in figure 1.2. The ORFs encoding EBV latent proteins -
Epstein-Barr Nuclear Antigens (EBNAs) and Latent Membrane Proteins (LMPs) are
shown in figure 1.2. Latent membrane protein 2 (LMP-2), not shown in this diagram,
originates from messenger RNA (mRNA) transcripts that are spliced across the
terminal repeats (TR) of the circularised genome (Young and Murray, 2003). The
circularised genome is shown in figure 1.3. The role of each of these proteins will be
discussed in section 1.2.1.2.
Figure 1.2: BamH\ digest of the EBV B95-8 genome (showing the ORFs of EBV
latent proteins). The fragments are named according to their size with A being the
largest and smaller fragments being identified by lower case letters. EBNA-LP:
Epstein-Barr Nuclear Antigen-Leader Protein. Reprinted by permission from
Macmillan Publishers Ltd: Young LS and Murray PG. Oncogene 22: 5108-512,
copyright (2003).
1.2.1.2 EBV encoded transcripts and proteins
EBV has the ability to express different combinations of genes and therefore
different proteins, depending on whether the infection is latent or lytic. EBV can
achieve this by using different gene promoters. Latent and lytic infections will be
described in subsequent sections of this chapter.
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a) EBV latent replication and proteins
During latency EBV can express up to nine latent viral antigens, six of which are
nuclear antigens (EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C and EBNA-
Leader Protein (LP)) and three of which are membrane proteins (LMP-1, LMP-2A
and LMP-2B). Epstein-Barr virus encoded small RNAs (EBER1 and EBER2) are
also transcribed, but not translated, during latency. Transcripts from the BamWl A
region are also detected and these have been implicated in growth regulation in some
cancers such as nasopharyngeal carcinoma (NPC) (Smith et al, 2000). All of the
latent genes are shown in figure 1.3 which represents the episomal genome ofEBV.
EBE2i EBER2
. i ^
Figure 1.3: EBV episomal genome. The genes encoding the latent proteins, marked
by purple arrows, are also shown in this figure. The origin of plasmid replication is
oriP. The promoters involved in the transcription of the message encoding these
proteins are also shown, promoter C (Cp), or Wp and Qp. Diagram from Murray and
Young (2001). Reprinted by permission from Cambridge University Press. Murray PG
and Young LS. Expert Reviews in Molecular Medicine 2001:1-20, Copyright.
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In a typical EBV infection of human B-cells in vitro, the EBV linear genome
circularises into its episomal form 24 hours post-infection (Hurley and Thorley-
Lawson, 1988), although Alfieri et al (1991) detected episomes as early as 12 hours
post-infection. All EBNAs arise from a single mRNA transcript that is differentially
spliced and under the control of the Cp and Wp promoters. The Wp promoter is
preferentially used in the initial stages of the infection, whilst the Cp promoter is
normally used in the latent infection and their use is mutually exclusive
(Woisetschlaeger et al, 1989; Woisetschlaeger et al, 1990). The LMP mRNA
transcripts are expressed under the control of promoters found in the DamlU N
region (Young and Murray, 2003). EBNA-2 and EBNA-LP are the first genes to be
expressed and their products can be detected between 8 and 12 hours post-infection
(Alfieri et al, 1991; Allday et al, 1989; Rooney et al, 1989; Wang et al, 1990b).
EBNA-2 is expressed under the control of the Wp promoter, which then leads to a
promoter switch to the Cp promoter (Woisetschlaeger et al, 1991). The switch in
promoter usage occurs approximately 36 hours post-infection, which coincides with
the expression of EBNA-1, EBNA-3A, B and C, although in one study these EBNAs
were detected sooner (12-18 hours post-infection) (Allday et al, 1989). LMP-1 is
expressed in parallel with or subsequent to EBNA-1 expression, as EBNA-1 acts as a
transcriptional transactivator upregulating the LMP-1 promoter (Rickinson and
Kieff, 2001). LMP-2A and -2B are not detected for up to 70 hours post-infection.
This pattern of gene expression, in which all nine latent proteins are expressed, is
known as "latency III". This latency programme, as well as latency programmes I
and II, will be discussed in section 1.2.1.2 b).
Concomitant with EBV antigen expression, there is upregulation of cellular gene
expression encoding cluster of differentiation (CD) 21, CD23, CD39 and CD40
(Cordier et al, 1990; Kieff and Rickinson, 2001; Wang et al, 1990a). Cellular
adhesion markers such as leucocyte-function antigen-1 (LFA-1 or CDlla), LFA-3
(or CD58) and intercellular adhesion molecule-1 (ICAM-1 or CD54) are also
upregulated upon EBV infection (Wang et al, 1990a). EBV also drives resting B-
cells into the G1-phase, from the GO-phase, and then into the S-phase of the cell's
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lifecycle, in which the viral genome is replicated only once, concurrently with the B-
cell genome, as EBV, like all other herpes viruses is dependent on the host cell
machinery for its replication (Adams, 1987; Murray and Young, 2001). All these
upregulatory/stimulatory events are co-ordinated by EBV antigens. The role of each
antigen is summarised below and is reviewed in Bornkamm and Hammerschmidt
(2001), Crawford (2001), Murray and Young (2001) and Young and Murray (2003)
unless otherwise stated.
EBNA 1
Reedman & Klein first identified an EBNA in 1973, now known as EBNA-1
(Reedman and Klein, 1973). EBNA-1 expression is initiated by the Cp or Wp
promoter in latency III, but in latency I and II it is transcribed from the Qp promoter.
EBNA-1 acts as a transcriptional transactivator upregulating the Cp and LMP-1
promoters. The primary role of EBNA-1 is to maintain the episomal genome, which
it does by binding to the EBV origin of replication, which has two clusters ofEBNA-
1 binding sites (Rawlins et al, 1985). In order to achieve this, EBNA-1 has glycine-
alanine repeats that inhibits its proteosomal degradation and therefore antigen
processing and expression by major histocompatibility class I (MHC I), a fact which
coincidently increases its half-life (Levitskaya et al, 1995; Levitskaya et al, 1997).
The glycine-alanine repeat has also been found to prevent translation of EBNA-1
mRNA (Yin et al, 2003).
EBNA-2
The P-H virus (now known as P3HR1) is unable to immortalise B-cells (Miller et al,
1974; Rabson et al, 1982) because it lacks the EBNA-2 gene, as well as the last 2
exons of the EBNA-LP gene (Hammerschmidt and Sugden, 1989). This suggests that
EBNA-2 is essential for B-cell immortalisation. It regulates the expression of all
other latent viral genes, such as LMP-1 and LMP-2, but also transactivates cellular
genes controlling the expression of cell surface markers such as CD21 and CD23
(Wang et al, 1987; Wang et al, 1990b). EBNA-2 interacts with the repression
domain of cp-binding protein factor-1 thus converting it to a transcriptional activator.
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In that respect, EBNA-2 acts in the same fashion as NotchIC (part of the Notch
pathway), which influences cell proliferation and differentiation (Hayward, 2004).
EBNA-2 also controls the switch from the Wp promoter to the Cp promoter in early
B-cell infection, which leads to the transcription of EBNAs-1, -3A, -3B and -3C and
LMP-1. EBNA-2 exercises a pivotal role in EBV immortalisation.
EBNA-3
EBNA-3A, 3B and 3C are transcribed from the Cp promoter. EBNA-3A and -3C are
essential for B-cell immortalisation, whereas EBNA-3B is not. EBNA-3B is involved
in the regulation of the transcription of cellular genes encoding CD40 (Silins and
Sculley, 1994), whilst EBNA-3C regulates viral LMP-1 and cellular CD23 (Allday
and Farrell, 1994). EBNA-3C interferes with at least two cell cycle checkpoints at
G1 and G2/M phases (Parker et al, 2000). Additionally, EBNA-3C can also repress
the Cp promoter, which is the major promoter controlling EBNA expression,
regardless of EBNA-2 activity (Radkov et al, 1997). Collectively, the EBNA-3s are
able to interact or interfere with EBNA-2 signalling but are also able to modulate
both viral and cellular promoter function.
EBNA-LP
EBNA-LP is not required for B-cell transformation/immortalisation but it promotes
the efficient outgrowth of lymphoblastoid cell lines (LCLs) in vitro (Allan et al,
1992; Hammerschmidt and Sugden, 1989). It interacts closely with EBNA-2 in
transcriptional activation and potentiates EBNA-2's transactivating functions, such
as the expression of LMP-1 (Nitsche et al, 1997). A number of roles have been put
forward for EBNA-LP, including cell cycle control and interaction with the tumour
repressors p53 and retinoblastoma, but to date none has been confirmed.
LMP-1
LMP-1 is essential for in vitro proliferation of B-cells and also for transformation of
B-cells therefore acting as an oncogene (Dirmeier et al, 2005). It can also induce the
expression of a number of cell surface molecules such as CD23, CD39, CD40, CD54
11
CHAPTER I introduction
(ICAM-l) and CD58 (LFA-3) in a variety of human B-lymphocytes cell lines (Wang
et al, 1990a). LMP-1 can also induce the upregulation of the anti-apoptotic molecule
Bcl-2 and the production of IL-6 and IL-8. Pro-apoptotic molecules such as Bax can
on the other hand be downregulated by LMP-1 (Dirmeier et al, 2005). LMP-1 is a
member of the tumour-necrosis receptor superfamily, which also activates a number
of downstream cellular pathways such as the NF-kB pathway, the JNK/AP-1
pathway, the p38/MAPK and the JAK/STAT pathway. As well as affecting cellular
pathways, LMP-1 functionally resembles CD40, which is responsible for B-cell
activation, and has been shown to be capable of replacing CD40 in vivo providing
proliferation and differentiation stimuli to B-cells. In conjunction with its signalling
properties LMP-1 has been shown to bind to BZLF-1 (BZLF-1 is a transactivator
that controls EBV lytic infection, discussed in section 1.2.1.2 c)) in cells that did not
express EBNA-2 (latency programme II discussed in section 1.2.1.2 b)), therefore
contributing to the maintenance of latency in vivo (Adler et al, 2002). CD40 was also
shown to bind to BZLF-1 and inhibit reactivation (Adler et al, 2002), highlighting
the extensive mimicry achieved by LMP-1. Whilst there are functional similarities
between LMP-1 and CD40, their signalling methods are quite distinct with LMP-1
involving tumour necrosis receptor-associated death domain (TRAAD) and CD40
involving tumour necrosis receptor-associated factor 6 (TRAF-6).
LMP-2
The LMP-2 gene encodes two distinct proteins LMP-2A and LMP-2B (a truncated
form of LMP-2A). The EBV genome is required to circularise for successful
transcription of both LMP-2A and LMP-2B. The promoters of both LMP-2A and
LMP-2B are under the control of EBNA-2, but LMP-2A can be expressed in vivo in
memory B-cells in the absence of EBNA-2, suggesting that cellular factors may take
over from EBNA-2. Neither LMP-2A nor LMP-2B is essential for B-cell
immortalisation in vitro, however LMP-2A may be involved in epithelial cell
transformation. LMP-2A disrupts B-cell signalling but in turn it acts as a
constitutively activated B-cell receptor homologue (Caldwell et al, 1998) and it also
appears to prevent EBV-infected cells from entering the lytic cycle. These functions
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are mediated by the N-terminal of LMP-2A that contains eight tyrosine residues.
Two of the tyrosine residue form immunoreceptor tyrosine-based activation motifs,
which play key roles in modulating cell proliferation and activation mentioned
above. The role of LMP-2B has yet to be established but it is thought that it may be
to dampen the effects of LMP-2A.
EBERs
EBERs-1 and -2 are small nonpolyadenylated RNAs, which are transcribed but not
translated. They are therefore not EBV antigens per se but have been found in all
forms ofEBV latency (Rickinson and Kieff, 2001). They are the most abundant EBV
RNAs. They are not required for immortalisation, however they may have a role in
tumourigenesis. Their reintroduction into an EBV-negative Akata BL cell line
restored the tumourigenicity in a severe combined immunodeficiency (SCID) mouse
model and conferred resistance to apoptosis induction (Komano et al, 1999).
Additionally, EBERs may induce interleukin-10 production in EBV positive BL cell
lines, enhancing their differentiation in autocrine fashion (Kitagawa et al, 2000).
Bam HI A rightward transcripts (BARTs)
Much like EBERs, BARTs are not EBV viral antigens per se but highly spliced
polyadenylated RNAs, which contain three ORFs (Brooks et al, 1993; Hayward,
2004). The function of BARTs remains unclear but they have been identified in a
number of malignancies such as undifferentiated nasopharyngeal carcinoma
(UNPC/NPC), BL and Hodgkin's disease (HD) and nasal T-cell lymphoma (Chiang
et al, 1996; Deacon et al, 1993; Tao et al, 1998). However, the products of two
ORFs, RPMS-1 and RK-BARF0, can interact with the Notch pathway (Hayward,
2004) and subsequent expression of LMP-1 (in the case of RPMS-1) (Smith, 2001).
The Notch pathway has been implicated in cellular differentiation and proliferation
and therefore interactions with this pathway may contribute to the development of
EBV malignancies (Hayward, 2004). BARTs have also been found in EBV infected
cells from healthy individuals (Chen et al, 1999).
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The size and cellular location of EBV latent transcripts described is summarised in





Cellular site Required for
immortalisation
EBNA-1 BKRF-1 65-97 Nucleus Yes
EBNA-2 BYRF-1 75-105 Nucleus Yes
EBNA-3A BLFR-3/BERF-1 130-195 Nucleus Yes
EBNA-3B BERF-2A/B 145-160 Nucleus No
EBNA-3C BERF-3/4 130-195 Nucleus Yes
EBNA-LP BWRF-1 20-130 Nucleus No
LMP-1 BNLF-1 58-63 Membrane Yes
LMP-2A BARF-l/BNRF-1 54 Membrane No
LMP-2B BNFR-1 40 Membrane No




Table 1.3: EBV latent transcripts (Johannessen and Crawford, 1999). kDa: kilo
Dalton.
b) EBV latency programmes
EBV antigens described above are differentially expressed in a variety of diseases,
which will be discussed in section 1.3. The patterns of differential expression are
known as latency programmes. There are three latency programmes, as well as the
antigen expression seen in B-cells in vivo in healthy seropositive individuals and






































Lymphoblastoid cell lines (LCLs) in vitro
Infectious mononucleosis
PTLD
Table 1.4: EBV latency programmes, antigen expression and associated diseases.
This table was compiled using information from Callan (2004), Crawford (2001),
Hopwood and Crawford (2000) and Thorley-Lawson and Gross (2004). (Callan,
2004; Crawford, 2001; Hopwood and Crawford, 2000; Thorley-Lawson and Gross,
2004). *EBNA-1 is not always detected in dividing cells in healthy seropositive
individuals. **only RNA detected.
c) EBV lytic replication
Briefly, EBV is also capable of lytic replication where the EBV genome is amplified
100- to 1000-fold and this replication originates from the origin of replication oriLyt
(Hammerschmidt and Sugden, 1988). Latent replication and lytic replication are
mutually exclusive within one EBV-infected cell. During lytic replication EBV
becomes more reliant on its own proteins, particularly DNA polymerase, to sustain
its replication (Tsurumi et al, 2005). Lytic replication is controlled by an entirely
different set of genes to those involved in latent replication. The gene product of the
BZLF-1 gene is the control switch between the latent and the lytic state of replication
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(Hammerschmidt and Sugden, 1988). The BZLF-1 gene product is a pleiotropic
protein that acts as a transactivator setting off the remainder of the lytic gene
expression as well as binding to the oriLyt and inducing viral replication (Tsurumi et
al, 2005). Another transactivator is BRLF-1, which acts in concert with BZLF-1, to
induce and activate both cellular and viral genes. Both BRLF-1 and BZLF-1 are
known as "immediate early" genes and BRLF-1 serves to activate viral DNA
polymerase (Hammerschmidt and Sugden, 1988; Liu et al, 1996). Thereafter "early
genes" are expressed and encode enzymes involved genome replication. Finally,
"late genes" are expressed and these encode structural proteins among them
glycoprotein 350 (gp350) and gp85. The role of these glycoproteins is discussed in
section 1.2.2.2.
1.2.2 EBV infection
1.2.2.1 Cells infected by EBV
EBV has been found to infect a number of different cell types in vivo and in vitro. It
primarily infects B-lymphocytes but also T-lymphocytes and natural killer cells (NK
cells) (Kieff and Rickinson, 2001; Pattengale et al, 1973). EBV has also been
detected in orpharyngeal (squamous) epithelial cells (Sixbey et al, 1984) and gastric
epithelium (cuboidal/columnar) (Shibata and Weiss, 1992). EBV has also been
detected in saliva and salivary glands (Wolf et al, 1984), although a recent
publication by Frangou et al (2005) indicated that salivary glands were not an EBV
reservoir. Genital secretions from both men and women have also tested positive for
EBV (Israele et al, 1991; Sixbey et al, 1986). EBV in genital secretions is mostly B-
cell-associated (Thomas et al, 2006).
1.2.2.2 EBV infection of B-cell in vitro
As mentioned above, EBV was found to infect B-cells and its transforming capacity
was established following in vitro transformation of B-cells and the generation of
tumours in nonhuman primates (Henle et al, 1967; Miller, 1974; Pope et al, 1968). In
vitro transformed B-cells are referred to as lymphoblastoid cells (LCLs). An
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experimentally invaluable method of generating LCLs from infected individuals was
developed by Bird et al in 1981; the T-cell immunosuppressive agent, cyclosporin A
(CsA), was added to peripheral blood mononuclear cells (PBMCs) preventing
cytotoxic T-cell activity and allowing outgrowth of LCL (from EBV released from
EBV-infected B-cells and infecting other B-cells present in PBMC) (Bird et al, 1981;
Rickinson, 1984)
EBV enters B-cells in vitro by binding to the C3d complement receptor of B-cells
using its envelope glycoproteins (Babcock et al, 1998; Nemerow et al, 1985). The
glycoproteins involved in binding and entry of EBV into B-cells are listed in table
1.5. This C3d complement receptor is also known as complement receptor 2 (CR2)
or CD21 and it is found abundantly at the surface of B-cells (Fingeroth et al, 1984;
Frade et al, 1985).
EBV protein Open reading frame * Known or proposed function
gp25 BKRF-2 Complexes with gp42 and gp85
gp85 BXLF-2 Complexes with gp25 and gp42
gp42 BZLF-2 Complexes with gp25 and gp85 and
binds to HLA class II
gpllO BALF-4 Virus maturation
gp350/220 BLLF-1 Initial binding by virion to CD21
Table 1.5: EBV glycoproteins involved in attachment and entry. Adapted from Speck
et al 2000 (Speck et al, 2000). HLA: Human Leucocyte Antigen. * Kieff and
Rickinson, 2001.
EBV binds to CD21 on target B-cells using the gp350-gp220 complex and leading to
aggregation of CD21 on the cell membrane (Tanner et al, 1987). This is followed by
fusion of the viral envelope with the target cell membrane or by fusion with an
endosomal membrane following endocytosis of EBV. Fusion is mediated by the
gp25-gp42-gp85 complex binding to HLA class II loci HLA-DP, -DQ or -DR, where
HLA-DP, -DQ and -DR act as co-receptors (Haan et al, 2000; Haan and Longnecker,
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2000; Kieff and Rickinson, 2001; Li et al, 1997; Li et al, 1995). The binding of gp42
to HLA-DQ, leading to EBV entry, was restricted further to particular HLA-DQ
alleles (Haan and Longnecker, 2000). The process of entry of EBV into a target B-
cell is summarised in figure 1.4.
Figure 1.4: EBV entry (Speck et al, 2000). Reprinted from Virology, Volume 277,
Speck P, Haan KM and Longnecker R, Epstein-Barr Virus entry into cells,
pages no 1-5, Copyright (2000), with permission from Elsevier.
Whilst CD21 is the principal target cell receptor for EBV, the presence of other
receptors is likely, as it has been reported that EBV deletion mutants lacking
gp3 50/220 are able infect B-cells but also epithelial cells (Janz et al, 2000).
1.2.2.3 EBV infection of epithelial cells in vivo and in vitro
EBV has also been shown to infect epithelial cells of the oropharnyx in vitro (Sixbey
et al, 1983) and also in vivo (Pegtel et al, 2004; Sixbey et al, 1984). CD21 has been
detected on epithelial cells of the oropharnyx (Young et al, 1986). However, the
mechanisms by which EBV enters epithelial cells are poorly understood, as epithelial
cells do not always express CD21 and are often refractory to EBV infection in vitro.
Research into the role of CD21 in epithelial cell infection has yielded mixed results
with some researchers describing infection of CD21-negative gastric epithelial cells,
implying a CD21-independent mechanism, (Yoshiyama et al, 1997) and others
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describing the infection of 293 epithelial cells expressing low level CD21, suggesting
a CD21-dependent pathway (Fingeroth et al, 1999). CD-21/major histocompatibility
class (MHC) II-independent infection did not require gp42 or the gp220-gp350
complex but instead required the use of the gp25-gp85 complex to bind to epithelial
cells (Borza and Hutt-Fletcher, 2002; Molesworth et al, 2000; Spear and
Longnecker, 2003; Tugizov et al, 2003; Wang et al, 1998). In 2003 Tugizov et al
proposed three CD21-independent pathways by which EBV could infect mucosal
oropharyngeal epithelial cells in a human polarised tongue model and pharyngeal
cells in culture. The proposed pathways are 1) by direct cell to cell contact of apical
cell membranes with EBV-infected lymphocytes; 2) entry of cell-free virions through
basolateral membranes, mediated in part by an interaction between pi or a.5 pi
integrins and the EBV BMRF-2 protein; and by 3) virus spread directly across lateral
membranes to adjacent epithelial cells following the initial infection. BMRF-2 is an
EBV envelope glycoprotein expressed in lytically infected cells (Modrow et al,
1992). Integrins are also involved in the binding ofmany other viruses to their target
cells including a3pi integrin acting as receptor for KSHV (Akula et al, 2002). The














Figure 1.5: CD21-independent pathways of oropharyngeal epithelial cell infection by
EBV. Reprinted by permission from Macmiilan Publishers Ltd: Tugizov SM,
Berline JW and Palefsky JM. Nature Medicine, 9: 307-314, copyright (2003).
19
CHAPTER 1 INTRODUCTION
The principal cellular receptor for EBV infection of epithelial cells has yet to be
clearly identified but integrins, such as those described by Tugizov et al (2003),
appear to be likely candidates.
Interestingly, EBV requires the gp25-gp42-gp85 complex for entry into B-cells,
during which gp42 binds to MHC class II and is essential for infection (Wang and
Hutt-Fletcher, 1998). However, infection of epithelial cells, which lack MHC class
II, does not require gp42 but requires the gp25-gp85 complex (Borza and Hutt-
Fletcher, 2002; Molesworth et al, 2000; Spear and Longnecker, 2003). EBV virions
"produced" by B-cells lack gp42 and are thus able efficiently to infect MHC class II-
negative epithelial cells but not MHC class Il-positive B cells. Conversely, EBV
virions "produced" by MHC class II negative-epithelial were able to infect B-cells
through interactions of gp42 with MHC class II (Borza and Hutt-Fletcher, 2002).
This alternate tropism may provide some clues to the natural in vivo infection and
persistence process, which still remains an area of controversy. This is discussed in
section 1.2.3.
1.2.3 EBV primary infection and persistence in vivo
The process of primary infection and subsequent persistence of EBV in vivo have
been a great source of controversy and remain so to date. One hypothesis is that EBV
directly infects B-cells underlying the squamous epithelium of the oropharynx. The
other hypothesis is that EBV infects squamous epithelial cells of the oropharynx and
subsequently the underlying B-cells.
1.2.3.1 B-cell only hypothesis
Salivary exchange was established as the transmission route for EBV by Gerber et al
in 1972 (Gerber et al, 1972). Waldeyer's ring is a ring of lymphoid tissue in the
throat comprising the palatine, lingual and pharyngeal tonsils. In the lymphoid tissue
ofWaldeyer's ring there are crypt structures that run deep into the lymphoid tissue of
the tonsils (Macsween and Crawford, 2003; Perry and Whyte, 1998). Within these
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crypts, epithelial cells are not so tightly bound to one another as in the remainder of
the oropharyx and B-cells have been found infiltrating these crypts (Faulkner et al,
2000). This is a potential gateway for EBV to infect B-cells directly in primary
infection, and conversely, this is likely to be a gateway for EBV to egress to the
saliva for transmission to other susceptible individuals. EBV infects quiescent naive
B-cells in Waldeyer's ring and drives their differentiation to proliferating B-cell
blasts in an EBNA-2-dependent fashion using the growth programme (latency III)
(Babcock et al, 2000; Babcock and Thorley-Lawson, 2000). These B-cells are now
in effect growth transformed by EBV. From that point, B-cell blasts progress to
germinal centre B-cells by switching to the default programme (latency II) with the
expression of LMP-1 (Babcock and Thorley-Lawson, 2000) providing a ligand-
independent CD40-like activation signal to the B-cell (Gires et al, 1997), the
expression of LMP-2A providing a ligand-independent rescue signal paralleling B-
cell activation with antigen (Caldwell et al, 1998). Thereafter, germinal centre B-
cells exit the cell cycle and become memory cells using the EBNA-1 only program
(latency I) that enables episomal maintenance and replication. This drive to
differentiate is the way that EBV creates its site of persistence - post-germinal centre
memory B-cells (Babcock et al, 1998). This is summarised in figure 1.6.
Memory B-cell EBNA-1 only
Figure 1.6: EBV infection of naive B-cells and its transition to persistence in
memory B-cells. Figure adapted from Thorley-Lawson and Gross, 2004.
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Antigen activated latently infected memory B-cells can recirculate back to
Waldeyer's ring, where they can differentiate into plasma cells and may switch to the
lytic cycle, producing progeny virus which can be released into the saliva and infect
other naive bystander B-cells (Macsween and Crawford, 2003). Such differentiation
linked with lytic replication was demonstrated in vitro by Crawford and Ando (1986)
and in vivo by Laichalk & Thorley-Lawson (2005) (Crawford and Ando, 1986;
Laichalk and Thorley-Lawson, 2005). Further support for this B-cell only hypothesis
comes from research by Faulkner et al (1999), which showed that individuals with
X-linked agammaglobulinaemia, who lack Bruton's thymidine kinase, and as a result
have no functional B-cells, were not infected by EBV (Faulkner et al, 1999). These
findings support the hypothesis that (naive) B-cells are not only the site of primary
EBV infection but are also the site of EBV persistence (memory) (Babcock et al,
1998).
1.2.3.2 Epithelial cell hypothesis
The second hypothesis is that EBV infects epithelial cells of the oropharnyx in the
first instance and then the B-cells underlying the epithelium (Allday and Crawford,
1988) and that epithelial cells may also act as a site of EBV persistence. Epithelial
cells were believed to be involved in EBV infection due to EBV's association with
epithelial malignancies such as UNPC (discussed in section 1.3.1.1 e)) (zur Hausen
et al, 1970) and gastric carcinoma (Shibata and Weiss, 1992). Additionally chronic
low level oro-/naso-pharyngeal shedding is seen in healthy EBV carriers (Yao et al,
1985), which may not be arising from B-cells, as they are poor producers of virus
(Allday and Crawford, 1988). Initially, epithelial cells were found to be refractory to
infection in vitro unless EBV receptors were reconstituted within these cells (Shapiro
and Volsky, 1983). But, EBV was conclusively found to infect epithelial cells in
vitro as well as in vivo by Sixbey et al in 1983 and 1984 and its receptor, CD21, was
identified on oropharyngeal epithelial cells, albeit at low level (Sixbey et al, 1984;
Sixbey et al, 1983; Young et al, 1986). Further work supporting the epithelial cell
hypothesis found that EBV originating from B-cells was "epithelial cell-tropic" and
conversely, EBV originating from epithelial cell was "B-cell-tropic" (discussed in
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section 1.2.2.3) (Borza and Hutt-Fletcher, 2002). This dual tropism may be a link
between epithelial cells and B-cells during primary infection and it could also be the
link between B-cells and epithelial cells during virus egress to the saliva. The
presence of a putative link between epithelial cells and B-cells was further supported
by the detection of EBV infection in ex vivo tonsil epithelial cell culture (Pegtel et al,
2004). This work suggested that epithelial cells from the tonsils of infected
asymptomatic individuals were either infected in vivo prior to explantation or shortly
post-explantation by direct contact with B-cells producing "epithelial cell-tropic"
EBV in the explant, and therefore, demonstrated that epithelial cells can support
EBV infection in vivo. Additional support has been leant to the epithelial cell
hypothesis in a recent publication showing that EBV particles attached at the surface
of resting B-cells, which had been recently exposed to EBV, could infect epithelial
cells in cell-to-cell mediated fashion (Shannon-Lowe et al, 2006). This route of
infection was considerably more effective than cell-free infection of epithelial cells,
due to the formation of intimate virological synapses between B-cells and epithelial
cells. Interestingly, the dual tropism situation detailed above could be overcome in
this system, with EBV lacking gp42 binding to B-cells and being efficiently
transferred to epithelial cells, suggesting that other binding mechanisms may be
involved. Glycoprotein 350 was deemed essential for transfer. The transfer of EBV
from B-cell to epithelial cell could be achieved within 10 minutes of cell-to-cell
contact (Shannon-Lowe et al, 2006).
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1.3 EBV: immune responses and associated diseases
1.3.1 EBV epidemiology, transmission and diseases
EBV infects in excess of 90% of the world's adult population. EBV, along with other
herpes viruses, is one of the most successful pathogens at establishing a lifelong
infection in its host generally without resulting in overtly pathogenic disease. This
may be the result of the exceptionally long history of co-evolution between herpes
viruses and man (McGeoch et al, 1995). EBV was first discovered in the context of
BL in 1964 and since then it has been established that there are two sub-types of
EBV - EBV type 1 and EBV type 2. EBV type 1 (or A) is found predominantly in
the West and EBV types 1 and 2 (or B) are found equally in Africa and Papua New
Guinea (Zimber et al, 1986). EBV was identified as the causative agent of IM in
1968 (Henle et al, 1968). Following primary infection, EBV establishes a persistent
infection, in which the virus can remain latent in memory B-cells but can also be
productive, with virus shedding in the saliva facilitating the spread of the virus to
susceptible individuals. Between 5 to 500 per 107 circulating B-cells are EBV-
infected and this level of viral load appears to remain constant over time (Miyashita
et al, 1995). Whilst salivary exchange is the most common transmission route, sexual
transmission may also occur, as EBV has been detected in genital secretions of both
men and women (Israele et al, 1991; Sixbey et al, 1986). These findings were
supported by research from Crawford et al (2002), who found that two thirds of IM
cases and a tenth of asymptomatic EBV infections were associated with sexual
intercourse or closely related behaviour in a cohort of 1006 university students
(Crawford et al, 2002). The acquisition of EBV resulting in an asymptomatic
infection was found to be associated with sexual behaviour in young women (aged
15 to 19 years) and increasing numbers of sexual partners increased the risk of
infection (Woodman et al, 2005).
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Since its discovery, EBV has been associated with a number of diseases, some
benign and others malignant. These diseases are predominantly of lymphoid or
epithelial origin but EBV-associated smooth muscle tumours have also been
described. These EBV-associated diseases have been listed in table 1.6, along with
cofactors/risk factors as well as the percentage of cases that are associated with EBV.
There is also an inextricable association between EBV-associated diseases and
immune status; therefore EBV-associated diseases will subsequently be discussed
within that context. EBV-associated diseases affecting immunocompetent individuals
have been highlighted in green in table 1.6 and those affecting immunocompromised
individuals have been highlighted in yellow. In some cases, disease can affect both
immunocompetent and immunocompromised individuals and hence these diseases
have been highlighted in both green and yellow.
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Disease Cofactors/Risk factors and % Association with EBV
individuals at risk
Lymphocyte origin
IM Delayed primary infection Majority of cases
BL African children - endemic BL 97%- 100%
Sporadic BL 10%-70%
HIV 30% - 40%
HD Children in developing ~ 65%
countries
Young adults in high
socioeconomic groups and/or ~ 80%
with history of IM
BLPD PTLD > 90%
HIV:
Primary central nervous <100%
system lymphoma
Peripheral lymphoma ~ 50%
XLPS cf offspring from carriers >90%
ofXLPS mutation
Primary effusion HIV 70% - 80% (with HHV-8)
lymphoma
NK/T-cell Chronic active EBV/ 10% - 100% depending on
HIV/AIDS histological type
Epithelial cell origin
NPC Southern Chinese & Inuit Non-keratinised 100%
races Keratinised 30%- 100%






Leiomyosarcoma HIV and other Not known
immunodeficiencies - mainly
in children
Table 1.6: EBV associated diseases - in green those affecting immunocompetent
individuals and in yellow those affecting immunocompromised individuals (Crawford,
2001; Hopwood and Crawford, 2000; Macsween and Crawford, 2003).
Abbreviations: BLPD: B-cell lymphoproliferative disease, HIV - human
immunodeficiency virus, NK cell - natural killer cell, OHL - oral hairy leucoplakia,




Other diseases that have been associated with EBV include salivary gland (parotid)
tumours (Raab-Traub et al, 1991), thymic carcinoma (Leyvraz et al, 1985),
hepatocellular carcinoma (Sugawara et al, 1999) and breast cancer (Bonnet et al,
1999). The link with breast cancer has since been refuted but remains controversial
(Perrigoue et al, 2005).
1.3.2 EBV diseases and immune status
In this section, some of the diseases associated with EBV, already mentioned in table
1.6, will be discussed. The presentation of diseases associated with EBV is closely
linked with immune status, hence these will be discussed in two separate sections
starting with diseases occurring in immunocompetent individuals, followed by those
affecting immunocompromised individuals. Particular emphasis will be placed on
post-transplant lymphoproliferative disease (PTLD), which will be discussed in
section 1.4. PTLD occurs in up to 10% of transplant patients but it is associated with
up to 60% mortality following solid organ transplantation (SOT) and up to 80%
following bone marrow transplantation (BMT) (Svoboda et al, 2006).
1.3.2.1 Immune competence and EBV-associated diseases
a) Infectious mononucleosis
Infectious mononucleosis is a self-limiting lymphoproliferative disease that occurs in
up to 25% of individuals when primary EBV infection is delayed to teenage/early
adulthood and this is mostly seen in industrialised countries (Crawford et al, 2006).
In Asia, South America and the African Sub-Continent almost all children have
seroconverted in early childhood and therefore IM occurs extremely rarely (Biggar et
al, 1978a). EBV was found to be the cause of IM in 1968 when a laboratory worker
presented with acute IM symptoms and seroconverted during the course of the
infection (Henle et al, 1968). Serology remains the main diagnostic method for IM.
The clinical presentation of IM can include fever, fatigue, pharyngitis,
lymphadenophathy, hepatosplenomegaly and in rare cases it can also include rashes
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such as urticaria (Macsween and Crawford, 2003). Infectious mononucleosis'
symptoms usually resolve within two to four weeks, although in extremely rare cases
the symptoms can persist constantly or intermittently as chronic active IM
(Crawford, 2001). The speed of resolution of symptoms may be associated with the
number EBV antigen epitopes (latent and lytic) targeted by CD8+ T-cells specific for
EBV antigens, as it was noted in a study that one patient (patient 1) with CD8+ T-
cells reactive to seven epitopes had a much shorter course of acute symptoms (2-3
weeks) in comparison to a patient (patient 2) with CD8+ T-cells reactive to only two
epitopes who experienced acute symptoms for four months (Bharadwaj et al, 2001).
Interestingly, the CD8+ T-cells from patient 1 were less cytotoxic in an ex vivo assay
than those of patient 2, so it was suggested that a broader but less cytotoxic response
may be more beneficial (Bharadwaj et al, 2001). Furthermore PBMC-associated
EBV DNA viral load remained detectable in patient 2 five months post-diagnosis
whilst patient 1 had no detectable EBV DNA following the acute phase of IM
(Bharadwaj et al, 2001). In another study covering the course of the convalescence
phase (6 months following diagnosis), EBV DNA loads associated with PBMCs and
in plasma were found to decrease overall, with some rebound peaks in EBV DNA
loads (Fafi-Kremer et al, 2005). This decrease EBV DNA load was not seen in the
saliva where EBV DNA loads remained elevated (Fafi-Kremer et al, 2005). So,
whilst patients may become asymptomatic following the acute phase of the disease
they can remain infectious throughout the convalescence phase.
The process of EBV primary infection is described in section 1.2.3 and the
immunological response, which induces the symptoms of IM, in particular the
cellular immune response, is discussed in section 1.3.3.2. The humoral response is




BL was first identified in African children by Dennis Burkitt in 1958, and it remains
the most common childhood malignancy in Central Africa. It usually presents as a
tumour of the jaw but it may also present at other anatomical sites such as the
gastrointestinal tract, the kidneys and the liver. There are two types of BL - endemic
BL, that occurs in equatorial Africa and Papua New Guinea and sporadic BL that
occurs worldwide though the frequency of sporadic BL is 50-fold less than endemic
BL (Rickinson and Kieff, 2001; Young and Murray, 2003). There are three key
factors in the pathogenesis of BL - EBV, the dysregulation of the oncogene c-myc
and malaria. EBV is detected in approximately 20% (ranges from 10% to 70%) of
sporadic BL tumours whereas it is detected in over 97% endemic BL tumours
(Macsween and Crawford, 2003; Rickinson and Kieff, 2001). BL tumours comprise
rapidly proliferating small B-cells (which are "trapped" in the cell cycle and
morphologically resemble germinal centre B-cells), and occasional infiltrating
macrophages (Crawford, 2001; Rickinson and Kieff, 2001; Thorley-Lawson and
Gross, 2004). BL cells exhibit a latency I expression profile, in which EBNA-1
maintains the virus in the cell and EBERs possibly contribute to pathogenesis by
inducing IL-10 production and upregulating the anti-apoptotic factor bcl-2 (Kitagawa
et al, 2000; Komano et al, 1999). BL cells consistently display one of three
chromosomal translocations (8:2, 8:14 and 8:22) where the c-myc oncogene, found
on chromosome 8, comes under the transcriptional control of the immunoglobulin
(Ig) heavy chain locus on chromosome 14 or the Ig light chain loci (lambda on
chromosome 22 and kappa on chromosome 2) and becomes constitutively expressed
(Crawford, 2001; Leder et al, 1983). These translocations are observed regardless of
EBV association. Malaria is strongly linked with endemic BL, as tumours occur only
in Papua New Guinea and equatorial Africa where malaria is holoendemic
(Rickinson and Kieff, 2001). Furthermore endemic BL levels diminished in areas of
Papua New Guinea where mosquito eradication programmes were brought in
(Crawford, 2001), thus corroborating the link between endemic BL and malaria.
Acute malaria induces a period of T-cell immunosuppression (Whittle et al, 1984)
and children suffering from acute malaria were found to have up to five times the
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number of EBV-infected cells in peripheral blood than in convalescent malaria,
suggesting a lack of cytotoxic T-cell control ofEBV-infected cells (Lam et al, 1991).
It has been postulated that this increase in EBV-infected cells may be associated with
an increased risk of genetic cellular abnormalities due to the high cell turnover which
may in turn contribute to the evolution/development of BL (Whittle et al, 1984).
c) Hodgkin's disease
HD is the most common lymphoma in young individuals in the Western world. HD
occurs worldwide, with two age peaks of disease onset - one in childhood and the
other in the over 50's but there are socio-economical/ geographical variations in the
time of disease onset (Macsween and Crawford, 2003). In more affluent societies,
the first peak of HD occurs between the ages of 15 and 35 and in less affluent
societies this occurs between the ages of 5 and 10. This delay in disease presentation
in the West parallels what has been seen in EBV infection and IM and pointed to a
link between HD and EBV (MacMahon, 1966). This link was undeniably established
by the detection of EBV genomes in tumour biopsies and specifically in the
malignant mononuclear Hodgkin cells and multinuclear Reed-Sternberg cells (HRS
cells) (Weiss et al, 1989). HD comprises four subtypes - nodular sclerosing (NS),
mixed cellularity (MC), lymphocyte depleted (LD) and lymphocyte predominant
(LP) (Rickinson and Kieff, 2001). NS, MC and LD HD are collectively known as
"classic HD" in which HRS cells are of monoclonal B-cell origin based on their
immunoglobulin gene (7g gene) rearrangement. These HRS cells are of germinal
centre origin (Thorley-Lawson and Gross, 2004), and some bear "crippling" Ig gene
mutations following somatic hypermutation that are not generally consistent with cell
survival in vivo (Mancao et al, 2005). HD HRS cells exhibit latency type II EBV
antigen expression pattern, therefore expressing the viral antigens (LMP-1 and LMP-
2A), which promote the survival of these otherwise non-viable cells. Worldwide,
between 60% to 80% of MC and LD tumours and 20% to 40% of NS tumours are
EBV positive and less than 10% of LP tumours are EBV positive (Rickinson and
Kieff, 2001); however, these percentages are subject to geographical variations. HD
30
CHAPTER 1 INTRODUCTION
is another example of EBV's versatility in causing disease by differential expression
of the necessary antigens for the survival of abnormal B-cells.
d) T-cell lymphoma
EBV was first detected in T-cells in 1988 in patients with chronic active EBV
infections (Jones et al, 1988; Kikuta et al, 1988). EBV entry into T-cells can occur
via CD21, which has been detected at the surface of activated T-cells (Fischer et al,
1991), however CD21 is not detected consistently on all tumour T-cells (Jones et al,
1988; Kikuta et al, 1988). T-cell lymphomas can be separated into two main
categories: virus-associated haemophagocytic syndrome (VAHS) T-cell lymphomas
and nasal NK/T-cell lymphomas (Rickinson and Kieff, 2001). VAHS in children is
intrinsically linked with EBV: T-cell proliferation is driven by EBV infection leading
to haemophagocytosis (Rickinson and Kieff, 2001). Nasal NK/T-cell lymphomas
mainly affect adults of Asian, Latin and Native American origin (Nava and Jaffe,
2005). These lymphomas primarily result in the destruction of the bone structure of
the nasal cavity, although other anatomical sites can be involved (skin,
gastrointestinal tract, testis and upper respiratory tract) which is a poor prognostic
factor (Nava and Jaffe, 2005). Both of these lymphoma types express EBV antigen in
a latency I/II pattern, as LMP-1 expression is low to almost undetectable. All of these
lymphomas are associated with EBV (Rickinson and Kieff, 2001). The prognosis of
both VAHS and NK/T-cell lymphomas is poor.
e) Nasopharyngeal carcinoma
NPC is a tumour of the squamous epithelium of the nasopharynx. NPCs can be
broadly separated into two categories based on the differentiation of the epithelial
tumour cells: differentiated (keratinised) and undifferentiated/poorly differentiated
(non-keratinised) (Rickinson and Kieff, 2001). NPC occurs worldwide at a relatively
low incidence of 0.5 per 100000 but this increases to 20 to 30 per 100000 in southern
China and the Inuit population (Crawford, 2001; Murray and Young, 2001;
Rickinson and Kieff, 2001). Interestingly, individuals of Chinese descent have a
higher incidence of the disease regardless of geographical location, suggesting a
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genetic susceptibility, which may be linked to HLA type (Lu et al, 1990; Young and
Rickinson, 2004). Other contributory factors to the disease include a diet rich in
salted/preserved foods such as fish that contains carcinogenic nitrosamines, as well
as the consumption of beer and strong alcohols and fresh pork/beef offal (Armstrong
et al, 1998). The use of Chinese herbal snuff is also associated with NPC (Yu and
Yuan, 2002).
The association between EBV and NPC was first established using serological
methods, in which antibodies generated to antigens in BL cells lines reacted with
serum from UNPC/NPC patients (Old et al, 1966). This link was further
substantiated when EBV DNA was detected in tumour biopsies by in situ
hybridisation (Wolf et al, 1973), and then, using Southern blotting, it was also shown
that EBV infection occurred prior to clonal expansion of malignant cells (Raab-
Traub and Flynn, 1986). There is up to a 100% association between
undifferentiated/poorly differentiated forms of NPC and EBV, however this
association may decrease in more keratinised forms of the disease (Rickinson and
Kieff, 2001). Nasopharyngeal tumours express the latency II EBV gene expression
programme (see table 1.3). EBERs, BARTs, LMP-2A and -2B transcripts are readily
detectable but the LMP-1 protein is not always detectable, being absent in
approximately 65% of tumours (Rickinson and Kieff, 2001). The EBNA-1 protein is
the only EBNA to be readily detectable in NPC (Lee, 2002). Whilst, high IgG and
IgA antibody levels to the lytic VCA and EA act as a marker for NPC and increase
with NPC severity (Henle and Henle, 1976), no lytic form of the genome has been
detected in cells from NPC tumour biopsies.
1.3.2.2 Immune deficiency and EBV-associated diseases
Immune deficiency may be of an acquired, inherited or iatrogenic nature. In each of
these situations EBV can give rise to diseases such as acquired immunodeficiency
syndrome (AIDS)-related lymphomas and oral hairy leucoplakia (Opelz and Dohler,
2004), in the case of acquired immune deficiency; X-linked lymphoproliferative
syndrome (XLPS) and B-cell lymphoproliferative disease (BLPD), in the case of
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inherited deficiency and PTLD, in the case of iatrogenic immune deficiency. PTLD
will not be discussed in this section but will be discussed at length in section 1.4.
a) Acquired immunodeficiency syndrome-related lymphomas
HIV-infected individuals have a high risk of lymphoma development due to the T-
cell immunosuppressive nature of the disease. The diseases that occur in HIV/AIDS
patients are listed in table 1.6. Sporadic BL can occur in HIV infected individuals
(Ziegler et al, 1982) where it is an AIDS-defining illness (Crawford, 2001). In such
cases there is a 30% to 40% association with EBV. BLPD, which encompasses
primary central nervous system (CNS) lymphoma and peripheral lymphoma, occurs
in end-stage AIDS. EBV is associated with nearly all primary CNS lymphomas and
approximately 30% to 50% of peripheral lymphomas (MacMahon et al, 1991).
Primary effusion lymphoma (PEL) also affects AIDS patients, though it is rare. PEL
is EBV positive in 70% to 80% of cases (HHV-8 is also associated with PEL).
Finally, in rare cases, HD can arise in HIV-positive individuals where there is a
100% association with EBV (defined by LMP-1 detection) (Audouin et al, 1992).
b) Oral hairy leucoplakia
OHL is a benign condition affecting the epithelium of the tongue, particularly the
edges of the tongue, which is caused by EBV lytic replication and presents
predominantly in AIDS patients (Greenspan et al, 1985). However OHL can affect
other immunosuppressed individuals, such as renal transplant recipients (Itin et al,
1988). The association with lytic replication of EBV was corroborated when
acyclovir treatment coincided with complete resolution of OHL lesions, in which
only EBV could be detected (Resnick et al, 1988). The replication of EBV associated
with OHL, as well as EBV DNA detection were restricted to the upper epithelium of
the tongue (Thomas et al, 1991).
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c) X-linked lymphoproliferative syndrome
XLPS or Duncan's Disease was identified over 30 years ago when a child from the
Duncan family, in which five other maternally-related males had died, succumbed to
IM and was found to have a thymus gland, lymph nodes and spleen depleted of T-
cells (Purtilo, 1983). In XLPS a primary EBV infection can present as fulminant IM
with acute B-cell proliferation, which is fatal in over 50% of cases. This occurs
because individuals with XLPS cannot control a primary EBV infection and those
who survive the acute phase of the disease may go on to develop lymphoma and
hypogammaglobulinaemia (Williams and Crawford, 2006). The product of the XLP
gene is SAP (signalling lymphocytic-activation molecule (SLAM) associated
protein) which is found in the cytoplasm of activated T-cells and NK cells (Coffey et
al, 1998). SAP interacts with the cytoplasmic domain of SLAM or CD150, which is
found at the surface of B- and T-cells (Sayos et al, 1998). The SAP acts as a cell
activation modulator by binding to SLAM, which is a member of the
immunoglobulin superfamily, as well as to four other member of the
immunoglobulin superfamily, including 2B4 or CD244 found on NK cells and
cytotoxic T-cells (Nakajima et al, 2000; Sayos et al, 1998). Based on this, it has been
postulated that the interaction between SAP and SLAM acts as a control in the
balance of the production of Thl/Th2 cytokines in response to cellular activation
(Williams and Crawford, 2006). Mutations affecting SAP may therefore compromise
this balance resulting in a lack of cytotoxic T-cell activation by helper T-cells
because these could not respond to antigen presentation by EBV-infected B-cells
(Sayos et al, 1998). Additionally, SAP mutations disrupt humoral responses in a
cytokine-independent fashion by affecting the expression of extracellular molecules
essential in T-cell-B-cell collaboration necessary in the generation of an appropriate
humoral response (Cannons et al, 2006). It has also been shown that SAP mutations
could detrimentally affect NK cell cytotoxicity towards EBV infected cells. This is
because mutated SAP failed to act on downstream activation pathways following the
binding of 2B4 on NK cells with CD48 expressed at the surface of EBV-infected
cells (Nakajima et al, 2000). Additionally the interaction of 2B4 with CD48 in XLPS
individuals resulted in further NK cell cytotoxicity inhibition (Parolini et al, 2000).
34
CHAPTER 1 INTRODUCTION
Most individuals with XLPS do not survive beyond their teenage years and treatment
ofXLPS is limited, though the monoclonal antibody to CD20 (expressed by B-cells),
also known as rituximab, has been used successfully in two patients who remain
disease free two years post-primary infection (Milone et al, 2005).
1.3.3 The immune response to EBV
As over 90% of the adult population is infected by EBV, but most remain
asymptomatic, the immune response to the virus plays a critical role. The importance
of the immune control is highlighted by immunocompromised individuals who often
present with severe EBV-associated diseases. Before describing the EBV-specific
immune response, the general immune response to viruses will be reviewed.
1.3.3.1 General immune response to viruses
Viruses are obligate intracellular pathogens. Innate immunity to viruses is centred on
the production of type I interferons (IFN), which include IFN-a and -(3. The
secretion of type I IFN is induced by two broad types of receptors: toll-like receptors
and cytosolic receptors. Both receptor types detect viral nucleic acids. The cytosolic
receptors are ubiquitous and found in all cell types, whereas the toll-like receptors
operate in endosomes of specialised cells (dendritic cells and macrophages) (Stetson
and Medzhitov, 2006). The stimulation of these receptors induces the production of
type I IFN, which acts in an autocrine and paracrine fashion, inducing an antiviral
state. This antiviral state is mediated by antiviral proteins (enzymes), which respond
to double-stranded RNA. One family of antiviral proteins is the 2'5' ogliadenylate
synthases family, which produce 2'5'oligoadenylates that stimulate RNases to
degrade both host and viral RNA. PI kinase, another antiviral protein, is also
activated by double stranded RNA and inhibits translation of both viral and host
messenger RNA. Both of these antiviral responses seek to halt viral replication and
lead to apoptosis of the cell, which prevents the spread of the virus to neighbouring
cells. In uninfected cells, type I IFNs induce the expression of MHC class I making
them resistant to NK cell activity, as downregulation ofMHC class I can be induced
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by viral infection. This makes newly infected cells more susceptible to CD8+
cytotoxic T-cells and NK cell lysis, due to increased antigen presentation via MHC
class I leading to more efficient elimination of the virus.
Apopotic cells and debris from lysis of virus-infected cells are subsequently taken up
by macrophages and dendritic cells or tissue-derived dendritic cells (if the infection
occurs in a non-lymphoid organ). This will lead to antigen presentation to CD4+ and
CD8+ T-cells in lymph nodes. Where the CD4+ T-cells and CD8+ T-cells recognise
antigen in an MHC class II and class I manner respectively, the cells undergo clonal
expansion. Appropriate activation of both cell types requires not only the interaction
of the T-cell receptor (TCR) with the MHC/peptide complex but also the interaction
of CD28, which is a receptor involved in the regulation of T-cell response, by
providing a co-stimulatory signal mediated by its ligands CD80 and CD86 (CD80
and CD86 were known as B7.1 and B7.2 respectively) (Lenschow et al, 1996).
CD27, another cell surface marker, interacts with CD70 (which is expressed by
EBV-infected lymphoblastoid cells) (Yamada et al, 2002). Both CD27 and CD28
expression decreases following antigenic stimulation and they are not re-expressed
(Appay et al, 2002a). Additionally, CD45RA (naive T-cell marker) and CD45RO
(antigen-experienced T-cell marker) expression change following antigen exposure
with a decrease in CD45RA and an increase in CD45RO expression. Many other
markers are upregulated or downregulated following antigen encounter, although
CD27 and CD28, in conjunction with CD45RA expression, have been repeatedly
used in studies to establish the differentiation status of CD4+ T-cell and CD8+ T-
cells in response to different viral infections (including EBV) (Appay et al, 2002a;
Appay et al, 2002b).
The generation of effective immune memory in terms of virus-specific CD8+ T-cells
relies on the presence of CD4+ T-cells during the course of the primary immune
response. In the absence of CD4+ T-cells, the primary CD8+ T-cell response takes




The humoral immune response also develops with the help of CD4+ T-cells
providing essential B-cell specific cytokines (such as interleukin-4 and -5). Virus-
specific antibodies can be detected in the late phase of an infection. These may
prevent cell-to-cell infection and may also confer resistance to further infection.
Additionally antibodies may neutralise virus particles released from infected cells
thus preventing spread within the body and to susceptible individuals (Guidotti and
Chisari, 2001).
As the majority of individuals infected with EBV undergo silent seroconversion,
information on the primary immune response to EBV is based on studies of IM
patients.
1.3.3.2 The humoral immune response to EBV
Primary EBV infection has been shown to occur at an earlier age in lower
socioeconomic groups than in higher socioeconomic groups (Biggar et al, 1978b). It
is usually asymptomatic but where there is a delay in primary infection to
adolescence/early adulthood this can result in IM in 25% of cases (Crawford et al,
2006). In IM patients EBV elicits both a humoral and a cellular response. The
primary humoral response can be demonstrated by enzyme-linked immunosorbent
assay and immunofluorescence detection of IgM and IgG antibodies to viral capsid
antigen (VCA) and early antigen (EA), of IgM and IgG antibodies to the membrane
antigen (MA, comprising gp350/220 and gp85) and the absence of IgG antibodies to
EBNA (Moss et al, 2001). In late IM, the pattern of detectable antibodies changes
with the detection of IgG antibodies only to EBNA, VCA and MA but no longer to
EA (Moss et al, 2001). The detection of these antibodies still forms part of IM
diagnosis today, along with the detection of heterophile antibodies using the Paul-
Bunnel and Monospot tests. Heterophile antibodies are IgM antibodies which react
with antigens of unrelated species, such as sheep and horse (agglutination of sheep
red blood cells forms the basis of the Paul-Bunnel test and agglutination of horse red
blood cells forms the basis of the monospot test). Heterophile antibodies can be
detected in approximately 85% of IM cases. All of the IgG antibodies generated
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above, but in particular the neutralising antibodies to gp350/220 (part of MA)
(Thorley-Lawson and Geilinger, 1980; Thorley-Lawson and Poodry, 1982), along
with IgA antibodies against gp350/220 found in the serum of 21% to 30% and in the
saliva of 12% to 19% of infected individuals, may serve to prevent superinfection
with other EBV isolates (in EBV seropositive individuals) and further spread of the
virus to susceptible individuals (Yao et al, 1991).
1.3.3.3 The cellular immune response to EBV
a) NK cell response
NK cells form an integral part of the innate immune response to viral infection,
including EBV. In one study, higher NK cell levels in IM patients corresponded with
a lower viral load (Williams et al, 2005) and the authors suggested that NK cell
activity may have an impact on the outcome of primary EBV infection.
b) CD8+ T-cell response
The cellular immune response to a primary EBV infection as detected in the
peripheral circulation is characterised by an antigen driven "atypical" lymphocytosis
comprising phenotypically activated CD8+ T-cells, which were found to be
monoclonal or oligoclonal based on their T-cell receptor (TCR) usage within
expanded families of the variable (3-chain (V|3) (Callan et al, 1996). These "atypical"
CD8+ T-cells were frequently found to recognise lytic antigen epitopes, from the
immediate early antigens BRLF-1 and BZLF-1 but also from other early lytic
antigens such as BMRF-1, BMLF-1 and BALF-2 (Steven et al, 1997). The number
of CD8+ T-cells specific for latent antigen was comparatively low during the course
of the primary response, with only up to 2.2% of CD8+ T-cells being specific for an
EBNA-3A latent epitope in the HLA-B8 context compared to 44% of CD8+ T-cells
being reactive to the lytic BZLF-1 peptide (Callan et al, 1998). The number of CD8+
T-cells reactive to lytic antigens generated during the acute phase of the primary
infection decreased dramatically and in some cases became completely undetectable
as the infection progressed (Hislop et al, 2002), with the most expanded CD8+ T-
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cells clones in the primary response being the most heavily culled (Callan et al,
2000). The CD8+ T-cells evolve in parallel to the progression from primary infection
with lytic replication to persistent phase with latent replication. Thus, CD8+ T-cells
specific to latent antigens are detected in long-term carriers (following resolution of
the primary infection) and must be involved in immunosurveillance. These CD8+ T-
cells are reactive to latent antigen and in particular EBNA-3 antigens (Murray et al,
1990; Rickinson and Moss, 1997). The immunodominant peptides to which CD8+ T-
cells respond have been mapped for specific HLA types (Moss et al, 2001). These
immunodominant peptides included EBNA-1 peptides to which CD8+ T-cells
respond strongly (when EBNA-1 presentation inhibition by the glycine-alanine
repeat was overcome).
Phenotypically, EBV-specific CD8+ T-cells progressed from a naive phenotype
(CD27+ CD28+ CD45RA+) to an antigen-experienced phenotype (CD27+/- CD28+
CD45RA+/-) following the model proposed by Appay et al (2002a). This phenotypic
change was associated with acquisition of the cytolytic proteins perforin and
granzyme A. Further differentiation can take place, leading to the loss of CD27 and
CD28 expression and increasing levels of perforin. The antigen-experienced
phenotype was associated with cells with a greater potential to proliferate whereas
those having undergone further differentiation had greater cytotoxic potential but a
reduced ability to proliferate.
c) CD4+ T-cells
The analysis of CD8+ T-cell responses to EBV was greatly facilitated by using MHC
class I EBV antigen tetramers (Callan et al, 1998) but this was not feasible for CD4+
T-cells as MHC class II EBV antigen tetramers were/are not available. However,
CD4+ T-cells from healthy blood donors have been shown to respond consistently to
EBNA-1 presented by dendritic cells (DC) and LCL in vitro (Munz et al, 2000).
Further work by the same group found that these EBNA-1-reactive CD4+ T-cells
exhibited T-helper (Th) type 1 properties by secreting IFN-y and inducing EBNA-1 -
specific lysis of target cells (Bickham et al, 2001). EBNA-1 was subsequently found
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to be the most immunogenic EBV latent antigen (compared with EBNA-3C, LMP-1
and LMP-2 respectively) for CD4+ Thl T-cell from healthy EBV carriers (Leen et
al, 2001). This hierarchy of immunogenicity is unlike that seen in CD8+ T-cells in
which the EBNA-3 family induces the strongest response, followed by EBNA-1,
LMP-2, EBNA-2, EBNA-LP and LMP-1 (Leen et al, 2001). Moreover, CD4+ T-
cells from healthy EBV carriers were shown to have an effector role, as their
addition prevented the proliferation of newly EBV infected CD23+ B-cells in culture
and conversely the removal of these CD4+ T-cell allowed newly EBV infected
CD23+ B-cells to grow in culture (Nikiforow et al, 2001). This effector role was
ascribed to IFN-y secretion and Fas/FasL interaction between CD4+ T-cells and
target B-cells and not to perforin secretion (Nikiforow et al, 2003). However,
perforin was detected in CD4+ T-cells of healthy blood donor but also in the CD4+
T-cells of individuals undergoing a primary EBV infection in whom cytotoxic
activity was mediated by perforin (Appay et al, 2002b). Another group of researchers
generated EBV-specific CD4+ cytotoxic T-cells in vitro and found that these cells
did not express perforin but instead expressed granulysin as a potential effector of
cytotoxicity (Sun et al, 2002). Whilst these findings do not clearly establish how
CD4+ T-cells respond to EBV latent antigen they do show that CD4+ T-cells have
the ability to respond to antigen beyond their helper functions.
Studies into CD4+ T-cell responses to EBV latent and lytic antigens in primary EBV
infection (IM) were only recently undertaken by Amyes et al (2003) and Percopio et
al (2003). The mean percentage of CD4+ T-cells from IM patients responding to
EBV lysate (the lysate was shown to contain BZLF-1, BMRF-1 and LMP-1) was
1.4% (ranging from 0.04% to 5.2%) (Amyes et al, 2003). EBV-specific CD4+ T-
cells were detected in all IM patients studied, with BZLF-1-specific CD4+ T-cell
detectable in 100%, BMLF-1 and EBNA-3A CD4+ T-cells detectable in 78%,
EBNA-1-specific CD4+ T-cells in 33% of IM patients (Precopio et al, 2003). Most
patients were found to respond to two or more proteins. The frequencies of CD4+ T-
cells specific for these antigens in the IM patients were 1.75% for BZLF-1 and <1%
for BMLF-1, EBNA-1 and EBNA-3A. The frequencies of all antigen-specific CD4+
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T-cells dropped below 0.12% six weeks post-diagnosis. At one year post-diagnosis
almost all EBV antigen-specific CD4+ T-cells were undetectable in all IM patients
(Precopio et al, 2003), however, other investigators have detected CD4+ T-cells
specific for latent EBV antigens in healthy EBV carriers (see paragraph above). So,
whilst CD4+ T-cells do expand following a primary EBV infection, they comprise
only a small fraction of the lymphocytosis seen in IM.
In contrast to CD8+ T-cells, CD4+ T-cells progressed from a nai've phenotype
(CD27+ CD28+ CD45RA+ CD45RO- perforin-) to antigen-experienced phenotype
(with a greater ability to proliferate and promote B-cell differentiation) without the
loss of CD27 and CD28 and without the acquisition of perforin or granzyme A
(CD27+ CD28+ CD45RA+/- CD45RO+) (Appay et al, 2002b). The acquisition of
these cytolytic proteins was concomitant with the loss of CD27 and CD28




1.4 Post-transplant lymphoproliferative disease
1.4.1 A brief history of transplantation
Transplantation of human teeth took place in ancient Egypt, Greece, Rome as well as
in pre-Columbian North and South America. Since then the discipline of
transplantation has thankfully evolved, although not without considerable ups and
downs. The successful autografting of a kidney in a dog in 1908 led to much
developmental work being undertaken in both animals and humans, without success
in most cases. This status quo of failures remained until the immunosuppressive
agent 6-mercaptopurine was discovered. In 1962 a modified, less toxic and more
effective version of 6-mercaptopurine, azathioprine, was used in a kidney transplant
leading to an uncomplicated post-operative course. The next key step in
transplantation was the pioneering use of the fungal metabolite CsA in 1978. It was
first used in seven renal transplant patients with encouraging post-transplant
outcomes with five patients supporting functioning allografts (Calne et al, 1978).
This prompted its extended use in 32 kidney, two liver and two pancreatic
transplants, in which no kidney was lost through rejection (Calne et al, 1979) and
CsA has been in use ever since. In the meantime, the first lung transplant and the first
heart transplant were carried out in 1963 and 1967 respectively and in 1970 the HLA
complex was discovered, which is of paramount importance in transplantation. At
present, as well as heart, kidney, lung and liver transplants, pancreas, corneal, skin
and small bowel transplants are also carried out (Hakim, 1997) and on the 30th
November 2005 the first face transplant was carried out successfully by French
surgeons in Amiens. Whilst a number of surgical/technical hurdles have been
overcome in transplantation, there are post-transplantation complications, such as
PTLD, which remain serious. Beyond post-transplantation complications, the lack of






1.4.2.1 Incidence of PTLD
The incidence of PTLD in haematopoietic stem cell transplants is approximately 1%
and in renal, heart and liver transplants this ranges from 1% to 3%, although figures
of up to 10% have also been published when lung transplant patients were included
(Burns and Crawford, 2004; Gottschalk et al, 2005). An incidence of PTLD of 1% is
approximately 20 times the incidence of lymphoma in the general population
(Newstead, 2005). The incidence of PTLD in intestinal transplants has been reported
to be approximately 20%, although an incidence reaching up to 26.8% in paediatric
recipients (9.3% in adults) has been observed (Reyes et al, 1996) and this is believed
to be due to the large amount of lymphoid tissue associated with an intestinal
transplant (Gottschalk et al, 2005; Newstead, 2005). PTLD is most likely to occur in
the year following the transplant due to the prolonged and intense
immunosuppression required to prevent graft rejection (Opelz and Henderson, 1993).
The incidence of PTLD one year post-transplant represents one fifth of the
cumulative incidence over 10 years with a median PTLD occurrence time of 5 years
post-transplant (Opelz and Dohler, 2004). The incidence of PTLD in solid organ




Penn et al recognised an increase in the incidence of lymphomas in transplant
patients in 1969 (Penn et al, 1969). In 1979 following the introduction of CsA a
dramatic rise in the number of cases of PTLD was noted and this was reduced
substantially following a decrease in the dose of CsA used (Beveridge et al, 1984;
Starzl et al, 1984). In 1980, Crawford et al were the first to identify an EBV-
associated lymphoma in a kidney transplant patient on CsA imuunosuppressive
treatment, thus establishing the link between immunosuppression and EBV-positive
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lymphoma development, as such lymphomas are not seen in immunocompetent
individuals. T-cell immunosuppression is a major risk factor in the development of
PTLD. Other immunosuppressive agents are now in use such as tacrolimus,
sirolimus and prednisolone alongside antiproliferative immunosuppressants such as
azathioprine and mycophenolate mofetil (Newstead, 2005). Monoclonal antibodies
such as OKT3 that bind CD3, and basiliximab and dacluzimab that bind the CD25
receptor, all of which deplete circulating T-cells, are also in use. Basiliximab and
dacluzimab are used prophylactically to prevent graft rejection (BNF, 2006; NICE,
2006), whereas OKT3 has been used for both the treatment and prevention of graft
rejection. The use of OKT-3 alone (Swinnen et al, 1990), tacrolimus alone (Cox et
al, 1995) or a combination of both (with high tacrolimus doses) (Sokal et al, 1997)
has been associated with a increased risk of PTLD, but compared to CsA, tacrolimus
reduces the incidence of graft rejection by 11% (Hakim, 1997), highlighting a fine
balance between PTLD development and graft rejection. However, a retrospective
study covering 30 years of heart and lung transplants in one centre found there to be
no correlation between immunosuppressive regimens consisting of OKT3,
azathioprine, prednisolone, mycophenolate mofetil and tacrolimus and PTLD
development, with the exception of high-dose CsA (Gao et al, 2003). Prolonged
and/or intense periods of immunosuppression have both been associated with an
increased risk of developing PTLD. Such periods would be seen in individuals with
heart, lung and liver transplants or individuals who are undergoing a second
transplant in whom the incidence of PTLD is five times greater than in other
transplant patients (Swerdlow et al, 2000).
b) EBV seronegativity
EBV seronegativity prior to transplantation is another a critical risk factor, as EBV
can be acquired naturally but it can also be transmitted through the transplanted
organ and lead to a primary infection and seroconversion (Haque et al, 1996). EBV
seronegative recipients of an EBV positive graft have between a 10-fold and 75-fold
increased risk developing PTLD as compared with EBV seropositive recipients
(Cockfield, 2001). This increased risk arises because seronegative individuals have
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no immunity to EBV nor do they have the ability to mount a response due to
iatrogenic immunosuppression. This is of particular relevance in paediatric transplant
recipients who are highly likely to be seronegative.
1.4.2.3 Tumour classification
The term PTLD disease refers to a heterogeneous group of tumours that are
principally of B-cell origin, although T- and NK-cell PTLD tumours have also been
observed (Nalesnik, 2001). Tumour cells generally express latency III pattern,
although some cells within a tumour may express latency I and II pattern also (Cen et
al, 1993). Antigen expression is therefore heterogeneous. PTLD tumours are distinct
from other EBV-associated tumours and they are histologically classified as 1)
hyperplastic PTLD (early lesions), 2) polymorphic PTLD and 3) lymphomatous
PTLD (monomorphic PTLD) (Nalesnik, 2001). Progression from early lesions to
monomorphic PTLD has been documented (Larratt et al, 2001). Monomorphic
lesions are the most aggressive and the most likely to be resistant to treatment
(treatment is discussed in section 1.4.3) (Williams and Crawford, 2006). In some
cases these lesions also carry genetic mutations in the p53 tumour suppressor gene,
the ras and/or c-myc oncogenes, which may contribute to disease development
(Knowles et al, 1995). PTLD tumours can be monoclonal, oligoclonal or polyclonal
with regards to their Ig gene rearrangement or cell surface/cytoplasmic Ig expression
and tumours arising in the same patient may exhibit variation in their clonality
(Cleary and Sklar, 1984; Hanto et al, 1982; Shearer et al, 1985).
1.4.2.4 Pathogenesis
EBV DNA was detected in tumour B-cells in PTLD patients (Young et al, 1989).
The cellular origins of PTLD are varied and not limited to memory B-cells. This was
established by genotyping of the immunoglobulin heavy chain (IgH) of the B-cell
receptor (BCR). The PTLD tumour cells consisted of either antigen-experienced
cells that had undergone BCR somatic hypermutation or naive B-cells that had not
(Timms et al, 2003). It was also established that B-cells bearing random BCR
mutations, as well as mutations leading to a sterile genotype, which would apoptose
45
CHAPTER 1 INTRODUCTION
in immunocompetent individuals, were present in PTLD tumours (Timms et al,
2003). B-cell receptor-deficient cells have also been found in PTLD tumours and are
prone to apoptose rapidly in a mouse model (Lam et al, 1997). As these tumour cells
are EBV-infected, it appears highly likely that EBV provided the cells with the
necessary signals for survival. LMP-1 would act as a CD40 homologue, therefore
providing proliferation and activation stimuli, and LMP-2A as a BCR homologue
(Bechtel et al, 2005; Caldwell et al, 1998; Mancao et al, 2005). Therefore, EBV
expresses the antigens that are necessary for the survival of its host cell, which would
otherwise be destined to apoptose; it also exploits the lack of immune surveillance to
express a full complement of antigens - latency III programme - to promote its
growth.
T-cells and cytokines are also believed to play a part in tumour outgrowth. Both
CD4+ and CD8+ T-cells have been detected in PTLD tumours, though CD4+ T-cells
appeared to be more abundant (Perera et al, 1998). Perera et al (1998) postulated that
these infiltrating CD4+ T-cells were contributing to the pathogenesis of the disease.
Research on the tumour microenvironment has been based on animal models such as
the hu-PBL-SCID mouse (human-peripheral blood lymphocyte-severe combined
immunodeficiency disease), in which a human immune system is restored in a B- and
T-cell deficient mouse by the injection of human PBMC (Mosier et al, 1988).
However, when PBMCs from EBV-positive donors were used, the SCID mice
developed EBV-positive lymphomas (Mosier et al, 1988) and as a result hu-PBL-
SCID mice have been used extensively to study lymphomagenesis and in particular
PTLD development (Rowe et al, 1991). Using the hu-PBL-SCID mouse,
Johannessen et al (2000) showed that without T-cells (CD4+ T-cells in particular)
tumour incidence was considerably reduced. Johannessen et al (2000) also put
forward a tumourigenesis model in which tumour cells initially required T-cell help
by way of cytokine production, with tumour cells then progressing to sustain
themselves in a cytokine-dependent autocrine fashion and becoming independent of
T-cell help altogether. The cytokines found to be produced by the tumour cells
generated in this model were IL-2, IL-4, IL-6, IL-10 and IFN-y and all of these
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cytokines are potential direct and indirect stimulators of B-cell growth (Johannessen
et al, 2000).
The pathogenesis of PTLD is a complex multi-step process that is dependent on a
large number of factors such as T-cells immunosuppression, graft type, T-cell
contribution to B-cell growth, accumulation of genetic mutations and also EBV's
oncogenic potential. There are undoubtedly other factors, host and viral, that
contribute to PTLD pathogenesis, although these have yet to be established.
1.4.2.5 Clinical presentation and prevention
The clinical presentation of PTLD is diverse and may present with a wide range of
signs and symptoms, which can include a persistent febrile illness and
lymphadenopathy (Crawford, 2001). These signs and symptoms are similar to those
seen in acute IM. The highest incidence of PTLD occurs in the first year post-
transplant and may involve the graft as well as other sites such as the gastrointestinal
tract, the lungs and the central nervous system (Gottschalk et al, 2005). As PTLD
presentation is diverse (and rather non-specific), much research has gone in the
development of reliable prevention/monitoring methods, such as measuring EBV
viral loads especially as early detection and diagnosis are associated with better
outcome (Gottschalk et al, 2005). Many PCR-based methods have been used to
measure EBV viral load but no standard "cut-off or indicator values for the
development of PTLD have been established and such methods do have limitations,
as PTLD has been seen in patients with no detectable increase in EBV viral load
(Anonymous, 2004; Axelrod et al, 2003; Straathof et al, 2002). Furthermore EBV
DNA can be detected in whole blood, plasma, PBMC and oropharyngeal secretions
but the levels in each of these secretions differ, such that there is good correlation
between whole blood and PBMC but a poor correlation between plasma and PBMC
(Wadowsky et al, 2003). This lack of correlation has been seen in heart, renal and
liver transplant patients diagnosed with PTLD, in whom oropharyngeal shedding of
EBV was high but correspondingly high levels were not detected in PBMC (Savoie
et al, 1994). Whole blood would appear to be the specimen of choice as it includes
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all blood fractions and may provide the most information regarding viral load
(Stevens et al, 2001a). Consensus has been reached with regards to serial monitoring
of EBV viral load in transplant patients. 50% of SOT patients present with elevated
EBV viral load but it is those whose viral load increases rapidly that are high risk of
developing PTLD (Gottschalk et al, 2005). This may happen very quickly: EBV viral
load has been found to double in 56 hours reaching levels indicative of PTLD
development (Stevens et al, 2001b). Clearly, serial monitoring is the only way to
detect such changes. The benefit of serial monitoring combined with pre-emptive
reduction in immunosuppression has been demonstrated in one centre where the
incidence of PTLD was reduced from 16% to 2% in paediatric liver transplant
recipients (Lee et al, 2005).
Recently, a group of researchers infected (with EBV) two EBV-negative individuals
who were due to receive EBV-positive grafts, through a series of three EBV-positive
blood transfusions (Babel et al, 2005). Both patients seroconverted prior to transplant
and, at the time of publication, both patients had been free of PTLD for a follow-up
period of five years. This may be a simple and promising, though unconventional,
way of reducing/eliminating the risk ofPTLD related to EBV seronegativity.
1.4.3 Treatment of PTLD
The therapies available for the treatment of PTLD in SOT patients aim to quench
tumour growth/kill tumour cells or to restore cellular immunity and in particular
EBV-specific cytotoxic T-cell activity. The therapies used for the treatment of PTLD
are discussed below. Reduction of immunosuppression aims to restore T-cell activity
and both chemotherapy and rituximab treatment aim to tackle tumour growth. When
combined with close serial monitoring of EBV viral loads, reduction of
immunosuppression may also be used prophylactically, as discussed above.
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1.4.3.1 Reduction of immunosuppressive drugs
As the occurrence of PTLD is intrinsically linked with iatrogenic
immunosuppression, the first line of treatment is a reduction in the dose of
immunosuppressive drugs in order to restore cellular immunity (EBV-specific
cytotoxic T-cells). The degree to which immunosuppression is reduced differs in
each patient, although in cases where PTLD has been formally diagnosed
immunosuppressive drugs should ideally be stopped altogether (Anonymous, 2004),
which may not be an option as this carries a high risk of graft-versus-host-disease
(GVHD) hence it is a very delicate balancing act, especially where there is no
secondary therapy (such as dialysis for renal transplant patients). Remission
following reduction in immunosuppression ranges from 25% to 63% in adults and
40% to 86% in paediatric patients (Gottschalk et al, 2005; Taylor et al, 2005).
Response usually occurs within three to four weeks of immunosuppression reduction
and persists beyond this initial period (Starzl et al, 1984). A good response to a
reduction of immunosuppression may be seen in PTLD patients whose tumour cells
are expressing all latency III antigens, as may be in most tumours occurring within
the first year post-transplant, but where antigen expression is restricted, as may be
seen in tumours occurring over one year post-transplant, the response may not be as
satisfactory. Mortality is high (50% to 90%) in patients who do not respond to a
reduction in immunosuppression (Taylor et al, 2005).
1.4.3.2 Chemotherapy
Chemotherapy is usually a second line therapy for PTLD, although a recent report
shows that it has been preferentially used in paediatric heart transplant patients
presenting with monomorphic lesions across a number of institutions (61% patients
treated with chemotherapy and 39% treated by reduction of immunosuppression)
(Webber et al, 2006). This method of treatment was associated with 75% survival at
one year and 65% at five years post-diagnosis. Chemotherapy would otherwise be
used in patients who have not responded to a reduction/cessation of
immunosuppression or in cases where reduction/cessation of immunosuppression
may lead to graft loss (Bollard et al, 2003). Mortality associated with chemotherapy
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toxicity and infection has been reduced through the use of low-dose chemotherapy
and granulocyte-macrophage colony stimulating factor by preventing neutropenia
(Davis, 2001). The severity of the side-effects of chemotherapeutic agents was
increased in PTLD patients due to profound immunosuppression (Oertel et al, 2003).
In one study involving such patients, where conventional chemotherapy regimens
were used, toxicity-related mortality was 26% and infections saw 52% of patients
requiring hospitalisation (Elstrom et al, 2006). The overall response rate to
chemotherapy was 74% in this study. In another study comprising 36 paediatric SOT
patients with PTLD (fulminant n=4 and non-fulminant n=32) who had not responded
to immunosuppression reduction/withdrawal, antiviral therapy, surgery, rituximab
therapy and interferon-a, treatment with low-dose chemotherapy was implemented:
the overall response rate was 83% and two-year overall survival rate was 73% (Gross
et al, 2005). However, the outcome for patients with fulminant PTLD was poor with
all patients dying within two years (Gross et al, 2005). So, whilst chemotherapy has
improved for the treatment ofPTLD, its use remains difficult.
1.4.3.3 Anti-CD20 monoclonal antibody (rituximab) therapy
Previously used anti-B-cell monoclonal antibodies include anti-CD21 and anti-CD24
antibodies and, although these are no longer commercially available (Newstead,
2005), they were shown to be safe and relatively effective in a cohort of 57 PTLD
patients with a complete response rate of 61%, a relapse rate of 8% and a survival
rate of 46% at 1 year (Benkerrou et al, 1998). The focus is now on rituximab, a
chimeric mouse/human anti-CD20 monoclonal antibody, which was first licensed in
the UK for the treatment of follicular non-HD in March 2002 (NICE, 2006). It has
also been used for the treatment ofPTLD (Cook et al, 1999), as over 90% of tumours
are CD20-positive B-cells. Responses to rituximab can range between 60% and
100%, although such response rates have been achieved when rituximab was used in
conjunction with other forms of therapy such as immunosuppression reduction,
chemotherapy and surgery (Berney et al, 2002; Gottschalk et al, 2005; Milpied et al,
2000; Oertel et al, 2005). In a recent study on the efficacy of rituximab monotherapy,
in which immunosuppression was maintained throughout the study, the overall
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response rate to treatment at 1 year was 34.1% (Choquet et al, 2006). This highlights
the possibility that the response range given above (60% to 100%) may be an
overestimate due to the use of other forms of combined therapy. However, rituximab
has been shown to be safe with no direct treatment-related deaths reported, although
side-effects such as hypertension, purpura with myalgia and intestinal perforation
and infections at the site ofPTLD have been documented (Blaes et al, 2005; Choquet
et al, 2006; Elstrom et al, 2006).
Whilst rituximab targets CD20-positive B-cells, it does not contribute to restoring
EBV-specifie T-cell immunity and it has been shown that PTLD may reoccur in
patients treated with rituximab (Savoldo et al, 2005). It has also been postulated that
the ablation of the B-cell compartment may remove essential antigenic stimulation
for T-cells, which may in turn hamper the recovery of T-cell mediated immunity.
(Bollard et al, 2003; Straathof et al, 2002). Repeated rituximab treatment has also
been associated with a loss of CD20 expression on non-HD tumour cells, thus
making these tumour cells refractory to further treatment by this means (Davis et al,
1999). Whilst this has not been documented in the context of PTLD, it may occur
nonetheless and be responsible for the non-response of some patients to multiple
courses of rituximab.
1.4.3.4 Other therapies for PTLD
Other therapies that have been used for the treatment of PTLD include surgical
resection, radiotherapy and the use of anti-IL-6 monoclonal antibodies and IFN-a.
Each of these forms of treatment has been implemented either concurrently with a
reduction of immunosuppression or following a failure to respond to a reduction of
immunosuppression. Treatment of PTLD by surgical resection has been successful in
patients with clearly localised tumours, as has radiotherapy (Foroncewicz et al, 2006;
Newstead, 2005). Such treatment is of clear benefit where the tumour is compressing
and compromising vital organs (Gottschalk et al, 2005).
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Immunotherapeutic methods using IFN-a and anti-IL-6 antibody have both been
used with varying success. IFN-a was used as it stimulates cytotoxic T-cell and NK
cell activity and 1L-6 was targeted as it is critical in promoting B-cell growth and
hence tumour growth. A 57% (8 out of 14 patients) response rate was achieved using
IFN-a in one study, although side effects including flu-like symptoms and
neutropenia were described and approximately 30% (4 out of 14 patients) of patients
presented with signs of graft rejection, which was treatable using steroids but was
dependent on the degree of immunosuppression used (Davis, 2001; Davis et al,
1998). Five of the eight patients who responded to IFN-a treatment subsequently
died due to infection and two required further chemotherapy. A study by Haddad et
al (2001) showed that the use of a murine monoclonal anti-IL-6. antibody achieved
complete remission in five, and partial remission in three out of 12 SOT PTLD
patients, whose PLTD was refractory to reduction in immunosuppression, without
relapse at 15 to 27 months follow-up. There were no severe side effects associated
with the use of monoclonal anti-IL-6 antibody (Haddad et al, 2001). Whilst these
immunotherapeutic methods demonstrated a degree of success, no controlled trial
was carried out and the studies described here were small.
Antiviral agents, such as aciclovir, ganciclovir and valaciclovir, have also been used,
especially to prevent PTLD in EBV seronegative recipients of EBV positive grafts
(Malouf et al, 2002). In the majority of cases "donor EBV" from the graft infects the
EBV-negative recipient's B-cells, in which lytic replication ofEBV takes place. This
can give rise to EBV infection, which may result in PTLD in cells of recipient origin
but following primary infection by graft donor EBV (Haque et al, 1996). The period
of primary infection of recipient B-cells may therefore be a useful time window in
which to administer antiviral agent. These antiviral agents only suppress lytic
replication of EBV and not latent replication, which is the source of PTLD
development, although evidence of lytic reactivation has been detected in up to 80%
of tumours with 30% to 40% of tumours positive for the EBV lytic antigen and
structural glycoprotein gp350 (Tanner and Alfieri, 2001). Other reports indicate that
only approximately 1% of EBV-infected B-cells undergo lytic replication at any one
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time and therefore these agents may only be of limited use (Newstead, 2005). A
recent report by Malouf et al (2002) suggested that antiviral therapy significantly
reduced PTLD in lung and heart/lung transplant patients: none of their EBV
seronegative patients on antiviral therapy developed PTLD (15 patients - although
the patients were not receiving anti-T-cell antibodies, a factor which may have
improved their prognosis) (Malouf et al, 2002). These data concur with earlier
reports of PTLD incidence of 0.5% in a large cohort (198 patients) who received
prophylactic antiviral therapy even whilst receiving anti-T-cell therapy (OKT3, anti-
thymocyte globulin and Minnesota antilymphocyte globulin) (Darenkov et al, 1997),
which has been associated with an increase in PTLD (Burns and Crawford, 2004;
Darenkov et al, 1997). Other research groups have sought to render EBV-infected
cells sensitive to ganciclovir by inducing the expression of viral thymidine kinase (in
vivo in the context of a clinical trial in phase I/II) (Faller et al, 2001) and by inducing
lytic replication using chemotherapy (in vitro in epithelial cells) in one case (Feng et
al, 2002). Another important factor to bear in mind is that some these antiviral agents
will also be effective against CMV, which has been postulated as a PTLD risk factor
(Newstead, 2005).
1.4.3.5 Summary of PTLD therapies
All of the therapies discussed above have demonstrated variable levels of success
over time. Each of these therapies is associated with side-effects ranging from flu¬
like symptoms to neutropenia and in some cases death due to treatment toxicity or
infection. Additionally, some of these therapies may not be effective in part due to
the therapy itself but also due to patients being highly immunosuppressed and/or
presenting with advanced or progressive PTLD disease. Central to of all these
considerations is the preservation of the graft, which may be compromised when
reducing immunosuppression or using IFN-a due to GVHD. A novel approach to
tackling this therapeutic conundrum has been the development of adoptive cellular
immunotherapy, which has shown promising results without significant side-effects




Adoptive T-cell immunotherapy is a novel form of therapy for the treatment of
PTLD, which was developed to overcome the shortcomings and side-effects of all
other conventional PTLD therapies. The aim of adoptive T-cell immunotherapy is to
restore EBV-specific T-cell activity in transplant recipients, with a view to targeting
EBV positive B-cell tumours.
1.5.1 Development of adoptive immunotherapy
1.5.1.1 Rationale and development of adoptive immunotherapy
T-cells are at the centre of immunological function and these are essential in the
control of latent and persistent viruses such as HIV, CMV and EBV. The T-cell
response that controls EBV is described in section 1.3.2. However, this T-cell
response is iatrogenically suppressed after organ transplantation and it can also be
suppressed by HIV infection. Both EBV and CMV can give rise to severe disease in
organ transplant patients (as described above for EBV). HIV leads to progressive
destruction of CD4+ T-cells and incidentally profound immunosuppression. Based
on the understanding of these diseases and their interaction with the immune system,
it was postulated that restoring T-cell immunity by adoptive immunotherapy would
overcome PTLD progression. Early work into development of immunotherapy for
HIV, CMV and EBV was undertaken in a variety of animal models but in 1992
Riddell et al were the first to restore CMV-specific T-cell immunity in three BMT
patients by adoptively transferring CMV-specific CTL clones generated from their
CMV-positive BMT donors. None of the three patients developed of CMV
pneumonitis (Riddell et al, 1992). In 1994, Papadopoulos et al used bone marrow
donor PBMCs to treat five recipients who had developed EBV-associated PTLD of
donor origin. Three of the five patients treated responded well and remained disease-
free up to 16 months post-transplant, though all three patients developed GVHD
(Papadopoulos et al, 1994). Two patients died of pulmonary complications not
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thought to be attributable to treatment (Papadopoulos et al, 1994). Some
investigators progressed from PBMCs to purified T-cells but with limited success
and high rates of GVHD due to the presence of alloreactive T-cells (Heslop et al,
2004). With an increasing understanding of EBV viral immunology and PTLD,
investigators have moved on to develop novel immunotherapeutic methods using
autologous and allogeneic EBV-specific CTLs for the treatment of PTLD. PTLD is
an "ideal candidate" disease for treatment by immunotherapy as PTLD tumours are
highly immunogenic and in most cases express all EBV latent antigens (latency III),
which are targets for CTLs.
1.5.1.2 Adoptive immunotherapy in bone marrow transplant patients
One year on from Papadopoulos et aT s (1994) treatment of BMT patients with
PTLD using PBMCs, Rooney et al (1995) infused 10 BMT patients (of whom seven
had received HLA-matched donations from unrelated donors and three had received
HLA-mismatched donation from family members) with donor-derived polyclonal
EBV-specific CTLs. Of the 10 patients included in this controlled trial, three patients
had signs of uncontrolled EBV replication (presenting as elevated EBV DNA viral
load or PTLD) and seven were infused prophylactically. All three patients who
presented with uncontrolled EBV replication responded to treatment with falling
EBV viral loads, additionally none developed CTL-induced GVHD (Rooney et al,
1995). None of the seven patients infused prophylactically developed PTLD. The
CTLs infused in the patients had been genetically modified with a neomycin
resistance gene so that they could be traced post-infusion. The CTLs could be
detected up to 10 weeks post-infusion (Rooney et al, 1995). The generation of donor-
derived EBV-specific CTLs using PBMCs overcame the problems of alloractivity
and GVHD previously encountered with PBMC.
A further study was carried out by Rooney et al (1998) involving 100 patients: 39
received CTLs (generated as above) and 61 did not receive CTLs and acted as
historical controls. The patients who received the CTLs were considered to be at high
risk of PTLD following allogeneic BMT. Of the 39 patients who received autologous
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CTLs none developed PTLD, whereas 11.5% of patients in the control group
presented with PTLD (Rooney et al, 1998b). Two patients who presented with PTLD
but who had not received prophylactic CTLs were treated successfully with CTL
infusions as part of the above study (Rooney et al, 1998b). Another patient who was
treated using the same method did not respond to CTL treatment and succumbed to
PTLD (Gottschalk et al, 2001). It emerged that this patient harboured more than one
EBV strain: one strain with wild-type EBNA-3B and one strain with an EBNA-3B
deletion. Prior to the transplant only the wild-type EBNA-3B virus could be detected
in both the donor and the recipient but after transplantation both strains could be
detected in the recipient. After CTL infusion only the EBNA-3B deletion mutant
strain was detectable indicating that the CTLs had selected out this resistant strain, as
the CTLs generated from donor PBMCs were only reactive to wild-type EBNA-3B
(Gottschalk et al, 2001). Such treatment escape mutants were found in one of four
patients treated by Rooney et al (1998) (Gottschalk et al, 2001) and may therefore
contribute to some of the treatment failures observed. Whilst treatment failure has
been documented, adoptive T-cell immunotherapy has clearly been shown to be safe
and effective as long-term prophylaxis and/or treatment for PTLD following BMT as
these genetically modified CTLs have been detected up to 78 months post-infusion
(Bollard et al, 2004).
1.5.1.3 Adoptive immunotherapy in solid organ transplant patients
The situation in SOT differs somewhat from BMT, as PTLD tumours are usually of
recipient origin and therefore the use of donor cells would not be appropriate
(especially as the majority of grafts will be of cadaveric origin). PTLD tumours in
EBV-nai've recipients may also be of recipient origin as EBV infection of recipient
B-cells occurs through the transfer of EBV via the grafted organ (Haque et al, 1996).
So instead of generating CTLs from the graft donor as in BMT, autologous (to the




Autologous immunotherapy for the treatment ofPTLD in SOT also initially involved
the use of PBMCs (Todo et al, 1995) and lymphokine-activated killer (LAK) cells
supplemented with IL-2 (Nalesnik et al, 1997). However, neither of these approaches
have been developed further and much like the progression of treatment seen in
BMT, the generation of EBV-specific CTL using autologous PBMCs was favoured
(Comoli et al, 2002; Haque et al, 1998; Khanna et al, 1999; Sherritt et al, 2003). The
CTLs generated were polyclonal, as these would recognise a number of EBV
epitopes. The CTLs generated by these investigators were used not only
prophylactically (Comoli et al, 2002; Haque et al, 1998) but were also used for the
treatment of PTLD (Khanna et al, 1999; Sherritt et al, 2003). The three patients
infused prophylactically by Haque et al (1998) all showed an increase in CTL
precursor (CTLp) frequency that in turn increased after each subsequent monthly
infusion (3 infusions were administered) concurrent with a decrease in EBV DNA
viral load. The CTLp were detected up to three months after the final infusion. The
seven patients treated by Comoli et al (2002) all also showed an increase in CTLp
frequency, although only five of the seven patients had a decrease in EBV DNA viral
load. None of the patients treated during the course of both studies developed PTLD.
Both PTLD patients treated by Khanna et al (1999) and Sherritt et al (2003)
responded to initial CTL infusions and to subsequent infusions following relapse,
however one patient died of pulmonary vein necrosis and haemorrhage (Khanna et
al, 1999). Such complications had been previously described by Rooney et al (1998)
in a patient with bulky disease who required ventilation following the administration
of CTLs. A point common to all four of these studies is that the infused CTLs could
only be detected up to three months post-infusion which was in stark contrast to
CTLs infused in BMT patients that can be detected up to 78 months post-infusion
(Bollard et al, 2004). The reduced survival time of infused CTLs in SOT is highly
likely to be associated with the permanent immunosuppression required for allograft
maintenance in SOT patients.
When adoptive CTL immunotherapy was being developed it was believed that it
would not be possible to generate EBV-specific CTLs from recipients who were
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EBV-negative at the time of transplant and who were also profoundly
immunosuppressed (Khanna et al, 1999). However, this was not the case as a number
of investigators succeeded using a variety ofmethods (Comoli et al, 2002; Comoli et
al, 2005; Khanna et al, 1999; Metes et al, 2000). Another technical consideration
was the potential effect of immunosuppression on the B-cell compartment, with
regard to growth of LCLs in vitro, as these are vital in the generation of EBV-
specific CTLs. A study by Savoldo et al (2001) found that there was a median delay
of 11 days in the establishment of LCLs from immunosuppressed patients compared
to those of healthy controls, however no damage to the B-cells was noted (Savoldo et
al, 2001). The mechanism underlying this delay was not established but it increases
the overall time taken for the generation of CTLs, which could be critical as PTLD
can be aggressive and rapidly progressing. The time for LCL generation was
estimated to range from four to six weeks, followed by another four to six weeks for
the generation of CTLs (Savoldo et al, 2000), although this may be longer depending
on the number of cells required. The CTL generation time is probably the greatest
drawback of autologous adoptive immunotherapy. There is also great disparity in the
approach to the generation of CTLs as Haque et al (1998) cultured CTLs pre-
transplant and cryopreserved these cells until required, whereas both Khanna et al
(1999) and Comoli et al (2002) generated CTLs using PBMCs from SOT patients
who had either seroconverted post-transplant (Khanna et al, 1999) or who were
presenting with elevated EBV viral loads (Comoli et al, 2002). The development of
autologous EBV-specific CTLs is time consuming, and also expensive, especially in
cases where CTLs are generated prior to transplant and not required by the patient. In
order to overcome these hurdles Dr Tanzina Haque and colleagues in our laboratory
sought to develop a bank of allogeneic HLA-typed EBV-specific polyclonal CTLs
generated from healthy blood donors, from which CTLs would be used to treat
PTLD patients based on a best HLA-matched basis as discussed below.
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1.5.2 Cytotoxic T-cell bank
The development of a CTL bank would provide an easily accessible resource for the
treatment of PTLD on a best HLA-matched basis, which would overcome the time
and technical constraints surrounding the generation of autologous CTLs. To this end
a bank of more than 100 CTLs have been generated by Dr Haque and colleagues.
Cytotoxic T-cell lines were grown for up to 10 weeks in order to generate sufficient
CTLs and these were subsequently cryopreserved until required. All cell lines were
microbiologically tested, and their cytotoxicity and extracellular phenotype assessed
as described by Wilkie et al (2004). Another advantage of such a cell bank is that a
wide spectrum of HLA-types could be covered, therefore increasing the likelihood of
having suitable CTLs for a wide variety of patients. Human leucocyte antigen-
matching (HLA) was based on MHC class I matching with at least one HLA-A
match and one HLA-B match and where possible MHC class II (HLA-DR) was also
matched (Wilkie et al, 2004). The effectiveness of the CTLs was assessed by in vitro
cytotoxicity assays using as targets patients' phytohaemagglutinin (PHA) blasts and
LCLs (where available), autologous PHA blasts and LCLs, HLA-mismatched LCLs
and K562 cells that are sensitive to NK cell killing.
CTLs generated as part of the bank described by Wilkie et al (2004) have been
infused in one bowel and liver transplant patient leading to complete regression of
PTLD with CTLp detectable up to 11 weeks post-infusion (Haque et al, 2001) and in
a further eight patients (who had not responded to other treatments) in the context of
a phase I/II clinical trial, with five patients completing treatment (Haque et al, 2002).
Of the three patients who did not complete the course, two died of causes unrelated
to CTL infusions and one patient received two infusions and then declined further
treatment. Of the five patients who completed treatment, three showed complete
response with tumour regression and improved graft function and two did not
respond, possibly due to widespread disease. The patients who responded had been
free of disease from 11 months to 28 months at the time of publication. No side-
effects or toxic effects and no GVHD were noted following the CTL infusions.
Whilst this was a small-scale trial, it demonstrated the fact that adoptive
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immunotherapy using partly HLA-matched allogeneic CTLs from a cryopreserved
bank of CTLs for the prompt treatment of PTLD was feasible, functional and useful.
The encouraging results of the trial conducted by Haque et al (2002) were further
supported when CTLs from the bank were used to treat an EBV-positive primary B-
cell lymphoma in the central nervous system in a case of primary immunodeficiency
(Wynn et al, 2005). The young girl concerned received cytotoxic and antiviral
chemotherapy but remained in a comatose state. However, she achieved a full
recovery with immunotherapy with partly HLA-matched allogeneic CTLs following
which, her immunodeficiency was corrected by a non-T-cell depleted peripheral
stem cell transplant from a matched unrelated donor (Wynn et al, 2005). This case
showed that CTLs were able to cross the blood-brain barrier and effect their
cytotoxic potential unhindered and overcame the question of whether concomitant
reduction of immunosuppression in the PTLD patients was the cause of their tumour
regression.
Whilst CTLs generated as part of the cryopreserved bank established in our
laboratory have clearly been shown to be effective in vivo, little is known about their
development in vitro. It may be that a greater understanding of CTL development in
vitro would enable a wider and more effective use of such cells in vivo.
1.5.3 Adoptive immunotherapy for other EBV-associated malignancies
Cytotoxic T-cells have been used for the treatment of other EBV-associated
malignancies such as HD and NPC, as both NPC tumours and HD tumours express
latency II EBV antigens. Autologous CTLs were generated using PBMCs from
patients with NPC (Straathof et al, 2005) and HD (Rooney et al, 1998a; Roskrow et
al, 1998) but allogeneic CTLs were also generated for the treatment of HD using
healthy EBV-positive blood donors (Lucas et al, 2004). These cytotoxic T-cells have
been used safely and relatively successfully in the treatment ofNPC (Straathof et al,
2005) and HD (Lucas et al, 2004; Rooney et al, 1998a; Roskrow et al, 1998). LCLs
were used as antigen presenting cells for the generation of both HD CTLs (Lucas et
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al, 2004; Roskrow et al, 1998) and NPC CTLs (Straathof et al, 2005) although LMP-
1- (Gottschalk et al, 2003) and LMP-2A- (Gahn et al, 2001; Rooney et al, 1998a; Su
et al, 2001) transduced DCs have also been used as antigen presenting cells. LMP-1
and LMP-2 are poorly immunogenic in comparison to the EBNA-3 family antigens
to which CTLs predominantly respond following in vitro culture with LCLs, which
may be why more specific methods of CTL growth were developed using other cells
besides LCL.
Until recently it was believed that EBNA-1 was in effect "immunologically
invisible" to CD8+ T-cells as it contains a glycine-alanine repeat that prevents its
proteasomal degradation (Levitskaya et al, 1995; Levitskaya et al, 1997) but also
prevents its translation (Yin et al, 2003). However it has now been reported that
EBNA-1 can be presented via MHC class I and recognised by CD8+ T-cells (Lee et
al, 2004; Voo et al, 2004). These CD8+ T-cells could recognise EBNA-1 expressed
by LCLs. In future it may therefore be possible to generate CTLs specific for LMP-1,
LMP-2 but also EBNA-1. If EBNA-1-specific CTLs could be generated and
expanded in vitro this could potentially be of great benefit in BL where tumour cells
only express EBNA-1, but also in other malignancies. Genetic modifications of both
T-cells and antigen presenting cells have also been carried out to improve LMP-1
and LMP-2 recognition. LMP-1 has toxic effects on antigen presenting cells
hindering the development of LMP-1-specific cytotoxic T-cells. A non-toxic non¬
functional deletion mutant form of LMP-1 was generated by Gottshalk et al (2003)
and successfully used to generate LMP-1-specific cytotoxic T-cells. LMP-1-specific
CTLs would be of particular interest for the treatment of HD, where LMP-1 is one of
the principal antigens expressed. Genetic modification of PBMCs and subsequent
generation of effective cytotoxic T-cell has also been developed. The transduction of
TCRs from LMP-2-specific clones into PBMCs gave rise to cytotoxic T-cells
capable of lysing LCLs expressing LMP-2 (Jurgens et al, 2006). The generation of






PTLD has been successfully treated with cellular adoptive immunotherapy using
EBV-specific CTLs. However, little is known about the development of these CTLs.
This project therefore sought to establish how the CTLs developed in terms of their
growth, phenotype and T-cell receptor (TCR) repertoire diversity. It also sought to
establish which cytolytic molecules were present in the CTLs and which pathways
they employed to effect their cytotoxic potential. It is hoped that this basic
characterisation of CTLs will reveal features that can potentially enhance the clinical
effects of CTLs.
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Chapter 2
Materials and methods
2.1 Details of suppliers and manufacturers
2.2 Tissue culture methods
2.3 Molecular methods
2.4 Fluorescence associated cell sorting
2.5 Western blotting
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Oakley Court, Kingsmead Business Park, London
Road, High Wycombe, HP11 1JU, UK
21 Between Towns Road, Cowley, Oxford,
0X4 3LY, UK
Rudolf-Wissell-Stra(3e 30, 37079 Goettingen,
Germany









4560 Horton Street, Emeryville, 94608-2926
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P.O. Box 114 Smestad, N-0309, Oslo, Norway
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Leicestershire, LEI 1 5RG, UK
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3 Fountain Drive, Inchinnan, Business Park,
Paisley, PA4 9RF, UK
Waterfield, Tadworth, Surrey, KT20 5HQ, UK
Almac House, Church Lane, Bisley, Surrey,
GU24 9DR, UK
447 March Road, Ottawa, Ontario, K2K 1X8,
Canada
5th floor, 86 Jermyn Street, London, SW1Y 6AW,
UK
Nalge (Europe) Ltd, Unit la, Thorn Business Park,
Hereford, HR2 6JT, UK
Wade Road, Basingstoke, RG24 8PW, UK
Chalfont Road, Seer Green, Beaconsfield,
HP9 2FX, UK
Acquired by Amersham Biosciences, Amersham
Place, Little Chalfont, HP7 9NA, UK
Delta House, Chilworth Science Park,
Southampton, SO 16 7NS, UK
Qiagen House, Fleming Way, Crawley, RH10
9NQ, UK
19 Barnton Lane, Abingdon Science Park,
Abingdon, Oxon, 0X14 3NB, UK
Roche Diagnostics Ltd, Bell Lane, Lewes,
BN7 1LG, UK
Unit 37, Woolmer Way, Bordon, GU35 9QE, UK
Monarch Way, Belton Park, Loughborough,
LE115XG, UK
Sigma-Aldrich Company Ltd, The Old Brickyard,
New Road, Gillingham, SP8 4XT, UK
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Sigma-Aldrich House, Homefield Business Park,
Homefield Road, Haverhill, CB9 8QP
Coatbridge Business Centre, 204 Main Street,
Coatbridge, ML5 3RB, UK
777 West Broadway, Suite 808, Vancouver,
V5Z 4J7, BC, Canada
11011 N. Torrey Pines Road, La Jolla,
California CA92307, USA
Barloworld Scientific Ltd. Beacon Road, Stone,
ST15 OSA, UK
Barloworld Scientific Ltd. Beacon Road, Stone,
Staffordshire, ST15 OSA, UK
The Ringway Centre, Edison Road, Unit 5,
Basingstoke, UK
Unit 1, Trinity Hall Farm Estate, Nuffield Road,
Cambridge, CB4 1TG, UK
Merck House, Poole, BH15 1TD, UK
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2.2. Tissue culture methods
2.2.1 Tissue culture consumables, chemicals, media and equipment
2.2.1.1 Tissue culture consumables
Tissue culture flasks, 96-well U-bottomed plates, 48-well plates and cryovials were
supplied by Nunc (Nalge Ltd, Hereford, UK). All other plasticware was supplied by
Greiner-Bione (Leighton Buzzard, UK), SLS (Coatbridge, UK) and Sterilin (Stone,
UK). LP-2 y-counter tubes were supplied by Thermo (Basingstoke, UK).
2.2.1.2 Chemicals and media
All media used in this section are detailed in table 2.1.
Media
names
Medium L-Glut P/S NEAA FBS BrdU
10% RPMI RPMI 2mM lOOIU/ml X 10% (v/v) X
20% RPMI RPMI 2mM lOOIU/mi X 20% (v/v) X
10% DMEM
with BrdU
DMEM 2mM lOOIU/ml 1 % (v/v) 10% (v/v) 15pg/m 1
10% DMEM DMEM 2mM lOOIU/ml l%(v/v) 10% (v/v) X
DC medium RPMI 2mM 1 OOIU/ml X 10% (v/v) X
HBSS HBSS X X X X X
RPMI RPMI X X X X X
Supplier Invitrogen Invitrogen Invitrogen Sigma InvitrogenHarlan Sigma
Table 2.1: Tissue culture media used (Invitrogen, Paisley, UK; Sigma, Gillingham,
UK and Harlan, Loughborough, UK). Abbreviations used: Rosewell Park Memorial
Institute (RPMI), Dulbecco's Modified Essential Medium (DMEM), Dendritic cell
medium (DC medium), Hank's Balanced Salt Solution (HBSS), L-Glutamine (L-Glut),
Penicillin/Steptomycin (P/S), Non-Essential Amino Acids (NEAA), Foetal Bovine
Serum (FBS), Bromodeoxyrudine (BrdU).
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Histopaque®-1077 was purchased from Sigma and unless otherwise stated, all
chemicals were purchased from Sigma. Radioactive chromium - Chromium-51 (5lCr)
- was purchased from Amersham Biosciences (Little Chalfont, UK) as sodium
chromate in sterile sodium chloride solution at 37MBq/ml (MBq - Mega Becquerels)
or lmCi/ml (Ci - Curie, ml - millilitre). The specific activity of the chromium was
>9.25GBq (Giga Becquerels)/mg of chromium or >250mCi/mg of chromium. Sterile
Phosphate Buffered Saline (SPBS) (137mM NaCl, 2.7mM KC1, lOmM Na2HP04,
2mM KH2PO4 in dH20, made to pH7.4 and autoclaved for 15 minutes at 121 °C) was
made in-house by Ms Deborah Allen, The University of Edinburgh, RDSVS,
Veterinary Pathology, Summcrhall, Edinburgh, UK.
2.2.1.3 Equipment used
All centrifugation steps were carried out using a Sanyo MSE Mistral 3000E (Rotor
43124-129) or a temperature controlled Sanyo MSE Mistral 3000i centrifuge (Rotor
43124-129) (Loughborough, UK). Centrifugation steps, where ? 1 Cr was involved,
were carried out using a Beckman Coulter TJ-6 centrifuge (High Wycombe, UK).
Counts per minute (cpm) of y-radiation released by chromium-labelled target cells
were measured using a Perkin Elmer 1480 Wizard 3" Automatic Gamma Counter
(Perkin Elmer, Beaconsfield, UK).
2.2.2 Cell culture - PBMC. CTL and LCL
2.2.2.1 PBMC isolation and HLA-typing
PBMCs were isolated from buffy coat fractions of whole blood taken from healthy
blood donors at the Scottish National Blood Transfusion Services, Edinburgh, UK
(SNBTS). The HLA class I and class II types of the donors were determined by
serology and the polymerase chain reaction (PCR) respectively and this was done by
the SNBTS. Buffy coats were diluted 1:2 in HBSS at room temperature and
subsequently overlayed on an equal volume of Histopaque®-1077 and centrifuged
for 20 minutes at 1200g at 20°C. The PBMC interface was collected and transferred
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to 10ml to 20ml of 10% RPMI. Numbers and viability of PBMC were established by
trypan blue exclusion as described below.
2.2.2.2 Cell counts by trypan blue exclusion
Cells were counted using the trypan blue exclusion method, where a 1:1 mixture of
cell suspension and 0.4% trypan blue (MP Biomedicals and Sigma) was applied to a
haemocytometer and both the live (unstained) and dead cells (stained) were counted
in the 25 central squares. This number was multiplied by the dilution factor of cells
and trypan blue and multiplied by 104 to give the number of cells per ml of cell
suspension. Where the volume of cells added to trypan blue was not in a 1:1 ratio the
dilution factor was modified accordingly for the calculations.
2.2.2.3 LCL establishment and maintenance
EBV-immortalised LCLs used were initially setup and grown by the Cancer
Research UK group, The University of Edinburgh, Laboratory for Clinical and
Molecular Virology, Summerhall, Edinburgh, UK. Briefly, LCLs were established
by mixing a loosened cell pellet of 2xl06 PBMC to 100 microlitres (pi) of in-house
EBV B958 virus preparation (EBV B958 virus preparation was carried out by the
Cancer Research UK group) and lOpl of lOOpg/ml cyclosporine A (Sandoz). The
total volume was made up to 1ml with 10% RPMI and transferred in one well of a
48-well plate. PBMCs were incubated at 37°C in a humidified 5% CO2 atmosphere.
Cultures were fed weekly, split when required and cells transferred to tissue culture
flasks upon establishment of the culture. LCLs were transferred to new tissue culture
flasks at least once a month.
2.2.2.4 LCL y-irradiation
LCLs were y-irradiated with 40 Grays using a Gammacell 3000 Elan irradiator as
source of 137Caesium (MDS Nordion). An irradiation indicator sticker was used at
each irridation to ensure that the LCLs had been subjected to sufficient radiation (ISP
Europe, Tadworth, Surrey, UK).
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2.2.2.5 EBV-specific CTL establishment and maintenance
EBV-specific CTLs were generated using fresh or cryopreserved PBMCs isolated
from buffy coats and corresponding autologous LCLs following the method
described by *. Briefly, y-irradiated autologous LCLs were used to stimulate PBMCs
at a 40:1 PBMC:LCL ratio. The PBMCs and LCLs at 40:1 ratio were resuspended at
a concentration of lxlO6 cells/ml in 20% RPMI. 10 days after initial stimulation,
CTLs were re-stimulated using y-irradiated autologous LCLs at a 4:1 CTL:LCL
ratio. 20IU/ml of recombinant interleukin-2 (IL-2) (Chiron, USA) were added to the
culture 14 days after the initial stimulation and every 3 days thereafter. At each
weekly stimulation, the CTL concentration was adjusted to lxl06 cells/ml and the
CTL were transferred to new tissue culture flask.
2.2.2.6 Cryopreservation of cells
The same cryopreservation protocol was observed for all cell types. Briefly, all cells
were centrifuged into a pellet and the supernatant discarded. The cell pellet was
loosened and resuspended in 1ml to 1.5ml of freezing medium (10% v/v Dimethyl
sulphomethoxasol (DMSO), 90% v/v FBS) and transferred to 1.8ml cryovials. Once
in cryovials, cells were stored at -80°C and then transferred to liquid nitrogen for
long-term storage.
2.2.2.7 Recovery of cryopreserved cells
Cells were thawed in a 37°C waterbath and transferred dropwise to 25ml of warm
wash medium (HBSS or RPMI). Where CTLs were thawed these were added
dropwise to 25ml of warm 10% RPMI. The cells were centrifuged at 300g for 7
minutes at 20°C and the supernatant discarded. The cells were resuspended in 10ml
to 30ml of 20% RPMI for CTLs and 10% RPMI for all other cell types and
subsequently counted by the trypan blue exclusion method (as described in section
2.2.2.2)
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2.2.3 Chromium release cytotoxicity assays
2.2.3.1 Standard 4-hour cytotoxicity assay
a) Target cells
0.5x106 target cells - autologous LCL, HLA-mismatched LCL, K562 cells (sensitive
to NK cell activity) - were centrifuged at 300g for 7 minutes and the supernatant was
discarded. The target cell pellets were resuspended in the residual supernatant. SOgCi
51Cr were added to each target cell type and these were incubated for 1 hour at 37°C
(the volume of 5lCr corresponding to 50pCi was determined at each assay due to the
daily decay of chromium - see chapter 7 appendix A2). The target cells were washed
twice with 12ml ofRPMI or HBSS and centrifuged at 300g for 5 minutes. The target
cells were then resuspended in a final volume of 5ml 20% RPMI to give a final
concentration of lxl05 cells/ml.
b) Effector cytotoxic T cells
Cytotoxic T cells were resuspended in 20% RPMI at 2xl06cells/ml with 0.6ml of
CTL suspension required per target cell triplicate. The 96-well U-bottomed plates




Triplicate 1 Triplicate 2 Triplicate 3 Triplicate 4
(^) 20:1 E:T (^) 10:1 E:T 5:1 E:T (^) Spontaneous Maximum
Figure 2.1: Set up of 96-well plate for 4-hour chromium-release assay.
200pl of CTL suspension at 2x106 cells/ml was added to each pink well of a 96-well
U bottomed plate. lOOpl of 20% RPMI were added to all the wells in rows B (yellow
row) and C (blue row). The CTL suspension was diluted 2-fold by taking 1 OOpl of
CTL suspension from row A and mixing it with 20% RPMI in row B. This was
diluted 2-fold again by taking lOOpl from row B and adding it to row C. lOOpl from
row C were discarded. The final volume of cell suspension in all wells at each
dilution was 1 OOpl and the final CTL concentration was 2x106 cells/ml in row A,
lxlO6 cells/ml in row B and 0.5x106 cells/ml row C.
c) Controls
lOOpl of 20% RPMI only were added to wells in row D (green wells) and a 1 OOpl of
1% v/v Triton® X-100 were added to wells in row E (red wells). Row D represented
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the spontaneous release of chromium by the targets cells and row E represented the
maximum release of chromium by the targets cells over the 4-hour period.
d) 4-hour incubation setup
lOOpl of chromium-labelled targets at lxl O5 cells/ml were added to all the wells of
the appropriate triplicate. Thus, the effector:target ratio in row A was 20:1, in row B
10:1 and row C 5:1. The effector and target cells were incubated for 4 hours at 37°C.
Thereafter, the 96-well plate was centrifuged for 5 minutes at 300g. lOOpl of
supernatant was collected from each well and transferred to LP2 y-counter tubes. The
tubes were loaded into y-counter racks and the chromium released was measured
using the automatic gamma counter. The percentage of specific cell lysis was
measured using the following formula:
% cell specific lysis = (cpm test release - cpm spontaneous release) ^ qq
(cpm maximum release - cpm spontaneous release)
for example: 33.3% cells lysis = (1229.9 cpm- 459.6 cpm) x 100
(2772.5 cpm- 459.6 cpm)
2.2.3.2 4-hour cytotoxicity assay using concanamvcin A, brefeldin A, ethylene
glycol-bis (B-aminoethvletherl-N.N.N'.N'-tetraacetic acid
a) Preparation ofCMA. BFA and EGTA
Concanamycin A (CMA) was dissolved in DMSO to a concentration of 100pM and
stored at -20°C. Brefeldin A (BFA) was dissolved in 100% biochemical grade
ethanol (BDH, Poole, UK) to a concentration of 40mM and also stored at -20°C.
Both CMA and BFA were stored in small aliquots to avoid multiple freeze/thawing
cycles. Ethylene glycol-bis (P-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA)
was dissolved in distilled water to a concentration of 300mM with the addition of
sodium hydroxide to increase its pH and solubility. The final pH of EGTA ranged
from pH 8 to 8.3. EGTA was stored at room temperature and was not kept for more
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than one month. pH was measured using a calibrated Hanna Instrument HI8521 pH
meter.
b) Pre-incubation of the effector CTLs with BFA, CMA and EGTA
CMA, BFA and EGTA were added to the CTLs at final concentrations of lOnM
CMA, 40pM BFA and 3mM EGTA. CMA and BFA stock solutions were diluted
1:100 and 1:10 in 20% RPMI respectively and lpl added to 99pl of CTL suspension
in all wells to achieve the final concentrations shown above, lpl of 300mM EGTA
was added to CTLs in all wells. The 96-well plate was subsequently incubated for 2
to 3 hours at 37°C in 5% CO2.
c) Target cells
Only autologous LCLs were used as targets in this cytotoxicity assay. These target
cells were prepared in the same way as described in section 2.2.3.1 a) except that the
number of cells used was lxlO6 to which lOOpCi of 51Cr were added. Following a 1
hour incubation with 5lCr the LCLs were washed twice with RPMI or HBSS as
previously described in 2.2.3.1 a) and finally resuspended in 10ml 20% RPMI. lOOpl
of these target cells were added to the CTLs as described below.
d) 4-hour incubation setup
The chromium-labelled autologous LCLs were added to the CTLs, pre-incubated
with CMA, BFA and EGTA, as described in section 2.2.3.1.d). The remainder of the
chromium release assay was performed as in section 2.2.3.1 d).
2.2.4 Recombinant vaccinia virus constructs
All work carried out using recombinant vaccinia virus constructs was done following
appropriate training in the handling of genetically modified organisms. All materials
that were in contact with recombinant vaccinia virus constructs were soaked in 1%
w/v Virkon (VWR, Poole, UK) solution and/or treated with UV light to inactivate
the virus.
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2.2.4.1 Recombinant vaccinia virus constructs
Recombinant vaccinia virus constructs were obtained from Professor Rickinson,
Cancer Research UK Institute for Cancer Studies, University of Birmingham,
Birmingham, UK. The recombinant vaccinia virus constructs express the following
EBV-antigens: EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, LMP-1,
LMP-2, LP and MA. A recombinant vaccinia virus construct not expressing an EBV
antigen was included as a control in all experiments where these constructs were
used.
2.2.4.2 TK-143B cells
TK-143B cells were purchased from the European Collection of Cell Culture
(ECACC 91112502). TK-143B cells are adherent human bone osteosarcoma cells,
which are thymidine kinase deficient but grow in DMEM with BrdU.
2.2.4.3 TK-143B cell bulk culture
Growing TK-143B cells were split by removing the 10% DMEM with BrdU cell
culture medium, washing the monolayer with 10ml of 0.02% v/v versene, adding
5ml of trypsin (Invitrogen, Paisley, UK) and 5ml of 0.02% v/v versene and
incubating for 3 to 5 minutes at 37°C in a 5% CO2 atmosphere to detach the cells
from the flask surface. Cells were decanted into a 50ml falcon tube and 20ml HBSS
added to the flask to collect any remaining cells and added to the 50ml falcon tube.
The cells were centrifuged at 300g for 7 minutes at 20°C and the supernatant was
discarded. The cells were resuspended in 10ml 10% DMEM with BrdU and counted.
Cells were seeded into fresh flasks - 5-6x106 cells for next day confluence and 2-
3x106 cells for confluence in 2 to 3 days - and 50ml growth medium added.
2.2.4.4 TK-143B cell culture in 6-well plates
TK-143B cells were also seeded into 6-well plates for vaccinia virus construct
titration. For confluence to be achieved the next day, cells were seeded at 3-
5xl0"Vwell; for confluence to be achieved in 2-3 days 1x10s cells were seeded/well,
and for confluence to be achieved in 4-5 days, 5x104 cells/well were seeded. Three
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ml of growth medium were added to each well and the plate was incubated at 37°C
in a 5% CO2 atmosphere.
2.2.4.5 Recombinant vaccinia virus infection of TK-143B cells and harvest of
recombinant vaccinia virus
10% DMEM with BrdU culture medium was removed from confluent monolayer of
TK-143B cells. The cells were overlayed with the appropriate vaccinia virus
construct (2xl07pfu/3.5ml SPBS) and incubated at 37°C in a 5% CO2 for 2 hours
with gentle rocking every 30 minutes to ensure an even spread of virus over the cell
monolayer. 45ml of 10% DMEM were added after the incubation and the cells were
incubated for a further 3 to 4 days. After this incubation the cells began to round up
and detach. Any remaining adherent cells were dislodged by gentle agitation and the
cell suspension was poured into a 50ml falcon and centrifuged for 15 minutes at
800g. The supernatant was discarded. The cell pellet was resuspended in 1ml SPBS.
The cell suspension was transferred to a 15ml falcon, ensuring that the tube was
tightly sealed and covered with parafilm. The cells were freeze/thawed 3 times in
liquid nitrogen/37°C waterbath and before each refreezing the cells were vortexed
for 30 seconds. After freeze/thawing the cells were centrifuged for 5 minutes at
1200g. The supernatant was collected and transferred to a fresh 15ml falcon,
aliquoted and stored at -80°C until required.
2.2.4.6 Recombinant vaccinia virus titration
900pl of SPBS was added to 7 wells of a 24-well tissue culture plate and 1 OOpl of
recombinant vaccinia virus was added to one well of the plate. 10-fold dilutions of
the recombinant vaccinia virus were prepared in the remaining wells - 10"' to 10"7.
10% DMEM with BrdU culture medium was removed from a 6-well plate with
confluent TK-143B cells and 400pl of recombinant vaccinia dilutions (10° to 10"7
prepared above) were added to the 6-well plate as shown in figure 2.2. A SPBS
control was also included.
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Figure 2.2: Titration of recombinant vaccinia virus.
The 6-well plate was incubated for 2 hours at 37°C in a 5% CO2 atmosphere with
gentle shaking every 30 minutes. 3ml of 10% DMEM were added to the wells
thereafter and the plate was incubated for 3 days. 10% DMEM was removed and 2ml
of 4% v/v normal buffered formaline (NBF) (made from 10% stock, BDH) was
added and left for 30 minutes and then poured off. Enough 1% w/v Toludene blue
(lg toludene blue, 10ml ethanol, 90ml dH20) was added to cover each well and left
for 20 to 30 minutes. This was discarded and each well was washed with 2ml of
PBS. The plate was left to dry and the plaques counted to calculate the recombinant
vaccinia virus titre.
2.2.4.7 Vaccinia virus infection of dendritic cells
a) Monocyte isolation from PBMC
i) Masnetic labelling ofnon-monocvtic cells
Dendritic cells were grown from monocytes isolated from fresh or frozen PBMC
using a Monocyte Isolation Kit II (Milteyni Biotech). The isolation of monocytes
was performed following the manufacturer's instructions. Briefly, PBMCs were
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washed in 1-2 ml of MACS buffer (SPBS, 0.5% w/v BSA, 2mM EDTA) per 107
total cells and centrifuged at 4°C for 10 minutes at 300g. The supernatant was
aspirated and the cell pellet was resuspended in 30pl MACS buffer per 107 total
cells. lOpl of Fc receptor (FcR) blocking reagent and lOpl of biotin antibody cocktail
(against CD3, CD7, CD16, CD19, CD56, CD123 and glycophorin A) were added per
107 total cells, mixed well and incubated at 4°C for 15 minutes. 30pl of MACS
buffer and 20pl of anti-biotin microbeads were added per 107 total cells, mixed well
and incubated at 4°C for 15 minutes. Cells were washed by adding lOx labelling
volume of MACS buffer and centrifuged at 4°C for 10 minutes at 300g. The
supernatant was discarded and the cells were resuspended in 500pl MACS buffer.
ii) Magnetic cell separation
The MACS columns and MACS magnetic separator were chosen following the
information given in table 2.2, which is adapted from the protocol supplied with the
monocyte isolation kit.
Column Max number of labelled cells Max number of total cells Separator
MS 107 2x108 MiniMACS
FS 108 2xl09 MidiMACS
Table 2.2: Capacity of MACS columns and magnetic separators
The appropriate column was placed in the magnetic field of a suitable MACS
separator dependant on cell number. The column was prepared by rinsing with the
appropriate volume ofMACS buffer: MS column - 500pl and FS column - 3ml. The
cell suspension prepared above was applied to the column and the unlabelled
monocyte-rich fraction was collected. The column was washed 3 times with MACS
buffer: MS column - 3x500pl and FS column - 3x3ml. The washings were also
collected and formed part of the unlabelled monocyte-rich fraction. The column was
removed from the MACS separator and MACS buffer was added to the column -
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MS column - 1ml and LS column - 5 ml. The magnetically labelled non-monocyte
fraction was flushed out of the column using the plunger provided with the column.
The purity of the labelled and unlabelled fraction was assessed by FACS staining as
described in section 2.4.
b) Dendritic cell culture
The monocytes isolated above were resuspended at lxlO6 cells/ml in DC medium
and interleukin (IL-4) and granulocyte-macrophage colony stimulating factor (GM-
CSF) were added to the monocytes at 40ng/ml (R&D Systems, Abingdon, UK). The
cells were cultured for 6 days with the addition DC medium when required. The
phenotype of the cells was established by FACS staining as described in section 2.4.
c) Infection of dendritic cells with recombinant vaccinia virus
104 dendritic cells generated above were infected with one recombinant vaccinia
virus in 1 well of 96-well plate at a multiplicity of infection of 10:1 in 200pl of DC
medium and incubated overnight at 37°C in a 5% CO2 atmosphere. This was done
for all 10 recombinant vaccinia virus constructs, including the control construct. 104
autologous LCL were also included in one well of the plate. The infected dendritic
cells and the LCL were transferred to 15ml falcon tubes the next day and washed in
10ml HBSS or RPMI and centrifuged at 300g for 7 minutes at 20°C. The supernatant
was discarded and the cell pellet loosened. The infected dendritic cells and LCL were
ready to be used as target cells in the cytotoxicity assay described below.
2.2.4.8 4-hour chromium release cytotoxicity assay
a) Target cells
10 pCi of 3lCr were added to each well of infected dendritic cells and to the LCLs
and these were incubated for 1 hour at 37°C. These target cells were washed twice as
described in section 2.2.3.1 a) and resuspended in a final volume of 300pl 20%
RPMI.
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b) Effector cytotoxic T-cells
Autologous CTLs were used as effector cells. 4xl06 CTL were resuspended in 4ml
20% RPMI and lOOpl of CTL suspension was added to 36 wells of a 96-well U-
bottomed plate. The assay was carried out at an E:T of 10:1.
c) Four-hour incubation step
lOOpl of each of the chromium-labelled target cells were added to lOOpl CTL in
triplicate wells. lOOpl of chromium-labelled target cells were also added to lOOpl 1%
v/v Triton® X-100 in triplicate wells giving the maximum release chromium release
by the target cells, and to lOOpl 20% RPMI in triplicate giving the spontaneous
release of chromium by the target cells. The effector and target cells were incubated
for 4 hours at 37°C and the remainder of the assay was carried out as described in
section 2.2.3.1 d).
2.2.5 Cell separations - CD4+ T-cell and CD56+ cell selection
CD4+ T-cells were positively selected from fresh and frozen PBMCs using three
different cell separation methods - MACS (Miltenyi Biotech), Dynal Dynabeads
with DETACHaBEAD (Dynal) and EasySep (StemCell Technologies). All three
methods were used following the manufacturer's instructions and the purity of all cell
fractions generated in all three methods was assessed by FACS staining as described
in section 2.4. CD56+ cells were positively selected using EasySep.
2.2.5.1 MACS
CD4+ T-cell selection was performed following the manufacturer's instructions. The
cells, buffer and MACS kit were kept at 4°C throughout the CD4+ T-cell selection.
a) Magnetic labelling of CD4+ T-cells
Briefly, PBMCs were washed in l-2ml of MACS buffer per 107 total cells and
centrifuged at 4°C for 10 minutes at 300g. The supernatant was aspirated and the cell
pellet was resuspended in 80pl MACS buffer per 107 total cells. 20pl of CD4
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MicroBeads were added per 107 total cells, mixed well and incubated at 4°C for 15
minutes. The cells were thereafter washed by adding l-2ml of MACS buffer per
107cells and centrifuged at 4°C for 10 minutes at 300g. The supernatant was
aspirated and the cell pellet was resuspended in 500pl of MACS buffer.
b) Magnetic separation ofCD4+ T-cells
The magnetic separation of labelled CD4+ T-cells was carried out following the
same protocol as described in section 2.2.4.7 a) ii), except that the fraction collected
when the column was placed in the magnet was the unlabelled non-CD4+ T-cells and
the fraction flushed out of the column once the column was removed from the
magnet was the labelled CD4+ T-cells. The CD4+ T-cells were centrifuged out of
MACS buffer for 7 minutes at 300g at 4°C. The supernatant was discarded and the
cells resuspended in 10% RPMI and counted by trypan blue exclusion as described
in section 2.2.2.2.
2.2.5.2 Dynal Pvnabeads CD4 with DETACHaBEAD
CD4+ T-cell selection was performed following the manufacturer's instructions,
except that FBS was used instead of FCS. The cells, buffer and Dynal Dynabeads
CD4 and DETACHaBEAD kit components were all kept at 4°C throughout the
CD4+ T-cell selection.
a) Dvnabeads CD4 washing procedure
The Dynabeads were resuspended by vortexing and the required volume was
transferred to a 5ml polystyrene round-bottom tube. 72pl of Dynabeads were
required for 1ml of PBMC suspension. 1ml of SPBS/2% FBS buffer (SPBS, 2% v/v
FBS) was added to the Dynabeads and mixed well. The 5ml polystyrene round-
bottom tube containing the beads was placed in the Dynal MPC magnet for 30
seconds and the supernatant aspirated thereafter. The washed Dynabeads were
resuspended in a volume of SPBS/2% FBS buffer equal to the volume required at the
start of the washing procedure.
81
CHAPTER 2 MATERIALS AND METHODS
b) PBMC preparation
Fresh PBMC were resuspended at 0.5x107 total cells/ml in SPBS/2% FBS buffer and
were ready to use.
c) Positive isolation of CD4+ T-cells from PBMC
The PBMC prepared above were cooled to 2-8°C, added to the washed Dynabeads
CD4 and incubated for 20 minutes at 2-8°C with both gentle tilting and rotating. The
rosetted CD4+ T-cells were then isolated by placing the 5ml polystyrene round-
bottom tube with the PBMC and the Dynabeads CD4 in the Dynal MPC magnet for
2-3 minutes. The supernatant was aspirated and the rosetted CD4+ T-cells remained
attached to the side of the test tube by the Dynal MPC magnet. The rosetted CD4+ T-
cells were washed 4-5 times in SPBS/2% FBS buffer. Finally, the rosetted CD4+ T-
cells were resuspended in lOOpl RPMI/1%FBS solution (RPMI, 1% v/v FBS). These
CD4+ T-cells were bound to the Dynabeads CD4.
d ) Detachment ofDynabeads CD4 from CD4+ T-cells
lOpl of DETACHaBEAD were added to every lOOpl of rosetted CD4+ T-cells and
incubated for 45 to 60 minutes at room temperature with gentle mixing. The tube
was subsequently placed in the Dynal MPC magnet for 2 minutes. This released the
CD4+ T-cells into the supernatant. These were transferred to a fresh test tube. The
beads remaining in the tube placed in the magnet were washed 2-3 times with 500pl
RPMI/1%FBS and the supernatant was collected. Finally, the detached CD4+ T-cells
were washed in 10ml RPM1/1%FBS and centrifuged for 7 minutes at 200g to remove
any remaining DETACHaBEAD. The supernatant was aspirated and the CD4+ T-
cells resuspended in 10% RPMI and counted by trypan blue exclusion as described
in section 2.2.2.2.
2.2.5.3 EasySep
CD4+ T-cells were positively selected from fresh or frozen PBMC and CD56+ cells
from frozen CTLs. The positive selection for both CD4+ T-cells and CD56+ cells
was performed following manufacturer's instructions.
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a) Cell suspension preparation tPBMCs and CTLs)
Cells were resuspended in EasySep buffer (SPBS, 2% v/v FBS, ImM EDTA) at a
concentration of lxlO8 cells/ml. Where 107 or less cells were used, these were
resuspended in lOOpl EasySep buffer. The PBMC suspension was made up in a 5ml
polystyrene round-bottom tube.
b) CD4+ T-cell and CD56+ cell selection
CD4+ T-cell or CD56+ cell EasySep positive selection cocktail (contains a
combination antibodies bound to bispecific tetrameric antibody complexes which are
directed against CD4 or CD56 and dextran) was added to the PBMC suspension at
lOOpl/ml of cell suspension. The positive selection cocktail and the PBMC were well
mixed and incubated at room temperature for 15 minutes. The EasySep magnetic
nanoparticles were vortexed to be in a uniform suspension and 50pl of nanoparticles
were added to 1ml of cell suspension. The cells and nanoparticles (magnetic dextran
iron particles in water) were mixed and incubated for 10 minutes at room
temperature. The volume of the cell suspension was brought up to 2.5ml using
EasySep buffer and mixed gently. The tube was placed in the magnet for 5 minutes.
The supernatant was thereafter poured out in one continuous movement. The tube
was removed from the magnet, 2.5ml EasySep buffer added to the tube and the cells
mixed gently. The tube was placed back in the magnet for 5 minutes. The final 2
steps where EasySep buffer was added to the tube and placed in the magnet were
repeated once more. Finally the cells remaining in the tube, after pouring out the last
2.5ml of EasySep buffer, were the selected cells. These were resuspended in 10%
RPMI and counted by trypan blue exclusion as described in section 2.2.2.2.
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2.3 Molecular methods
2.3.1 Consumables, kits, reagents and equipment used
2.3.1.1 Molecular methods' consumables
96-well U-bottomed plates were supplied by Nunc and all other plasticware was
supplied by Greiner-Bione, SLS and Sterilin. Thin-walled 0.2ml PCR tubes and 24-
well PCR plates were supplied by Anachem.
2.3.1.2 Kits, reagents and PCR primers
Qiashredder spin columns and RNeasy Mini Kit were both purchased from Qiagen.
P-mercaptoethanol and multi-purpose agarose were supplied by Sigma. Biochemical
grade ethanol and nuclease-free water were supplied by BDH. Primers were obtained
from Sigma-Genosys. ThermoScript™ Reverse Transcriptase cDNA synthesis kits
and 100 base pair (bp) ladder were both purchased from Invitrogen and the RQ1
RNase-Free DNase kits were purchased from Promega. Ethidium bromide was
supplied by Fisher Scientific. All components required for T-cell receptor
spectratyping PCR reactions were AmpliTaq Gold® reagents purchased from
Applied Biosystems and T-cell receptor spectratyping size standard GeneScan™-500
LIZ™ and Hi-Di™ formamide were also purchased from Applied Biosystems.
2.3.1.3 Equipment used
All centrifugation steps were carried out using an MSE Microfuge (Sanyo). Reverse-
transcriptase PCR (RT-PCR) reactions were carried using a T3 Thermalcycler
(Biometra) and Robocycler 96 (Stratagene). T-cell receptor spectratyping was carried
out on an ABI Sequencer 3730 (Applied Biosystems) at the School of Biological
Sciences Sequencing Services, The University of Edinburgh. Spectratyping analysis
was performed using GeneMapper Software v3.7 from Applied Biosystems.
84
CHAPTER 2 MATERIALS AND METHODS
2.3.2 RNA/cDNA methods
2.3.2.1 RNA extraction
All cells from which total ribonucleic acid (RNA) was to be extracted were washed
in SPBS twice before being pelleted and either used immediately or stored at -20°C
until required. Total RNA was extracted using an RNeasy Mini Kit and Qiashredder
spin columns. All buffers mentioned below were included in the RNeasy Mini Kit.
Cell pellets were loosened and resuspended in proprietary RLT buffer (which
contains guanidine thiocyanate that has a strong but temporary effect on protein
denaturation) supplemented with [3-mercaptoethanol (which is a reducing agent that
irreversibly denatures RNases by reducing disulfide bonds and destroying native
conformation of the enzymes) (lOpl P-mercaptoethanol/ml of RLT buffer) - 350pl
for <5x106 cells and 600pl for 5-10xl06 cells. The RLT buffer mixed with [3-
mercaptoethanol was stored at room temperature and kept for no more than 2 weeks.
This cell suspension was added onto a Qiashredder spin column and centrifuged at
8000g for 2 minutes to generate a cell lysate. An equal volume of 70% v/v ethanol,
made using nuclease-free water, was added to the cell lysate. A maximum of 700pi
of lysate was applied to RNeasy mini spin column and centrifuged for 15 seconds at
8000g and the flow through discarded. If the volume exceeded 700pl this step was
repeated, using the same RNA mini spin column. The flow through was again
discarded. 700pl of RW1 buffer were added to the column and this was centrifuged
for 15 seconds at 8000g and the flow through discarded. The RNeasy mini spin
column was thereafter transferred to a clean 2ml collection tube. 500pl of proprietary
RPE buffer (which also contains guanidine thiocyanate) were added to the column
and this was centrifuged again for 15 seconds at 8000g. RPE buffer was made by
adding 45ml of 100% technical grade ethanol to 11ml of stock RPE provided by the
manufacturer. Another 500pl of RPE buffer were added to the column and
centrifuged for 2 minutes at 8000g. The flow through was discarded and the
centrifugation step repeated for 1 minute. The RNeasy mini spin column was
transferred to a clean 1.5ml eppendorf tube. Finally, the RNA was eluted from the
RNeasy mini spin column by adding 30pl to 50pi of RNase-free water to the column
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and centrifuging this for 1 minute at 8000g. The concentration of eluted RNA was
measured using a spectrophotometer as described below.
2.3.2.2 Measurement of RNA concentration
RNA concentration was determined using the following formula:
RNA concentration = Absorption at 260nm (A260) x 40 x dilution factor where an
A260 of 1.0 is equivalent to 40mg/ml of RNA using a GeneQuant UV
spectrophotomer (Pharmacia Biotech, Little Chalfont, UK). The spectrophotometer
was blanked at A260 using 4pi of RNase-free water from the RNeasy Mini kit that
was used to elute the RNA. 4pl of eluted RNA were added to a quartz capillary
(Amersham) to determine the RNA concentration, ratio and absorbance. Pure RNA
has an A260/A280 ratio between 1.8 and 2. A value above 2 indicated protein
contamination and a value below 1.8 indicated poor RNA quality (Sambrook and
Russell, 2001).
2.3.2.3 DNase treatment of RNA
All RNA samples were systematically treated using an RQ1 RNase-Free DNase kit
to remove any contaminating DNA. DNase digestion was carried out following the
manufacturer's instructions as outlined in table 2.3.
Kit component Volume Component composition
RNA in water l-8pl -
RQ1 RNase-Free DNase lpl 400mM Tris-HCl (pH 8.0), lOOmM
1 Ox Reaction Buffer MgS04 and lOmM CaCl2
RQ1 RNase-Free DNase lU/pg RNA RQ1 DNase supplied in lOmM
(from bovine pancreas) HEPES (pH 7.5), 50% v/v glycerol,
lOmM CaCl2 and lOmM MgCl2.
Nuclease-free water to a lOpl
final volume of
Table 2.3: RQ1 DNase treatment of RNA.
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The RNA and RQ1 components were incubated at 37°C for 30 minutes. The above
reaction was terminated by adding lpl of RQ1 stop solution followed by a 10 minute
incubation at 65°C. This inactivated the DNase. RNA was thereafter stored at -80°C
until required.
2.3.2.4 Complementary DNA synthesis
A ThermoScript™ Reverse Transcriptase kit was used for the synthesis of first-
strand complementary DNA (cDNA) from the RNA generated above. This was
performed following the manufacturer's instructions. Briefly, components of the kit
were added to the RNA (between 50ng and 5pg RNA) as indicated in table 2.4. Only
DNase-treated RNA was used.
Kit component Volume Component composition
50ng/pl random hexamers lpl N/A
1 OmM dNTP mix 2pl N/A
lOpg to 5pg RNA x pi -
DEPC-treated water To a final volume of 12pl -
Table 2.4: Components of ThermoScript Reverse Transcriptase kit added to RNA.
This mixture was incubated for 5 minutes at 65°C to denature the RNA. The
components listed in table 2.5 were added thereafter to the denatured RNA:
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Kit components Volume Component composition
5x cDNA synthesis buffer 4pl 250mM tris acetate (pH 8.4 at room
temperature), 375mM potassium
acetate, 40mM magnesium acetate
0.1MDTT lpl 0.1M dithiothreitol
RNaseOUT™ (40U/pl) lpl Recombinant ribonuclease inhibitor
DEPC-treated water lpl -
ThermoScript™ RT (15U/pl) lpl Avian reverse transcriptase
Table 2.5: Components of ThermoScript Reverse Transcriptase kit added to
denatured RNA.
cDNA was finally synthesised when the components in table 2.5 were added to the
denatured RNA and incubated following at 25°C for 10 minutes, 50°C for 60
minutes and 85°C for 5 minutes. The cDNA generated was stored at -20°C until
required.
2.3.3 Reverse Transcriptase-Polymerase Chain Reaction methods
2.3.3.1 Reverse transcriptase-polymerase chain reaction master-mix
A master-mix was prepared for all RT-PCR reactions described below. The reagents
of this master-mix, their composition and their supplier are given in table 2.6.
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Reagents Composition/Concentration Suppliers
lOx PCR buffer
lOmM Tris-HCl (pH 9.0 at 25°C),
50mM KC1 and 0.1% Triton® X-100
Promega
25mM Mg2+ 25mM MgCl2 Promega
dNTPs
dATP, dCTP, dGTP, dTTP (20mM
of each dNTP)
Amersham
Forward primers lOOpM Sigma-Genosys
Reverse primers lOOpM Sigma-Genosys
Nuclease-free water h2o BDH
Taq DNA polymerase
from Thermus DNA polymerase Promega
aquaticus strain YT 1
Table 2.6: RT-PCR master-mix components, compositions and suppliers.
All primers used were at a concentration of lOOpM. All PCR products were
visualised by agarose gel electrophoresis as described in section 2.3.3.4. All PCR
products were stored at -20°C.
2.3.3.2 B-actin RT-PCR
(3-actin PCR was performed on all cDNA samples to check the quality of the cDNA
synthesised. [3-actin PCR was also performed on all RNA used to generate cDNA to
check for any DNA contamination of the RNA. The primer sequences used are given
in table 2.7 below:
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Primer
name






CTC CTT AAT GTC ACG CAC GAT TTC
CGC CCC CGC CCC AGG CAC CA
540
Table 2.7: (B-actin primer sequences.
The composition of the master-mix for P-actin RT-PCR is given in table 2.8.
Reagent Volume in pi
lOx PCR buffer 2.5
25mM Mg2+ 1.5
dNTPs 0.25
P-actin forward primer 0.2
P-actin reverse primer 0.2
Nuclease-free water 18.23
Taq DNA polymerase 0.125
cDNA or RNA 2
Table 2.8: p-actin RT-PCR reaction master-mix.
The RT-PCR was performed using the T3 Thermalcycler under the conditions given
in table 2.9. A positive control for P-actin was included in each RT-PCR run. A
negative control consisting of 2pl of NFH2O instead of cDNA or RNA was included
in each RT-PCR run.
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Table 2.9: (3-actin RT-PCR cycling conditions.
2.3.3.3 FasL. Granulvsin. Granzyme B and Perforin RT-PCR
The sequences of the primers used are given in table 2.10. These were designed
using the Primer3 software available at:
http://frodo.wi.mit.edu/cgi-bin/primer3/primer3 www.cgi.





















Table 2.10: FasL, granulysin, perforin and granzyme B primer sequences.
The master-mix for each RT-PCR reaction is given in the table below:
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Reagent Perforin Granzyme B Granulysin FasL
lOx PCR buffer 2.5pl 2.5pl 2.5pl 2.5pl
25mM Mg2+ 1.5pl 1.5pl 1.5ptl 1.5(0.1
dNTPs 0.25 pi 0.25pl 0.25pl 0.25pl
Forward primer (50pM) 0.20pl 0.20pl 0.20pl 0.20pl
Reverse primer (50pM) 0.20pl 0.20pl 0.20pl 0.20pl
Nuclease-free water 17.65(4.1 17.65pl 17.65(ol 17.65(0.1
Taq DNA polymerase 0.125ja.l 0.125pl 0.125(0.1 0.125(0.1
cDNA 2.5pl 2.5pl 2.5(0.1 2.5(0.1
Table 2.11: FasL, granulysin, perforin and granzyme B RT-PCR master-mix. The
minimum volume of cDNA used was 1pl, and although the volume of cDNA was
increased in some cases, this volume never exceeded 2.5pl. Where the volume of
cDNA was increased, the volume of NFH20 was decreased accordingly to maintain
a total reaction mix volume of 25pl.
The RT-PCR cycling conditions (duration and temperature of the melting, annealing
and elongation phases as well as the number of cycles) were established based on the
data provided with the primers (melting temperature and expected RT-PCR product
sizes). As the melting temperatures of the primers and the expected RT-PCR product
sizes were similar for all four cytotoxic molecules the same conditions were used.
The RT-PCR cycling conditions for FasL, granulysin, perforin and granzyme B were
all the same and are given in table 2.12.
RT-PCR cycling conditions
94°C - 5 min lx
95°C - 30 s
57°C - 30 s 35x
72°C - 45 s
72°C - 8min lx
4°C - hold
Table 2.12: FasL, granulysin, perforin and granzyme B RT-PCR cycling conditions.
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2.3.3.4 Agarose gel electrophoresis of RT-PCR products
2% agarose was prepared using multi-purpose agarose and 0.5% TBE buffer (45mM
Tris-borate, ImM EDTA in 20 litres (1) dH20). The solution was heated in a
microwave with regular swirling until the agarose had dissolved. The agarose was
allowed to cool and lpl of ethidium bromide (lOmg/ml) (Fisher Scientific) was
added to every 100ml of agarose. The molten agarose was poured into the
appropriate cast with comb and allowed to set.
The solidified gel was submerged with 0.5% TBE. lOpl of RT-PCR products were
mixed with 2pl of PCR loading buffer lOx (1ml 0.5M EDTA pH 8.0, 3g sucrose,
500pl 1% bromophenol blue, 500pl 1% xylene cyanol, 3ml dH20) and loaded into
the wells of the gel. 10pl of 100 base pair ladder (Invitrogen) was also loaded into
every gel. The electrophoresis was run until the 100 base pair ladder had separated
appropriately along with the RT-PCR products.
The 100 bp ladder and RT-PCR products were visualised in the gel using a UVP
Transilluminator (Ultra-Violet Products, Cambridge, UK). Gel images were printed
on Sony heat-sensitive paper supplied by SLS.
2.3.4 T-cell receptor Vp spectratyping
T-cell receptor (TCR) repertoire diversity was characterised by TCR V(3
spectratyping by RT-PCR. This was done following a method previously described
by Foster et al (2004), which measures the differing length of the CDR 3 of the TCR
(3 chain.
2.3.4.1 Primer sequences
The primer sequences used in TCR spectratyping are given in table 2.13. These
consist of 23 forward primer for Vp sequences and 1 reverse primer for constant
chain CP conjugated to the fluorescent dye carboxyfluorescein (FAM) (Foster et al,
2004).
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Table 2.13: 23 \/p forward primer sequences and 1 reverse constant chain (C(3)
primer conjugated to FAM.
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All the primers were diluted to lOOpM stock solutions. Primers V[3 1-25 were diluted
further to 4pM. 5pi of each forward primer was aliquoted in 23 wells of a 0.2ml 24-
well PCR plate.
2.3.4.2 Reaction master-mix
The TCR RT-PCR reaction master-mix is given in table 2.14.
Reagent Volume in pi Final concentration
10 x PCR Buffer 2 1 X
25mM Magnesium 1.6 2mM
20mM dNTP's 0.2 200pM
lOOpM 3'primer (C(3-FAM) 0.2 lpM
Amplitaq gold (5U/pl) 0.1 0.5U
nfh2o 9.9 N/A
cDNA 1 N/A
Table 2.14: TCR RT-PCR reaction master-mix. N/A: not applicable.
The volume of each reagent was multiplied by the number of primers being
amplified. A new reaction master-mix was prepared for each cDNA sample to be
tested. cDNA used in any master-mix was synthesised using lpg of RNA (as
described in section 2.3.2.1). This RNA was DNase treated and the quality of the
cDNA synthesised was checked by |3-actin RT-PCR (as described in sections 2.3.2.3
and 2.3.3.2). The master-mix was vortexed, pulse centrifuged briefly and 15pl of
master-mix was added to each well of a 24-well PCR plate containing 5pi of forward
primer.
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2.3.4.3 T-cell receptor RT-PCR cycling conditions
The RT-PCR cycling conditions used are detailed in table 2.15.
Number of cycles Temperature (°C) Time
1 95°C 5 minutes
95°C 30 seconds
3 58°C 30 seconds
72°C 45 seconds
1 72°C 5 minutes
1 4°C hold
Table 2.15: TCR RT-PCR cycling conditions.
1 Oja.1 of TCR RT-PCR products were visualised as described in section 2.3.3.4.
2.3.4.4 T-cell receptor RT-PCR product preparation
A 1:10 dilution of the TCR RT-PCR products generated above was prepared in 96-
well U-bottomed plate using NFH2O. The size standard GeneScan™-500 LIZ™ and
Hi-Di™ formamide mix was prepared by adding 2pl of size standard to 1ml of
formamide. 9pl of formamide/standard mix was added to each well of a 96-well plate
specifically designed for use with the ABI 3730 sequencer, lpl of 1:10 diluted TCR
RT-PCR product was added to the 9pl of formamide/standard mix. The plate was
then sealed and analysed in the ABI 3730 sequencer.
2.3.4.5 Data analysis
All data generated by the ABI 3730 sequencer was analysed using GeneMapper
software v3.7.
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2.4 Fluorescence associated cell sorting
2.4.1 Antibodies and controls
Details of all the antibodies used are given in table 2.16.
Antibody Clone Isotype Conjugated Volume used/ Manufacturer
fluorochrome 106 cells
Extracellular markers
CD3 UCHT-1 IgGl, K FITC, PE, PE 20|ol/106 cells BD Pharmingen
Cy5
CD4 RPA-T4 IgGl, K APC, FITC, 20|il/106 cells BD Pharmingen
PE, PE Cy5
CD8 RPA-T8 IgGl, K APC, FITC, 20gl/106 cells BD Pharmingen
PE, PE Cy5
CDllc B-Ly6 IgGl, K PE 20pl/I06 cells BD Pharmingen
CD14 rmC5-3 IgGl, K PE 20pl/106 cells BD Pharmingen
CD19 HiB19 IgGl, K FITC, PE 20pl/106 cells BD Pharmingen
CD27 M-T271 IgGl, K FITC 20(0.1/106 cells BD Pharmingen
CD28 CD28.2 IgGl, K FITC 20gl/106 cells BD Pharmingen
CD45 HI30 IgGl, K FITC 20(0.1/106 cells BD Pharmingen
CD45RA HI 100 IgG2b, K FITC 20(0.1/106 cells BD Pharmingen
CD45RO UCHL-1 IgG2a, K FITC 20|o.l/106 cells BD Pharmingen
CD56 B159 IgGl, K FITC, PE 20(0.1/106 cells BD Pharmingen
CD62L Dreg-56 IgGl, K FITC 20(0.1/106 cells BD Pharmingen
CD69 FN50 IgGl, K FITC 20(0.1/106 cells BD Pharmingen
DC-SIGN NA IgG2b, K FITC 20(0.1/106 cells R&D Systems
Intracellular markers
Perforin 5G9 IgG2b, K PE 20(0.1/106 cells BD Pharmingen
Granzyme B GB12 IgG, PE 10gl/106 cells Caltag Medsystems
FasL Alf-2.1 IgG2a PE 10gl/106 cells Caltag Medsystems
Table 2.16: Antibodies used in extra- and intra-cellular FACS staining. APC:
allophycocyanin; FITC: fluorescent isothiocyanin; PE: phycoerythrin; PE Cy5:
phycoerythrin cychrome 5. NA: not available.
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Corresponding isotype controls were used for all of antibodies shown in table 2.16
and detailed in table 2.17.
Antibody Clone Conjugated Concentration Manufacturer
isotype fluorochrome
IgGi, K MOPC-21 APC, FITC, PE, 20gl/10b cells BD Pharmingen
PE Cy5
IgG2a, K G11-178 FITC 20(0.1/106 cells BD Pharmingen
IgG2b, K 27-35 FITC, PE 20(0.1/106 cells BD Pharmingen
IgG, NA PE lOgl/106 cells Caltag Medsystems
IgG2a NA PE lOgl/106 cells Caltag Medsystems
Table 2.17: Isotype control antibodies. NA: not available.
2.4.2 Solutions and buffer used
Fluorescence associated cell sorting (FACS) buffer was made up using SPBS, 1%
w/v bovine serum albumin (BSA), 5mM EDTA, 0.1% w/v sodium azide. Both BSA
and EDTA were supplied by Sigma and sodium azide by BDH. BD FACS™
Permeabilizing Solution 2 lOx concentrate (BD Biosciences) and CellFIX™ lOx
concentrate (BD Biosciences) were both diluted 1:10 with dHiO before use. 1:10
diluted CellFIX™ was kept for up to 1 month at room temperature.
2.4.3 Equipment used
All centrifugation steps were carried out using a Sanyo MSE Mistral 3000E (Rotor
43124-129). FACS was performed using either a FACScan or a FACSCalibur in
conjunction with the CellQuest Software (Becton Dickinson). Acquired events were
analysed using the CellQuest Software.
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2.4.4 Extracellular marker staining
50pi of FACS buffer were added to 5ml round-bottomed tubes. The appropriate
volume of extracellular marker antibody was added to the appropriate tubes. An
unstained control was included in every experiment where no antibody was added to
the buffer. lOOpl of cell suspension, at 1 x 106 cells/ml in FACS buffer, was added to
each tube, mixed gently and incubated for 20 minutes at 4°C in the dark. The cells
were washed twice in 1ml of FACS buffer and centrifuged at 200g for 5 minutes.
The supernatant was discarded and the cell pellet loosened. The cells were fixed in
200pl of 1:10 diluted CellFIX™ and incubated on rotating shaker for 10 minutes at
room temperature. 300pl of FACS buffer were finally added to the cells, which were
stored at 4°C in the dark until flow cytometry acquisition and analysis.
2.4.5 Intracellular staining
The cells were first stained for extracellular markers, as described in section 2.4.4
above, except that the cells were not incubated with CellFIX™ after the second wash
but were instead incubated with 500pl BD FACS™ Permeabilizing Solution 2
diluted 1:10 for 10 minutes at room temperature. The cells were washed twice with
lml FACS buffer and centrifuged at 200g for 5 minutes. The supernatant was
discarded and the appropriate volume of intracellular antibody was added to the
cells, mixed gently and incubated for 30 minutes at 4°C in the dark. Thereafter, the
cells were washed twice with lml FACS buffer and centrifuged at 200g for 5
minutes and fixed as described in section 2.4.4.
2.4.6 Acquisition and analysis of events
Between 1000 and 10000 events, depending on the number of stained cells available,
were acquired on either the FACScan or the FACSCalibur. These acquired events
were subsequently analysed using the CellQuest software.
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2.5 Western blotting for granulysin
2.5.1 Consumables and equipment used for western blot
CellLytic™-M mammalian cell lysis buffer and protease inhibitor cocktail for
mammalian cells were both purchased from Sigma. Pre-cast NuPAGE® Novex
High Performance 12% Bis-Tris Gel were purchased from Invitrogen, as well as all
other reagents used, except the Rainbow Ladder size standard, which was purchased
from Amersham Biosciences. Methanol was supplied by BDH. Hybond ECL
nitrocellulose membranes were purchased from Amersham Biosciences. Whatman
filter paper was supplied by VWR. Blocking solution was made using PBS (Oxoid,
Basingstoke, UK) (1 tablet in 100ml dH20 (NaCl 8g/l, KC1 0.2g/l, Na2HP04 1.15g/l,
KH2P04 0.2g/l, pH7.2) 2% w/v BSA, 0.01% v/v Triton®-X). NBT/BCIP ready-to-
use tablets were bought from Roche (Lewes, UK).
2.5.2 Equipment used for western blot
The cell lysis step was carried out using a Blood Tube Rotator SB1 (Stuart Scientific,
Stone, UK). The centrifugation step was carried out using a temperature-controlled
SciQuipl-15K centrifuge (Sigma - rotor ID 12124). Running and blotting ofwestern
blot was done using an Xcell SureLock™ Mini-Cell from Invitrogen. Antibody
incubations were carried out on a Roller Mixer SR T (Stuart Scientific).
2.5.3 Antibodies
The details of the antibodies used in western blot are detailed in table 2.18.
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Antibody Clone Isotype Concentration Supplier
Anti-granulysin DH4 Mouse anti- 1.64mg/ml Gift from Prof
- 10 antibody human IgGi.K C Clayberger1
Goat anti- NA Goat anti-mouse NA Sigma






Table 2.18: Antibodies used in western blotting for granulysin. 1Professor Carol
Clayberger, Dept Pediatrics, Stanford University, Stanford, California, USA. mg:
milligram. NA: not available.
2.5.4 Cell lysis
All cells used for western blotting were washed with SPBS before being stored at -
20°C as dry cell pellets. These cell pellets were allowed to thaw before being lysed.
125ja,l of cell lysis buffer and 1.25pl protease inhibitor cocktail were added to the
loosened cell pellet and this was incubated, with continuous rotation, using the blood
tube rotator at 4°C for 25 minutes. The cell lysate was then centrifuged at 15000g for
10 minutes at 4°C. The protein supernatant was stored at -80°C in 15ul aliquots until
required or used immediately and the pellet discarded.
2.5.5 Protein sample preparation and gel running
5pi of NuPAGE® LDS sample buffer (4x) and 2pl of NuPAGE® reducing agent
(lOx) were added to 13pl of protein sample and heated to 70°C for 10 minutes, lx
SDS running buffer was prepared by adding 50ml 20x NuPAGE® MES SDS
running buffer to 950ml dHiO. The upper buffer chamber of the Ace 11 SureLock™
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Mini-Cell was filled with 200ml lx SDS running buffer and 500pl NuPAGE®
antioxidant. The lower chamber was filled with 600ml SDS running buffer. The
entire prepared sample was loaded in the gel. lOpl of Rainbow Ladder was loaded
into every gel, as well as a positive control. The positive control for granulysin was a
CD56+ rich T-cell line. The gel was run for 35 minutes at 200V constant.
2.5.6 Western transfer protocol
11 of lx NuPAGE® transfer buffer was prepared by adding 50ml of 20x NuPAGE®
transfer buffer, 100ml methanol and 1ml NuPAGE® antioxidant to 850ml dH20.
Soaking pads, Hybond ECL nitrocellulose membrane and Whatman filter paper were
soaked in 700ml of lx NuPAGE® transfer buffer. A sandwich comprising 2 soaking
pads, 2 Whatman filter paper squares, the gel, the Hybond ECL nitrocellulose
membrane, 2 further filter paper squares and 2 further soaking pads was made and
placed into the cathode core of the blot module. The blot module was finally
assembled and fitted in the Ace 11 SureLock™ Mini-Cell. Enough lx NuPAGE®
transfer buffer was added to the blot module until the soaking pads/Whatman filter
paper/gel/Hybond ECL nitrocellulose membrane sandwich was covered. The lower
buffer chamber was filled with 650ml dH20. The gel was transferred using 30V
constant for 1 hour.
2.5.7 Primary and secondary antibody incubations
The sandwich of soaking pads/Whatman filter paper/gel/Hybond ECL nitrocellulose
membrane was disassembled and the Hybond ECL nitrocellulose membrane was
blocked for 30 minutes at room temperature with blocking solution on the roller
mixer. The membrane was thereafter washed 3 times in PBS for 1 minute. 5ml of
blocking solution and 5pl of anti-granulysin antibody (1:1000 dilution) were added
to the membrane and incubated for 30 minutes at room temperature and then
overnight at 4°C on the roller mixer. The membrane was washed 3 times in PBS for
102
CHAPTER 2
_ MATERIALS AND METHODS
1 minute. 5ml of blocking solution and 5jil of goat anti-mouse IgG (Fab specific)
alkaline phosphatase conjugated antibody (1:1000 dilution) were added to the
membrane and incubated for at least 2 hours at room temperature on the roller mixer.
The membrane was washed 3 times in PBS for 1 minute.
2.5.8 Development Hybond ECL nitrocellulose membrane
The membrane was developed using an NBT/BCIP tablet dissolved in 10ml dH20.
The membrane was developed in the dark for 3 to 5 minutes or until bands reached
the desired intensity and washed in dHoO to stop the reaction and allowed to dry.
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2.6 Statistical analysis
The Mann-Whitney test was used to analyse non-parametric data. This was carried
out using the software Prism 4.0 for Macintosh (GraphPad software, Inc., San Diego,
USA).
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CHAPTER 3 GROWTH AND PHENOTVPB OF CTLs
3.1 Introduction
Ex vivo generated EBV-specific CTLs can take up to three months to produce. They
have already been used to treat PTLD successfully in iatrogenically
immunosuppressed transplant patients (Haque et al, 2001; Haque el al, 2002),
however little is known about their development during the production period.
Therefore, the growth and phenotype of CTLs was investigated in order to establish
how the CTLs evolved in response to weekly autologous LCL stimulations.
3.2 Ex vivo generation and phenotype of CTLs
3.2.1 Growth of CTLs
The CTLs were generated using peripheral blood mononuclear cells (PBMCs) from
12 healthy EBV positive blood donors enrolled in a phase II clinical trial funded by
Cancer Research UK. The HLA-type of each donor is given in table 3.1.
Donor number HLA type
3 A2,68(28); B50(21),60(40); DR17(3),4
12 A3,24; B7; DR11(5), 13(6)
16 A26,32; B55(22),64(14); DR7,14(6)
28 Al,2; B39(16),18; DR17(3),7
31 Al,2; B7,57(17); DR7,9
55 A2,68(28); B51(5),62(15); DR4,(13)6
66 A3,26; B7,41; DR15(2)
68 A2; B7; DR15(2)
75 A3; B35, DR1,13(6)
81 A3,30; B7,57(17); DR15(2),7
Table 3.1: HLA type of PBMC donors.
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14 CTLs were generated using PBMCs from above mentioned donors. As a
proportion of the CTLs were cryopreserved at particular weekly stimulations (S), the
absolute CTL growth number could not be determined but, as at every weekly
stimulation the density of the CTLs was adjusted to lxl06 CTL/ml, this value was
taken as a "benchmark" to follow any proportional increase or decrease in CTL
numbers. The average proportional growth of the CTLs generated is shown in figure
3.1 as red bars. The lxlO6 CTL/ml "benchmark" is shown in figure 3.1 as a bold line.
The average viability of the CTLs was also determined and this represented by the
blue line in figure 3.1.
Average proportional growth and viability of CTLs
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Weekly stimulations with autologous LCL
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Figure 3.1: Average proportional growth (red bars) and viability (blue line) of CTLs
at each weekly stimulation with autologous lymphoblastoid cells (LCLs). S:
stimulation. See table 3.2 for data used to generate this figure.
The CTLs were grown in culture for up to 15 weeks, although some CTLs were not
cultured for so long because cell numbers naturally decreased before that time and in
other cases technical constraints halted the expansion of the cell lines. Figure 3.1
shows that there is a proportional increase in cell number from SI to S4. From S4
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onwards, there is a decrease in cell number week on week. This is paralleled by a fall
in viability of the CTLs. From stimulations 10 to 15 there was break in the
proportional growth and viability trends but fewer CTLs were growing over that
period and therefore a low sample number may be responsible for this.
The data used to generate figure 3.1 is given in the table 3.2. The numbers in
brackets in the percentage viability column are the numbers of CTLs for which these









S1-S2 1.1 x 106 CTLs/ml 72% (11) 14
S2-S3 2.0 x 106 CTLs/ml 67% (13) 14
S3-S4 2.1 x 106 CTLs/ml 63% (13) 14
S4-S5 2.0 x 106 CTLs/ml 63% (13) 14
S5-S6 1.7 x 106 CTLs/ml 61% (13) 14
S6-S7 1.4 x 106 CTLs/ml 56% (12) 13
S7-S8 1.4 x 106 CTLs/ml 53% (9) 9
S8-S9 1.2 x 106 CTLs/ml 47% (4) 4
S9-S10 0.9 xlO6 CTLs/ml 33% (2) 2
S10-S11 0.9 x 106 CTLs/ml 35% (3) 3
S11-S12 0.9 x 106 CTLs/ml 56% (2) 2
S12-S13 1.2 x 106 CTLs/ml 49% (3) 3
S13-S14 1.1 x 106 CTLs/ml 55% (1) 1
S14-S15 1.1 x 106 CTLs/ml 45% (1) 1
Table 3.2: Average CTL number/ml of culture, percentage of viable CTLs and the
number of growing CTLs at each weekly stimulation. S: stimulation.
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3.2.2 Basic phenotype of ex vivo generated CTLs
The basic phenotype of seven CTLs was investigated by FACS analysis. Based on
the proportional growth trends of the CTLs as shown in figure 3.1, the analysis was
divided into two phases - phase 1 from SI to S4 where the proportional increase in
CTL numbers continuously rose and peaked at S4 and phase 2 from S5 onwards
where the proportional increase in CTL number fell. Basic phenotyping was based
on CTL staining for CD4, CD8, CD 19, CD45 and CD56 co-stained with CD3, as this
is expressed only by T-cells. CD4 and CD8 staining was used to determine the
phenotype of the T-cells; CD19 staining was used to detect B-cells and CD56
staining was used to detect NK cells. Staining with CD45 complemented staining
with CD3 for the detection of T-cells, as all haematopoietic cells express CD45.
3.2.2.1 FACS analysis
FACS data were acquired for CTLs by gating on the lymphocytes based on their
forward scatter and their side scatter. The forward scatter is a measure of the size of
the cells and the side scatter is a measure of the granularity of the cells. Both the
forward scatter and side scatter can be used to differentiate between live and dead
cells, with dead cells having a lower forward scatter and higher side scatter than live
cells. Based on this information, a gate was set around live lymphocytes (including
T-cells) being acquired but also analysed, as shown in figures 3.2 a) and b). In figure
3.2 a) and b) every dot represents a cell, however in figure b) areas of high cell
density can be identified (high cell density area appearing light red). The gate in
figure 3.2 named R1 distinctly surrounds the live lymphocyte population (including
T-cells) in figures 3.2 a) and b). The more diffuse and less dense population of cells,
which is surrounded by blue lines, had a lower forward scatter and a higher side
scatter indicating that these were dead cells. Figures 3.2 a) and b) represent the same
CTL.
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Forward scatter
Figure 3.2: Identification of live lymphocytes within a CTL based on forward and
side scatter in a) a dot plot and b) a density plot. Black gate R1- live lymphocytes.
Blue gate - dead cells.
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3.2.2.2 Basic phenotyping of ex vivo generated CTLs
Once this gate (shown as R1 in figure 3.2) was set for lymphocytes, the phenotype of
these cells was determined by staining with fluorochrome-labelled antibodies
specific for the extracellular markers discussed in section 3.1.2.
Figure 3.3 shows representative dot plots for CD3 and CD8 double staining obtained
for one CTL in phases 1 and 2 of growth. The data shown in these dot plots as well
other data collected for that CTL are given in table 3.3. Data for two other CTLs are
also included in table 3.3.
a) CTL 14 at SI (phase 1 of growth)
PE
Unstained control
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Figure 3.3: FACS analysis plots for CTL 14.
Phase 1 Phase 2
CTLs 1 14 1 6 14
CD4 15.6% 10% 2.7% 0.5% 5.8%
CD8 65.9% 43% 93.2% 97.8% 96.9%
CD19 0.2% NA 0.3% 0.4% 0.1%
CD45 81.6% NA 97% 98.5% 99.1%
CD56 1.4% NA 1.9% 0.1% 1%
Table 3.3: Phenotype of CTLs 1, 6 (not phase 1) and 14. NA: not available.
The basic phenotype of four other CTLs, across phases 1 and 2 of growth, was
determined and is shown in figures 3.4, 3.5, 3.6 and 3.7. Figures 3.4 to 3.7 show that
the phenotype of the CTLs in phase 1 of growth persisted into phase 2. This was seen
in all CTLs (whether the CTL became predominantly CD8+ (CTL 4 and CTL 3) or
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whether it became predominantly CD4+ (CTL 13 and CTL 2)). These figures also
show that in CTLs, which became predominantly CD4+ (CTLs 2 and 13) there was
an initial decrease in the proportion of CD4+ T-cells followed by an increase at S3.
This, though, was not seen in CTLs that became predominantly CD8+.
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Figure 3.4: Phenotype of CTL 4.
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Phenotype of CTL 3
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Figure 3.5: Phenotype of CTL 3.
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Figure 3.6 Phenotype of CTL 13.
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Figure 3.7: Phenotype of CTL 2.
In the CTLs which were phenotyped there was <2% CD56+ cells, <1% CD19+ B-
cells and >97% of T-cells in phase 2 of growth. Where the CTL was predominantly
CD4+ or CD8+ in phase 2, >79% of the CTLs expressed the dominant marker.
3.2.3 Extended phenotype of ex vivo generated CTLs
Having established the basic phenotype of the CTLs above, other CTLs were
phenotyped more extensively by assessing the expression of activation and
differentiation markers, such as CD27, CD28, CD45RA, CD45RO, CD62L and
CD69. Phenotyping of CTLs was undertaken in growth phase 1 and phase 2. It was
undertaken in phase 1 because phenotype determination, with regard to CD4 and
CD8 expression, occurred during that phase. Therefore, the expression of the above-
mentioned markers was investigated in conjunction with CD4 and CD8 expression.
This was carried out to determine whether there was a pattern in phenotypic changes
undergone by the CTLs that extended beyond CD4+ and CD8+ T-cell expression
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and whether the same phenotypic changes occurred in CD4+ and CD8+ T-cells alike
in the CTLs.
The categorisation of T-cells is a difficult issue with a wide variety of markers used
to define particular cell subsets. CD45RO is a marker of antigen-experienced/mature
cells. CD45RA is a marker of naive T-cells, which is lost upon antigenic stimulation
but can be re-expressed on late-differentiated cells. CD27 and CD28 are both T-cell
co-stimulatory molecules, which are expressed on naive T-cells. CD27 expression is
upregulated upon antigenic stimulation of the TCR and it is subsequently
downregulated (Hendriks et al, 2000). CD28 expression is downregulated upon TCR
stimulation. Once CD27 or CD28 expression is lost neither marker can be re-
expressed by either CD4+ T-cells or CD8+ T-cells, indicating that the cells
differentiate into mature cells (Appay, 2004; Hendriks et al, 2000). Detection of
these markers complements the detection of CD45RA to identify nai've T-cells in the
CTLs. Additionally, the expression of CD62L, a lymphoid homing marker, was also
investigated. It is expressed on both naive CD4+ and CD8+ T-cells. Its expression is
also downregulated upon antigenic stimulation. Finally, the expression of CD69,
which is a marker of early T-cell activation, was also investigated.
3.2.3.1 Study of nhenotvne development of CTLs
The extended phenotype of two CTLs was studied in this part of the project. The
basic phenotype of one CTL is shown in figure 3.8. This figure shows that by S4, in
excess of 80% of the cells in the CTL expressed CD8 and fewer than 10% expressed
CD4. It also shows that nearly 100% of the cells expressed CD3 after four weeks of
culture.
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Basic phenotype - CTL 9
CD3 CD4 CD8 CD19 CD56
Figure 3.8: Basic phenotype of CTL 9.
The extended phenotype of the CTLs was established and is shown in figures 3.9 and
3.10. Figures 3.9 and 3.10 show that there was an overall decrease from stimulation 0
(PBMC) to S4 in the proportion cells co-expressing CD4 or CD8 and the naive T-cell
markers CD45RA, CD62L, CD27 and CD28. These figures also show that there was
an overall increase in the proportion of cells co-expressing CD4 or CD8 and
CD45RO (a marker of T-cell maturity) and CD69 (a marker of T-cell activation).
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Figure 3.9: Phenotype of cells co-expressing CD4 and CD45RA, CD45RO, CD62L,
CD69, CD27 and CD28 in CTL 9.
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Figure 3.10: Phenotype of cells co-expressing CD8 and CD45RA, CD45RO,
CD62L, CD69, CD27 and CD28 in CTL 9.
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As the proportion of CD4+ T-cells and CD8+ T-cells in the CTL changed during the
course of culture, the expression profile of CD4+ and CD8+ T-cells respectively was
also investigated in order to determine whether similar phenotypic changes occurred
in each cell type. The results of this are shown in figures 3.11 and 3.12. The
proportion of CD4+ T-cells decreased and the proportion of CD8+ T-cells increased
over time (figure 3.8). Figures 3.11 and 3.12 show that there was a decrease in the
proportion of both CD4+ and CD8+ T-cells expressing CD45RA and CD62L,
indicating that the cells were losing naive marker expression. The expression of both
CD27 and CD28 also decreased during the first four weeks of culture, with a greater
decrease in expression in CD8+ T-cells. Conversely, the proportion of CD4+ T-cells
and CD8+ T-cells expressing CD45RO increased dramatically, with over 90% of
both cell types expressing this antigen-experienced/mature marker. These findings
indicate that CD4+ T-cells were becoming antigen-experienced/mature cells even
though their overall proportion in the CTL was decreasing (figure 3.8). The same
applied to CD8+ T-cells, although their proportion increased over time in the CTL.
Proportion of CD4+ T-cells expressing cell surface markers in CTL 9
100
Figure 3.11: Proportion of CD4+ T-cells expressing CD45RA, CD45RO, CD62L,
CD69, CD27 and CD28 in CTL 9. This was determined by gating on CD4+ T-cells in
the CTL.
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Proportion of CD8+ T-cells expressing cell surface markers in CTL 9
100
Figure 3.12: Proportion of CD8+ T-cells expressing CD45RA, CD45RO, CD62L,
CD69, CD27 and CD28 in CTL 9. This was determined by gating on CD8+ T-cells in
the CTL.
The phenotypic pattern seen in figures 3.8 to 3.12 for CTL 9 was also seen in CTL 5,
which was also immunophenotyped at stimulations 0, 2 and 4. Data for CTL 5 are
shown in figures A3.1 to A3.5 in appendix 3.
The phenotype of two other CTLs (7 and 12) was established at stimulation 0
(PBMC) and in growth phase 2. Figures 3.13, 3.14 and 3.15 show the phenotype of
CTL 12. These figures indicate that the phenotype observed in phase 1 of growth
persisted into phase 2 of growth, with this cell line also displaying a mature
phenotype. The data for CTL 7, which was phenotyped at stimulation 0 and at two
stimulations in growth phase 2, are given in figures A3.6 to A3.10 in appendix A3.
In this CTL the proportion of cells expressing both CD4 and CD8 increased from
stimulation 0 (PBMC) to stimulations 5 and 6. Upregulation of CD4 on activated
CD8+ T-cells has been documented (Sullivan et al, 2001).
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Growth phase 2 (S6)
Figure 3.13: Basic phenotype of CTL 12.
Phenotype of CTL 12 - CD4+ T-cells
I PBMC (SO)
Growth phase 2 (S6)
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Figure 3.14: Phenotype of cells co-expressing CD4 and CD45RA, CD45RO,
CD62L, CD69, CD27 and CD28 in CTL 12.
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Figure 3.15: Phenotype of cells co-expressing CD8 and CD45RA, CD45RO,
CD62L, CD69, CD27 and CD28 in CTL12.
The phenotypic changes seen in the CD4+ and CD8+ T-cells of CTL 12 (in phase 2
of growth) are similar to those described for CTLs 5 and 9 (in phase 1 of growth).
This is shown in figures 3.16 and 3.17. These findings indicate that CD4+ T-cells
were becoming mature cells even though their overall proportion in the CTL was
decreasing (figure 3.13). The same applied to CD8+ T-cells, although their
proportion increased over time in the CTL.
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Figure 3.16: Proportion of CD4+ T-cells expressing CD45RA, CD45RO, CD62L,
CD69, CD27 and CD28 in CTL 12.
Proportion of CD8+ T-cells expressing cell surface markers in CTL 12
PBMC (SO)
Growth phase 2 (S6)
//
Figure 3.17: Proportion of CD8+ T-cells expressing CD45RA, CD45RO, CD62L,
CD69, CD27 and CD28 in CTL 12.
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3.2.3.2 Summary of results on phenotypic development
These results indicate that beyond CD4 and CD8 phenotypic evolution described in
section 3.2.2, there are extensive phenotypic changes occurring during the first 4
weeks of culture (growth phase 1), with these changes persisting in growth phase 2.
The CTLs overall displayed a mature phenotype with decreased expression of
CD45RA, CD62L, CD27 and CD28 and increased expression of CD45RO and
CD69. The CD4+ and CD8+ T-cells within the CTLs also showed increased
expression CD45RO and CD69 and a decrease in expression of CD45RA, CD62L,
CD27 and CD28 indicating that both cell types were contributing to the overall
mature phenotype of the CTLs.
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3.3 Investigation into CD4+ T-cell and CD8+ T-cell
interactions
It appears from the FACS analyses carried out on the CTLs that phase 1 is the key
phase in terms of phenotypic development. In order to carry out basic investigations
into potential polyclonal CD4+ T-cell and CD8+ T-cell interactions, three methods
of positive cell selection were assessed.
3.3.1 EasySep. MACS and Dynal cell separation methods
Three different cell separation systems were trialled: EasySep, MACS and Dynal.
All three of the methods were designed to positively select CD4+ T-cells from
PBMCs. The detailed methods for each cell separation system are given in section
2.2. These three methods were first assessed using fresh PBMCs from three healthy
laboratory volunteers. The method (EasySep) that yielded the largest fraction of
enriched CD4+ T-cells was subsequently used on frozen PBMCs from three other
donors. The purity of the positively selected enriched CD4+ T-cell fraction was
assessed by FACS analysis. The percentage of total live cells recovered (from the
CD4+ T-cell enriched fraction as well as CD4+ T-cell depleted supernatant) was
determined by trypan blue exclusion cell counts.
3.3.1.1 Positive selection of CD4+ T-cells from fresh PBMCs
The purity of the positively selected CD4+ T-cell enriched fraction and the
percentage of cells recovered post-selection for all three donors are summarised in
figure 3.18. The purity of the positively selected CD4+ T-cell enriched fraction was
comparable for all three methods: the EasySep method achieved on average 97%
purity and the MACS and Dynal methods achieved on average 98% (98% MACS
and 98.3% Dynal) purity based on the proportion of cells expressing CD3 and CD4.
The percentage of cells recovered varied considerably with 66% of cells recovered
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following EasySep separation, 52% following MACS separation and only 6%
following Dynal separation.
Summary of CD4+ T-cell positive selection from







Average purity of Average recovery
CD4+ T-cell following
positive selection
Figure 3.18: Summary of CD4+ T-cell positive selection from fresh PBMCs from
three donors using EasySep, MACS and Dynal positive selection methods. (CD4+
T-cells were co-stained with CD3).
The presence of CD8+ T-cells within the positively selected CD4+ T-cell enriched
fraction was also assessed by FACS analysis for all three donors and results are
summarised in table 3.4.
% CD8+ T-cells EasySep MACS Dynal
Donor A 2% 3% 1%
Donor B 2% 1% 1%
Donor C 10% 9% 5%
Mean % CD8+ T-cells 4.7% 4.3% 2.3%
Table 3.4: Percentage of CD8+ T-cells in the positively selected CD4+ T-cell
enriched fraction.
126
CI IAFTER 3 GROWTH AND PHHNQTYPH OF CTLs
The percentage of CD4+ T-cells remaining in the CD4+ T-cell depleted supernatant
was also established and the results are given in table 3.5.
% CD4+ T-cells EasySep MACS Dynal
Donor A 2% 2% NA
Donor B 1% 3% NA
Donor C 2% 3% NA
Mean % CD4+ T-cells 1.6% 2.7% NA
Table 3.5: Percentage of CD4+ T-cells remaining in the CD4+ T-cell depleted
supernatant (NA: not available - not enough cells for analysis).
Additionally, the percentage of T-cells expressing both CD4 and CD8 was
established as such cells may have been positively selected during each cell
separation and may be responsible for part of the CD8+ T-cell contamination of the
positively CD4+ T-cell enriched fraction seen in all three donors using all three cell
separation methods (table 3.4). The percentages of T-cells positive for CD3+/CD4+,
CD3+/CD8+ and CD4+/CD8+ in the PBMCs from each donor are given in table 3.6.
PBMC CD3+/CD4+ CD3+/CD8+ CD4+/CD8+
Donor A 38% 33% <1%
Donor B 30% 24% 1%
Donor C 28% 32% 1%
Table 3.6: Percentages of CD3+/CD4+, CD3+/CD8+ and CD4+/CD8+ T-cells in all
three donors.
Based on the very low percentages of double positive CD4+/CD8+ T-cells in all
three donors, these cells should not contribute to contamination of the positively
selected CD4+ T-cell enriched fraction with CD3+/CD8+ T-cells. In order to
confirm this the percentages of double positive CD4+/CD8+ T-cells in the CD4+ T-
cell enriched fraction following CD4+ T-cell positive selection were established and
are given in table 3.7.
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CD4+/CD8+ T-cells EasySep MACS Dynal
Donor A 1% 1% NA
Donor B 1% 1% <1%
Donor C 6% 3% 5%
Table 3.7: Percentage of double positive CD4+/CD8+ T-cells in the CD4+ T-cell
enriched fraction. NA: not available - not enough cells.
The percentage of double positive CD4+/CD8+ T-cells in the CD4+ T-cell enriched
fraction following all three separation methods were similar to those seen in PBMCs
(table 3.6) for donors A and B. This suggests that double positive CD4+/CD8+ T-
cells did not form part of the CD3+/CD8+ T-cell contaminating fraction (table 3.7)
in these donors. However, following CD4+ T-cell positive selection this percentage
was elevated in donor C compared with the percentage seen in PBMCs. The
percentage of double positive CD4+/CD8+ T-cells in donor C though remained
lower than the percentage of double positive CD3+/CD8+ T-cells following all three
cell separation methods as shown in table 3.7. It may therefore be posited that double
positive CD4+/CD8+ T-cells are part of the overall contaminating CD3+/CD8+ T-
cell fraction and may also be expressing CD3.
3.3.1.2 Summary of CD4+ T-cell positive selection methods on fresh PBMCs
Based on the results obtained above, the Dynal separation method was not
considered for further experiments due to the poor recovery of cells post-separation,
even though the CD4+ T-cell enriched fraction in all three donors was on average
98% pure. The MACS separation method also yielded on average a 98% pure CD4+
T-cell enriched fraction as well as a far greater total cell recovery than the Dynal
separation method (MACS 52% vs Dynal 6%). The EasySep separation method
yielded on average a 97% pure CD4+ T-cell enriched fraction but a total cell
recovery of 66%, which was greater than with the MACS and Dynal separation
methods. Additionally the EasySep separation method was technically more
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straightforward than the two other methods. The EasySep separation method was
therefore tested further on frozen PBMCs.
3.3.2 Positive selection of CD4+ T-cells from frozen PBMCs using
EasySep
The EasySep method was used to positively select CD4+ T-cells from frozen
PBMCs from two donors. The results of these positive selections are given in table
3.8.
% CD4+ T-cells % CD8+ T-cells % cells recovered
Donor 1 72% 27% 26%
Donor 2 96% <1% 38%
Table 3.8: Summary of purity of the CD4+ T-oell enriched fraction and the
percentage of cells recovered post-separation.
The purity of the CD4+ T-cell enriched fraction for donor 2 was in line with the
results obtained using the fresh PBMCs. However, the purity for donor 1 was lower
with only 72% of CD4+ T-cells and 27% of contaminating CD8+ T-cells.
Furthermore, the percentage of cells recovered from both donors was poor. This was
due to the cell clumping during the separation procedure.
3.3.3 Summary of cell separation trial
The enrichment ofCD8+ T-cells from PBMCs (fresh or frozen) was not investigated,
as this uses the same method as CD4+ T-cell enrichment. The results of the CD4+ T-
cell enrichment trials were not adequate for the downstream experiments planned.
Another method would have to be developed in order to investigate CD4+ T-cell and
CD8+ T-cell interactions in CTL development, but this was not carried out as part of
this project.
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3.4 Discussion
3.4.1 Growth of CTLs
Cytotoxic T-cell lines have been generated and used in the treatment of PTLD. Such
CTLs were shown to expand up to 2xl09 cells over the course of 10 weeks of culture
(Wilkie et al, 2004). The pattern of proportional growth of the CTLs generated in
this project was the same as previously reported (Wilkie et al, 2004). The CTLs
proportionally increased between S2 and S4, after which numbers decreased. The
viability of the CTLs decreased from S2 onwards and decreased more rapidly after
S4. Proportional growth is likely to occur as activation-induced cell death is
overcome by the addition of IL-2, which maintains T-cell proliferation (Seder and
Ahmed, 2003). The growth trend of the CTLs was established as this may provide an
indication for the mechanism that limits CTL proliferation and therefore suggests
ways by which this may be manipulated.
There would appear to be a limit to the potential growth that the CTLs could achieve.
In vitro mitogen-stimulated CD8+ T-cells express a protein, pl6INK4a, essential in
cell proliferation control (Migliaccio et al, 2005). Expression of this protein is
associated with cessation of proliferation of a large proportion of in vitro mitogen-
stimulated CD8+ T-cells. The CD8+ T-cells were stimulated every 10 to 15 days and
upon the fifth round of stimulation the greatest proportion of cells expressing
pl6INK4a was observed indicating that the greatest proportion of cells exiting the cell
proliferation cycle occurred at that time. A parallel may potentially be drawn
between this finding and the fact that the CTLs grown in this project showed a
decrease in proportional growth following five weeks of culture, equivalent to five
rounds of stimulation. However, the CTLs generated here, as well as those
characterised by Wilkie et al (2004) were not purified CD8+ T-cell cultures,
although the majority of these CTLs comprised >80% ofCD8+ T-cells.
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Another potential factor limiting the period of in vitro CTL growth may be related
replicative senescence. Replicative senescence occurs when telomere shortening
becomes critical and it is no longer possible for the cell to divide appropriately, at
which point cell cycle arrest occurs. Transduction of human telomerase reverse
transcriptase, which can reverse the effects of replicative senescence, into CD8+ T-
cells specific for melanoma antigen recognised by T-cell 1 (MART-1) resulted in the
ability to culture these CD8+ T-cells for at least 10 months (Schreurs et al, 2005).
However, following 12 months of culture these cells progressed into
immunosenescence where functional activity was lost. This was in stark contrast to
untransduced CD8+ T-cells whose lifespan was limited to three to four months,
which is in line with the lifespan of the CTLs generated here.
3.4.2 Basic phenotype of the CTLs
There was a contrast between the two CD4+ predominant CTLs (2 and 13, in which
there was an initial decrease in CD4+ T-cells followed by an increase) and CD8+
predominant CTLs (which showed a steady increase in proportion of CD8+ T-cells).
This may due to the period of antigen exposure required to initiate the proliferation
of naive CD4+ T-cells, which appears to be longer than for CD8+ T-cells.
Additionally, it may be due CD8+ T-cells dividing earlier and at a faster rate than
CD4+ T-cells following exposure to antigen. This may be linked to fundamental
differences in the differentiation and function undertaken by both cell types (Seder
and Ahmed, 2003). These differences may also underlie the fact that the majority
(82% - 9 out of 11 CTLs) of CTLs generated in this project were predominantly
CD8+. Where the CTL was predominantly CD4+ or CD8+ in phase 2 of growth
>79% of the CTLs expressed the dominant marker.
3.4.3 Phenotype of the CTLs
The results of extended phenotyping show that during the first four weeks of culture
the phenotype of the CTLs progressed from a nai've phenotype seen in PBMC
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(stimulation 0) to an antigen-experienced/mature phenotype. Additionally, the
phenotype observed in phase 1 persisted in phase 2. This indicates that there is a
pattern in the phenotypic development of the CTLs in response to antigen
stimulation.
The increase in CD4+ T-cells and CD8+ T-cells co-expressing CD45RO in the CTLs
and the concurrent decrease in CD4+ T-cells and CD8+ T-cells co-expressing
CD45RA observed at S2 indicates that both cell types are responding to antigenic
stimulation of the TCR and that both cell types are progressing towards an antigen-
experieneed/mature phenotype (Figures 3.9, 3.10 and A3.2 and A3.3). The increase
in the proportion of cells expressing CD45RO was comparable in the two cell types,
as was the decrease in the proportion of cells expressing CD45RA indicating that the
cells had responded to antigen exposure. Progression towards an antigen-
experienced/mature phenotype was also supported by a gradual decrease in CD4+
and CD8+ T-cells co-expressing CD27 or CD28 in the CTLs. However, the decrease
in expression of both CD27 and CD28 was slower in CD4+ T-cells than in CD8+ T-
cells. The proportions of CD4+ T-cells expressing either markers at stimulations 2
and 4 were higher than those observed for CD8+ T-cells. This may indicate that
CD4+ T-cells in the CTLs differentiate more slowly in response to antigenic TCR
stimulation. The progressive loss of these markers in CTLs in vivo is paralleled with
the acquisition of cytolytic proteins, such as perforin, in both cell types, which would
suggest that CD4+ T-cells acquire cytolytic potential later on in the culture period
(Appay, 2004; Appay et al, 2002a). In conjunction with the gradual loss of CD27
and CD28 in the CTLs there was also a decrease in CD4+ T-cells and CD8+ T-cells
co-expressing CD62L in the CTLs. This drop occurred during the first four weeks of
culture, which indicates that both cell types were progressing towards an antigen-
experienced/mature phenotype. A decrease in CD62L, on both CD4+ and CD8+ T-
cells, would be critical in the context of PTLD immunotherapy as it is essential for
the CTLs to home to the tumour and not to the lymph nodes. There was an increase
in the proportion of CD4+ T-cells and CD8+ T-cells co-expressing CD69 in the
CTLs indicating that the T-cells were activated following antigen exposure.
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Based on these findings it would appear that weekly stimulations with autologous
LCLs generate CTLs which display all the extracellular hallmarks of antigen-
experienced/mature cells and that there is a pattern in CTL development beyond
CD4+ and CD8+ expression. There were, however, differences between CD4+ T-cell
and CD8+ T-cell differentiation, with CD8+ T-cells not only responding sooner to
antigenic stimulation of the TCR, but also differentiating faster than CD4+ T-cells.
As TCR stimulation is the key to the development of the CTLs in terms of growth
and phenotypic evolution, investigation in the development of the TCR was carried
out next, with a view to determine whether changes in TCR development also
occurred. Additionally, the presence of cytolytic molecules such as perforin was
investigated (to establish whether the CTLs were acquiring cytolytic molecules) and
the results are presented in chapter 5.
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4.1 Introduction
The T-cell receptor (TCR) is an immunoglobulin-like heterdomeric protein. It can be
composed of membrane-bound a and |3 or y and 6 glycopeptide chains. Each chain is
encoded by a series of variable (V), diversity (D), joining (J) and constant (C) gene
segments. Recombination of these segments (V-J in the a chain and V-D-J in the (3
chain), as well as imprecise joining, random mutations and nucleotide insertion result
in a wide variety of TCRs being generated. Variability in the TCR is concentrated
around three complementarity determining-regions (CDRs). Complementarity
determining-regions 1 and 2 are encoded by germline DNA in the V gene segments
whereas CDR3 is formed by V-D-J joining and is more variable. The CDR3 of the
TCR (3 chain is the most diverse (Sourdive et al, 1998). It is encoded in part by the
variable (3 chain segments ofDNA, and in part arises from imprecise joining, random
mutations and nucleotide insertions. The CDRs are essential in binding the antigenic
peptide/major histocompatibility complex (MHC), with CDR1 and CDR2 primarily
binding the MHC and CDR3 binding antigenic peptide. CDR3 length is therefore
used to assess diversity of the TCR.
The diversity of the TCR repertoire in CTLs stimulated weekly with autologous LCL
was investigated by TCR spectratyping, an RT-PCR-based technique that measures
the length of the CDR3. This was done by using 23 pairs of primers, specific for
known sequences of variable (3 (V|3) chain segments, the products of which are
referred to as Vp families. Products within these families vary in length within a
given size range and identify different CDR3s. The TCR repertoire can become
skewed following antigen exposure, with the preferential use of particular V[3
families (Kolowos et al, 1999).
CTLs are already in clinical use for PTLD treatment (Haque et al, 2001; Haque et al,
2002; Wilkie et al, 2004), however the diversity of their TCR repertoire has not been
established. TCR spectratyping was therefore carried out on CTLs. Using TCR
sepctratyping the number and the frequency of V|3 families in use in the CTLs during
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the period of culture were established. Further investigations were carried out to
determine the clonality of the V(3 families and how this evolved during culture time.
Finally, the persistence of specific clones within polyclonal and clonal/biclonal
families over time was studied.
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4.2 T-cell receptor Vp families in the CTLs
4.2.1 Cytotoxic T-cell lines
T-cell receptor sprectratyping was carried on CTLs across phases 1 and 2 of growth.
Details of the CTLs analysed are given in table 4.1 where "S" refers to the weekly
stimulation with autologous LCLs. Additionally, TCR spectratyping was carried out
on the PBMCs used to generate CTLs 3, 4, 5 and 7.
Stimulations at which TCR spectratyping was carried out
CTLs Phase 1 of growth (SI to S4) Phase 2 of growth (S5 - onwards)
2 S2, S3, S4 S5
3 S3 S5
4 S4 S5, S6, S7, S8, S9
5 SI, S2, S3, S4 S5, S6
7 SI, S2, S3, S4 S5, S6, S7, S8, S15
9 SI, S2, S3, S4 S5, S6
12 S2, S4 S5, S6, S7
13 S4 S5, S7, S8
Table 4.1: CTLs whose TCR was spectratyped. S: weekly stimulation with
autologous LCL.
4.2.2 T-cell receptor spectratypinq
T-cell receptor reverse-transcriptase polymerase chain reaction (TCR RT-PCR) and
sequencing were carried out as described in section 2.3.4 of chapter 2. Figure 4.1
represents a typical agarose gel of TCR RT-PCR on one CTL obtained before
sequencing. The TCR RT-PCR for CTLs 5 (SI to S6), 7 (SI to S8) and 9 (SI to S6)
were carried out by Karen McAulay.
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lOObp
1. lOObp 5. Vp-4 9. Vp-8 13. Vp-13 17. vp-17 21. Vp-22
ladder 334-346 bp 355-373 bp 408-425 bp 226-241 bp 234-252 bp
2. Yp-1 6. Vp-5 10. Vp-9 14. Vp-14 18. Vp-18 22. Vp-23
195-207 bp 354-375 bp 194-212 bp 328-383 bp 325-337 bp 358-370 bp
3. Vp-2 7. Vp-6 11. Vp-11 15. Vp-15 19. VP-20 23. Vp-24
195-207 bp 329-347 bp 321-333 bp 193-208 bp 218-227 bp 353-368 bp
4. Vp-3 8. Vp-7 12. Vp-12 16. Vp-16 20. Vp-21 24. Vp-25
190-208 bp 190-214 bp 267-290 bp 241-256 bp 185-200 bp 226-241 bp
Figure 4.1: Agarose gel of TCR RT-PCR on one CTL at one stimulation and table of
expected product sizes, bp: base pair.
The data generated following sequencing of the RT-PCR products visualised on
agarose gels, as seen in figure 4.1 are presented in graph form. One graph was
generated for each V(3 family. A typical graph of one V|3 family is shown in figure

























Figure 4.2: Graphical representation of one Vp family. Blue peaks: CDR3 length
and orange peaks: size standard.
In figure 4.2, there are two peaks, each corresponding to a T-cell clone with a
particular CDR3 length for that VP family (359bp and 368bp). The difference
between each peak is approximately a multiple of 3bp, which corresponds to one
amino acid change in the CDR3. The relative fluorescence units (RFU) correspond to
the relative expression of the T-cell clone in question within the CTL. Peaks with a
RFU <1000 were considered as background.
4.2.3 Vp family usage by the CTLs
The usage of VP families by the CTLs in the different phases of growth (including
PBMCs) was investigated, as CTL usage of VP families had not been previously
established. The usage ofVp families by one CTL is summarised in table 4.2. Table
4.2 shows that the number of families used by the CTL varied from week to week
but over the six-week culture period it shows that all Vp families had been used with
the exception of Vp-25. The same was seen in the CTLs for which data are given in
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appendix A4. Such tables were drawn up for all CTLs and are included in appendix
A4.












15.3 All families were used over the course of six
stimulations with LCLs, except V(3-25
Table 4.2: V(3 families used by one CTL during six weeks of culture with weekly
stimulations with LCLs. Nb: number.
The percentage of V(3 family usage by all CTLs at each stimulation analysed (given
in table 4.1) is summarised in table 4.3 (i.e.: 100% means that a V|3 family was used
by a CTL at each stimulation analysed and 50% means that a V|3 family was used in
half of the stimulations analysed). This table shows that three of the CTLs used all of
the V (3 families during the course of culture and five did not. Family V(3-18 was not
used by CTL 3, family V|3-20 was not used by CTLs 3, 4 and 5 and family V(3-25
was not used by CTLs 3, 4, 9 and 13. It also shows that the most frequently used V|3
family is V|3-3, which was used by all CTLs at all weekly stimulations. V|3 families
2, 4, 5, 6, 9, 12, 21 and 22 were also frequently used, with an average of more than
80% of the CTLs using these families during culture. Other families were, on
average, not as frequently used but this varied from one CTL to another, as seen with
family V|3-20 that was used by two CTLs at all stimulations analysed but was not
used at all by three other CTLs. This indicated that V(3 family usage varies between
CTLs but also within CTLs over time (table 4.2 and tables A4.1 to A4.7).
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vp CTLs Avg
families 2 3 4 5 7 8 12 13 %
vp-i 75% 33% 57% 57% 80% 71% 60% 25% 57%
Vp-2 100% 100% 100% 71% 78% 71% 100% 75% 87%
Vp-3 100% 100% 100% 100% 100% 100% 100% 100% 100%
VP-4 75% 66% 100% 83% 100% 86% 100% 75% 86%
VP-5 50% 100% 100% 71% 80% 100% 100% 75% 85%
Vp-6 75% 66% 100% 57% 100% 86% 80% 100% 83%
VP-7 75% 33% 50% 100% 67% 71% 80% 100% 72%
VP-8 75% 33% 100% 86% 90% 71% 80% 75% 76%
VP-9 100% 100% 86% 86% 100% 86% 80% 100% 92%
vp-n 100% 66% 29% 43% 60% 57% 40% 50% 48%
Vp-12 100% 100% 100% 29% 70% 100% 100% 100% 87%
VP-13 75% 66% 100% 57% 70% 43% 60% 100% 71%
VP-14 75% 33% 100% 57% 80% 57% 100% 33% 67%
Vp-15 75% 100% 71% 57% 90% 86% 80% 33% 74%
VP-16 100% 33% 57% 86% 90% 57% 100% 50% 60%
Vp-17 75% 66% 57% 100% 70% 86% 60% 75% 61%
VP-18 25% 0% 14% 17% 60% 43% 20% 50% 29%
VP-20 100% 0% 0% 0% 70% 29% 60% 100% 45%
Vp-21 100% 66% 100% 40% 80% 100% 100% 100% 86%
VP-22 100% 66% 83% 83% 89% 86% 100% 100% 88%
Vp-23 50% 66% 86% 86% 78% 43% 80% 50% 67%
Vp-24 100% 33% 43% 66% 78% 29% 40% 50% 55%
VP-25 25% 0% 0% 66% 20% 0% 20% 0% 16%
Table 4.3: Frequency of V(3 family use by all the CTLs over the course of their
culture period.
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Having found that the TCR repertoire of the CTLs was broad and hence diverse in
terms of VP family usage during the course of culture families, the clonality of the
families was investigated next.
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4.3 Evolution and clonality of vp families in CTLs
4.3.1 Definition of clonal, biclonal and polyclonal vp families
The clonality of all the V(3 families used by the CTLs was investigated next, in order
to determine whether the V(3 families evolved during the course of culture. Families
were described either as polyclonal, biclonal or clonal depending on the number of
peaks shown on the analysis graphs. The number of peaks corresponds to the number
of T-cell clones expressing CDR3s from a family. Figure 4.3 shows a) a clonal
family, where there is only one peak (one T-cell clone), b) a biclonal family, where
there are two peaks (two T-cell clones with CDR3s of different lengths derived from
the same Y (3 family) and c) a polyclonal family, where there are in excess of two
peaks (more than two T-cell clones with CDR3s of different lengths derived from the
same V(3 family). Clonal and biclonal families were grouped for the purpose of
analysis, as these are quite distinct from polyclonal families.
Figure 4.3: Definition of clonal, biclonal and polyclonal families.
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4.3.2 Evolution and clonality of Vp families in CTLs
The evolution of the V(3 families in the CTLs was established, with regard to the
number of clonal/biclonal and polyclonal families being used by the CTLs at each
weekly stimulation. Figure 4.4 shows the evolution of one CTL.
CTL 7 - TCR development
16
PBMC S1 S2 S3 S4 S5 S6 S7 S8 S15
Weekly stimulations with LCL
■ Polyclonal families ■ Clonal and Biclonal families
Figure 4.4: Development of TCR V0 families in CTL 7.
4.3.2.1 Evolution of polyclonal families
The number of polyclonal families being used by each CTL changed from the first
weekly stimulation analysed in phase 1 of growth (SI to S4) to the last stimulation
analysed in phase 2 of growth (S5-onwards). In CTLs 2, 3, 9 and 13 there was an
increase in the number of polyclonal families in use over the course of each CTL's
culture period, and there was a decrease in the number of polyclonal families in use
in CTLs 4, 5 and 12. There was no change in the number of polyclonal families used
by CTL 7 at the first stimulation and at the last stimulation analysed. With the
exception of CTL 12, where the number of polyclonal families used decreased
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continuously during the course of culture, the number of polyclonal families used by
all other CTLs fluctuated over time.
Further analysis of results was carried out to determine whether there were particular
families that remained polyclonal throughout the CTL culture period. This analysis is
summarised in table 4.4. This table shows that the family V(3-3 remained polyclonal
in six of the CTLs investigated. This family was also in use in CTLs 7 and 13 but it
was not polyclonal at all stimulations analysed. The family V|3-12 remained
polyclonal in five of the CTLs tested.
CTLs 2 3 4 5 9 12 13
VP families 2, 3, 12, 20, 22 2, 3, 5, 9,12 3,4,12 3 3 3, 12 12
Table 4.4: Persistently polyclonal families in CTLs.
The V|3-3 and V|3-12 families were two of the most frequently used families by all of
the CTLs during their course of culture (table 4.3). The V(3-3 family was in use in all
CTLs at all stimulations tested and the V|3-12 family was in use at all stimulations
tested in five CTLs (see table 4.3). Two of the most frequently used families
therefore appear to remain polyclonal.
4.3.2.2 Evolution of clonal and biclonal families
In five CTLs - CTLs 3, 5, 7, 9 and 12 - there was an increase in the number of
clonal and biclonal families from the first weekly stimulation with LCL analysed in
phase 1 of growth (SI to S4) to the last stimulation analysed in phase 2 of growth
(S5-onwards). This increase was only continuous over time in CTLs 5 and 12. In the
other four CTLs the number of clonal and biclonal families was variable over time.
Further analysis of results was carried out to determine whether the increase in clonal
and biclonal families could be attributed to particular families persisting over time
becoming and/or remaining clonal or biclonal. There was no persistence of particular
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V[3 families in CTLs 3 and 7, however families were found to persist in CTLs 4, 5, 9
and 12. These results are shown in table 4.5 a) to d).
a) CTL 4 PBMC S4 S5 S6 S7 S8 S9
Clonal/Biclonal
Polyclonal 21
21 21 21 21 21
21




17 17 17 17
c) CTL 9 PBMC SI S2 S3 S4 S5 S6
Clonal/Biclonal 12,22
Polyclonal
12 12 12 12,22 12,22
12* 22 22 22
* Vpi2 was polyclonal at SI only.
d) CTL 12 S2 S3 S4 S5 S6
Clonal/Biclonal
Polyclonal 2, 4, 14, 16
4, 14. 16 4, 14, 16 2, 4, 14, 16 2, 4, 14, 16
2 2
Table 4.5: Persistent Vp families in CTLs a) 4, b) 5, c) 9 and d) 12.
These tables show that there was not one particular Vp family that preferentially
became and remained clonal or biclonal during the course of culture of the CTLs.
Tables 4.5 a) and b) also show that in CTLs 4 and 5 respectively only one VP family
remained clonal/biclonal during the course of culture; tables 4.5 c) and d)
respectively show that in CTL 9 two VP families remained clonal/biclonal during the
course of culture and in CTL 12 four VP families remained clonal/biclonal. This
accounts only for a small portion of the clonal and biclonal families used at any one
stimulation by the CTLs. The progression to clonality/biclonality is therefore
variable in terms of which families become clonal/biclonal following stimulation
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with LCL but it is also "reversible" as families were found to be clonal/biclonal at
one stimulation and polyclonal at the next stimulation.
The evolution of two persistent clonal/biclonal V |3 families in two different CTLs is
represented in figures 4.5 and 4.6. Family V(3-17 from CTL 5 is shown in figure 4.5
and the family V(5-22 from CTL 9 is shown in figure 4.6. Each bar represents one
clone.





PBMC S1 S2 S3 S4 S5 S6
Weekly stimulations with LCL
Figure 4.5: Evolution of family Vp-17 in CTL 5. Each bar represents one clone.
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CTL 9 - Evolution of family VP-22
30000
w
Weekly stimulations with LCL
Figure 4.6: Evolution of family V|3-22 in CTL 9. Each bar represents one clone.
4.3.2.3 Summary
In four CTLs (4, 5, 7 and 12) the number of polyclonal families used decreased and
the number of clonal/biclonal families increased during the period of culture,
resulting in there being more clonal/biclonal families than polyclonal families at the
last stimulation tested for each CTL. In two CTLs (2 and 13) the number of
polyclonal families increased and the number of clonal/biclonal families decreased
resulting in there being more polyclonal families than clonal/biclonal families at the
last stimulation tested for each CTL. In CTL 3 both the number of polyclonal and
clonal/biclonal families increased, resulting in there being more polyclonal families
than clonal/biclonal families at the last stimulation tested. In CTL 9, the number of
polyclonal families increased and the number of clonal/biclonal families was the
same in the PBMC than at S6, but there remained more clonal/biclonal families than
polyclonal families.
Stimulation with LCL appeared to favour the use of family Vj3-3, which was used by
all CTLs at all stimulation tested. The use of family V(3-3 was preferentially
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polyclonal as found in six CTLs. Interestingly, family V|3-12, which was found to be
preferentially polyclonal over time in five CTLs, was found to have become and
remain clonal/biclonal in another CTL. Stimulation of the CTLs using autologous
LCL did not appear to drive preferential clonal/biclonal use of particular V|3 families
in the CTLs over time.
Based on these results it appears that development of the V|3 families is a fluid and
dynamic process where families may be in use at one stimulation but not at the next.
Furthermore, these families may be polyclonal or clonal/biclonal families at one
stimulation and the converse at the next stimulation.
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4.4 Development of T-cell clones within Vp families
The development of T-cell clones within V (3 families was studied next, in order to
determine whether the dynamic and fluid development of VP families was associated
with the presence, absence or persistence of certain T-cell clones during culture.
4.4.1 Investigation of T-cell clones within clonal/biclonal families
The families that became clonal/biclonal were V|3-2, V|3-4, Vp-12, V|3-14, V(3-16,
V|3-17, Vp-21 and V|3-22. These are listed in table 4.5 along with the CTLs in which
they were identified. The development of two of these clonal/biclonal families is
represented in figures 4.7 and 4.8.
Figure 4.7 shows that family V|3-17 was polyclonal for the first four stimulations,
although by S3, a dominant T-cell clone with a TCR CDR3 length of 239bp emerged
in CTL 5. This clone persisted over time, whilst the other TCR clones became less















Figure 4.7: Development of clonal/biclonal family VJ3-17 in CTL 5.
Development of clonal/biclonal family Vp-17
all l.ll.
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Figure 4.8 shows that at SI there were three T-cell clones with different TCR CDR3
length, with one dominant clone with a CDR3 of 280bp in CTL 9. This dominant
clone persisted throughout the period of culture, whilst the two other clones
disappeared. The clonality of family V|3-12 was due to the persistence one particular
clone over time (from SI).
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The development of the other V|3 families, which became clonal/biclonal is
summarised in tables 4.6 a) to f). The columns highlighted in blue show which




a) V0-2 - CTL 12 Relative expression of TCR clones in rfu
CDR3 length 196bp 199bp 202bp 205bp
S2 14720 rfu 11147 rfu 16362 rfu 5627 rfu
S4 9988 rfu 6844 rfu 6049 rfu 3927 rfu
S5 10960 rfu 5713 rfu 6040 rfu 1127 rfu
S6 1708 rfu 2015 rfu
S7 3749 rfu 1227 rfu
b) VP-4-CTL 12 Relative expression of TCR clones in rfu
CDR3 length 334bp 337bp 340bp 343bp 346bp
S2 2535 rfu 2373 rfu 5621 rfu 30883 rfu 5416 rfu




c) VP-14-CTL 12 Relative expression of TCR clones in rfu
CDR3 length 373bp 376bp 379bp 380bp
S2 1688 rfu 2592 rfu 32670 rfu
S4 1164 rfu 24530 rfu
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d) VP-16 - CTL 12 Relative expression of TCR clones in rfu
CDR3 length 242bp 245bp 248bp 254bp
S2 2580 rfu 1768 rfu 2046 rfu 32427 rfu




e) Vp-21 - CTL 4 Relative expression of TCR clones in rfu
CDR3 length 184bp 187bp 190bp 193bp 196bp 199bp
PBMC 5862 rfu 4120 rfu 6326 rfu 4055 rfu 3331 rfu 3035 rfu
S4 1201 rfu 9567 rfu 2260 rfu
S5 17339 rfu 1268 rfu
S6 7606 rfu
S7 23889 rfu 1054 rfu
S8 7751 rfu
S9 2663 rfu
f) Vp-22 - CTL 9 Relative expression of TCR clones in rfu
CDR3 length 238bp 241bp 244bp 253bp
PBMC 1457 rfu
S2 1328 rfu 1245 rfu 5709 rfu 20768 rfu
S3 2016 rfu 6863 rfu 22640 rfu
S4 1049 rfu 10315 rfu 25508 rfu
S5 4954 rfu 11230 rfu
S6 8312 rfu 16621 rfu
Table 4.6: Development of clonal/biclonal family a) Vp-2, b) Vp-4, c) Vp-14, d) Vp-
16, e) Vp-21 and f) Vp-22. Relative expression of peaks is expressed in relative
fluorescence units (RFU).
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One T-cell clone was found to persist in culture for families V|3-2, V|3-4, V(3-14, V(3-
16 and V[3-17. One clone (244bp) persisted for family V(3-22 and family V|3-12
(280bp) from the S2 but not from SO (PBMC). The clonality of five out of eight
clonal/biclonal families (V|3-2, V|3-4, V(3-14, V(3-16 and V(3-21) was attributable to
the persistence on one T-cell clone throughout the period of culture. In families V(3-
17 and V|3-22, the clones found at the last stimulation analysed were not detected
throughout the period of culture analysed.
4.4.2 Investigation of T-cell clones within polyclonal families
The V|3 families which remained polyclonal throughout the culture of the CTLs,
were investigated in order to determine whether the same T-cell clones persisted over
time. The V|3 families which were investigated are given in table 4.4.
4.4.2.1 Polyclonal families VB-2. VB-4. VB-5. VB-9. VB-20 and VB-22
In CTL 2 family Vp-2, there were four clones, which were present at S2 through to
S5. In family VP-22, there were four clones at S2 and six at S5, four of which were
also present as at S2. For family VP-20, there were four clones at S2 and three at S5,
two of which were the same as at S2.
In CTL 3 family VP-5, there were six clones at S3 and three at S5, all three of which
had also been found at S3. In family VP-9, there were three clones at S3 and three at
S5 but only one of those clones had been found at S3.
In CTL 5 family VP-4, there were five clones in the PBMC (four at S4) and three at
S9; all three of these clones were found throughout the period of culture.
Based on the data gathered for CTLs 2, 3 and 5 T-cell clone persistence also occurs
in polyclonal families but the number of clones found in a family can vary during
culture.
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4.4.2.2 Polyclonal families VB-3 and VB-12
As family Vp-3 was found to be polyclonal at all stimulations in six CTLs, the
persistence of T-cell clones was investigated within the CTLs but also between the
CTLs. The same was done for family VP-12 as it was detected in five of the CTLs.
a) Family VP-3
Between three and six clones were detected at the earliest stimulation analysed. The
size of the CDR3 lengths of these T-cell clones were: 192bp, 195bp, 198bp, 201bp,
204bp and 207bp. Between two and five of these clones were detected at the latest
stimulation analysed in the CTLs. However, the T-cell clone with the CDR3 length
of 204bp was found in all CTLs tested at all stimulations tested.
b) Family VP-12
Between six and eight clones were detected at the earliest stimulation analysed. The
CDR3 lengths of these T-cells clones were: 267bp, 270bp, 273bp, 276bp, 279bp,
282bp, 285bp and 288bp. No single clone was detected in all CTLs, but three clones
(273bp, 276bp and 279bp) were detected at all stimulations in four CTLs. The
polyclonality of the VP-12 family was not centred around one clone, as with family
VP-3, but three clones.
4.4.3 Summary
The families that remained or became clonal/biclonal during the course of culture of
the CTLs investigated were all different. The clonality/biclonality of six VP families
was attributable to the presence of one clone from the earliest stimulation analysed
(SI to S4) to the last stimulation analysed (S5 onwards). In two VP families, the T-
cell clone (s) that conferred the family its clonality/biclonality was not present
throughout the period of culture.
There were eight polyclonal families, which were detected throughout the course of
culture in seven CTLs. Family VP-3 was detected in all CTLs and family VP-12 was
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detected in five of the CTLs. The other polyclonal families were found only once in
four CTLs. In family VP-3, polyclonality in all CTLs revolved around one T-cell
clone and in family VP-12, polyclonality in all CTLs revolved around three T-cell
clones. This suggest a degree of conservation of CDRs in a polyclonal setting. It also
suggests that LCLs present antigen (s) of a similar nature to CTLs in order for these
particular clones to persist in CTLs generated from PBMC of donors with different
HLA types.
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4.5 Discussion
Memory T-cells to common pathogens (CD62L negative), such as HCMV, display a
restricted TCR repertoire in terms of VP family clonality, which may be associated
with chronic antigen exposure (Foster et al, 2004). The CTLs analysed in this project
were stimulated weekly with LCLs, providing the CTLs with chronic antigen
exposure. However, the CTLs analysed demonstrate that at the level of VP family
usage and also at the level of the clonality of the VP families there was no restriction
in the TCR repertoire. There was usage of almost all VP families and there was no
discernable pattern in terms of specific VP families becoming clonal/biclonal during
the course of culture. This type of TCR repertoire has been termed "private" with
considerable inter-CTL (hence PBMC donor) diversity and variation, making each
CTL unique. There was, however, the persistence of one clone from family VP-3,
which was present in all CTLs at all stimulations analysed. This would be considered
a "public" clonotype, which is not specfic to one CTL (hence PBMC donor).
"Public" clonotypes such as the one found in family Vp-3, have been found in HLA-
A2 individuals reactive to the EBV lytic antigen BMLF-1 (Lim et al, 2000). In this
setting, the detection of this clonotype was not restricted to a specific HLA type.
Taken together, these results indicate that weekly LCL stimulation maintained a
broad and diverse TCR repertoire in the CTLs. The presence of antigen/MHC class I
complexes with prominent features on the LCLs may be responsible for this, as it has
been shown that featureless antigen/MHC class I complexes reduced the diversity of
TCR usage (Turner et al, 2005). Additionally, this diversity and breadth of the TCR
repertoire may have also arisen because the contraction of initially expanded cells
following primary antigen stimulation was prevented by the addition of IL-2 to the
CTLs.
Such breadth and diversity in the TCR repertoire may be essential in the context of
PTLD treatment with allogeneic CTLs, along with the potential structural flexiblity
of the CDR3 of the TCR (Garcia et al, 1998), as it may increase the likelihood of
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CTL recognition of antigen presented particularly in a partially HLA-matched
context.
Antigen recognition by the TCR is the key to triggering the effector mechanisms of
the CTLs. Having established that there was no distinct pattern in the development of
the TCR but that its stimulation did induce phenotypic changes, consistent with an
antigen-experienced/mature phenotype, the function of the CTLs was investigated
next.
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CHAPTER 5 CYTOTOXIC PATHWAYS AND CYTOLYTIC PROTEINS
5.1 Introduction
Investigation into the cytotoxic pathways of the CTLs was carried out on three of the
CTLs (5, 7 and 9) described in previous chapters. There were not enough stored cells
from the other CTLs to carry out further investigations. In order to complement these
results, 9 other CTLs (15-24) were also investigated. These CTLs were in phase 2 of
growth. The cytolytic proteins and the cytotoxic pathway(s) employed by these CTLs
in vitro had not been previously established. Additionally, it was established in
chapter 3 that CTLs progressed towards a highly differentiated antigen-experienced
phenotype that has been associated with the acquisition of cytolytic molecules such
as perforin in ex vivo CTLs (Appay et al, 2002a; Appay et al, 2002b). The cytolytic
pathways and cytolytic proteins of the CTLs were therefore investigated next.
The cytolytic proteins investigated were perforin, granzyme B, FasL and granulysin,
which have all been found in both NK cells and cytotoxic T-cells (Lieberman, 2003).
However these cytotoxic T-cells were not generated using the method used in this
work and described by Haque et al (2001) and Wilkie et al (2004). Perforin is
synthesised as a 70kDa inactive pro-protein that undergoes cleavage at the C-
terminus resulting in the 60kDa active cytolytic form of the protein, which is stored
in cytolytic granules (Uellner et al, 1997). Perforin bears a degree of homology to the
C9 component of the complement pathway and it has the ability to penetrate
membrane lipid bilayer and polymerise leading to pore formation. Granzyme B is a
32kDa serine protease (Trapani and Sutton, 2003), which is found, in conjunction
with perforin, in cytolytic granules. Granzyme B can induce apoptosis by cleavage of
pro-caspase 3, as well as by causing outer mitochondrial membrane damage
triggering the caspase cascade and leading to the release of pro-apoptotic factors, all
ofwhich ultimately lead to DNA fragmentation and target cell apoptosis (Lieberman,
2003). Fas ligand (FasL, also known as CD95L) is a type II transmembrane protein
typically expressed at the surface of cytotoxic T-cells and NK cells. FasL is a
member of the tumour necrosis factor family that binds to Fas (also known as
CD95). The binding of FasL to Fas induces a series of events that leads to the
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activation of caspase 8 and in turn of caspase 3 culminating in apoptosis of the target
cell (Aggarwal, 2003). Granulysin is a 9kDa saposin-like protein, which is found in
NK cells and cytotoxic T-cells (Pena et al, 1997). It is synthesised as a 15kDa
inactive precursor, which is post-translationally cleaved into the active 9kDa from
and it is found in cytolytic granules (Hanson et al, 1999). Apoptosis results from
granulysin binding to the target cell membrane, leading to a disruption in the flux of
calcium and potassium ions as well as the generation of ceramide, both of which
cause mitochondrial membrane damage and ultimately lead to the activation of
caspase 3 resulting in apoptosis of the target cell (Kaspar et al, 2001; Krensky and
Clayberger, 2005).
The main pathways by which the cytotoxic T-cells may effect their cytotoxic role
were investigated in the first instance, followed by the expression of the cytolytic
protein mRNA and finally the expression of the proteins themselves.
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5.2 Cytotoxicity assays of CTLs
The cytotoxicity of the CTLs in phase 2 of growth was assessed using a standard 4-
hour chromium release assay as described in chapter 2 section 2.2. The targets used
in these assays were autologous LCLs, HLA-mismatched LCLs and NK-cell
sensitive K562 cells. A modified 4-hour chromium release assay was used to
determine the nature of the cytotoxic pathways used by the cells within the CTLs.
Autologous LCLs were used as the sole target in the modified 4-hour chromium
release assay, which was carried out as described in chapter 2 section 2.2.
5.2.1 Standard 4-hour chromium release cytotoxicity assay
The results of the standard 4-hour chromium release cytotoxicity assays carried out
are given in table 5.1. Table 5.1 gives the percentage of target cell lysis by each of
the CTL at effector celhtarget cell (E:T) ratios of 20:1, 10:1 and 5:1.
CTLs E:T ratio - 20:1 E:T ratio - 10:1 E:T ratio - 5:1
Auto Mis K562 Auto Mis K562 Auto Mis K562
LCL LCL LCL LCL LCL LCL
5 65.4% 16.8% 1.7% 58.8% 11.3% 0.5% 51.9% 6.8% 0%
7 49.0% 2.4% 0% 27.1% 2.4% 0.3% 31.2% 0% 0%
9 55.5% 15.9% 5.4% 49.1% 11.8% 3.9% 37.7% 8.6% 4.1%
15 36.7% 0.9% 1% 33.9% 0% 0.5% 30.6% 0% 0%
16 27.7% 0.4% 2.8% 29.5% 0.5% 1.1% 22.8% 0.6% 0.3%
17 43% 2.8% 3.1% 41.2% 0.8% 0.6% 33.7% 0% 0%
19 79.5% 0.3% 0% 77.9% 62.4% 1.3% 86.1% 40.7% 0%
20 47.2% 3.8% 5.8% 48.8% 0% 3.6% 48.6% 0% 2%
21 23.8% 0.1% 2.7% 16.2% 2% 1.6% 14.4% 0.9% 0.5%
22 23.7% 5.7% 5.6% 19% 13% 1.3% 15.2% 12.6% 2.1%
23 38.6% 16.4% 11% 34.2% 17.6% 7% 21.3% 10.8% 2.3%
24 34% 10% 1.3% 29% 9% 0.5% 20% 5% 1.5%
Table 5.1: Standard 4-hour chromium release cytotoxicity assays results.
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Figure 5.1 represents the results of the cytotoxicity assay results given in table 5.1 at
an E:T ratio of 20:1.

















Figure 5.1: Standard 4-hour chromium release cytotoxicity assay at E:T 20:1.
Figure 5.2 is graphical representation of full cytotoxicity results for one CTL (CTL
9) at E:T ratios of 20:1, 10:1 and 5:1.
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Standard 4-hour chromium release cytotoxicity assay - CTL 9
Autologous LCL HLA-mismatched K562
LCL
Target cells
Figure 5.2: Standard 4-hour chromium release cytotoxicity assay for CTL 9 at E:T
ratios of 20:1, 10:1 and 5:1.
The cytotoxicity results demonstrate that all of the CTLs exhibit greatest lysis
towards their autologous LCL, which is indicative of target specificity. Hence, the
cytotoxic pathway(s) employed by these CTLs were investigated using the modified
4-hour chromium release cytotoxicity assay described below.
5.2.2 Modified 4-hour chromium release cytotoxicity assay
A modified 4-hour chromium release assay using concanamycin A (CMA), brefeldin
A (BFA) and ethylene glycol-bis (P-aminoethylether)-N,N,N',N'-tetraacetic acid
(EGTA) was set up to identify the potential pathways by which the cytotoxic T-cells
in the CTLs effect their cytotoxic role. CMA prevents the acidification of vacuoles
containing perforin, which leads to their degradation (Kataoka et al, 1996; Kataoka
et al, 1994). BFA inhibits Golgi-mediated transport (Zenewicz et al, 2004). The last
inhibitor used was EGTA, which chelates free extracellular calcium that is necessary
for the exocytosis of cytolytic granule-containing vacuoles (Sun et al, 2002). This
modified 4-hour chromium release assay was carried out as described in section 2.2.
164
CHAPTER 5 CYTOTOXIC PATHWAYS AND CYTOLYTIC PROTEINS
5.2.2.1 Modified 4-hour chromium release cytotoxicity assay results
The results of this modified 4-hour chromium release cytotoxicity assay are shown in
figure 5.3 (E:T 20:1). Figure 5.3 is a scatter diagram, where the bold line represents
the median of each data set. The results of the modified 4-hour chromium release
cytotoxicity assay used to generate figure 5.3 are shown in table A5.1 in appendix
A5.
Autologous LCL lysis in modified 4-hour chromium release
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Figure 5.3: Autologous LCL lysis in modified 4-hour chromium release cytotoxicity
assay (E:T 20:1). n=12 CTLs.
This modified 4-hour chromium release cytotoxicity assay was also carried out at
E:T 10:1 and 5:1 and the results are shown in figure 5.4 and figure 5.5 respectively,
where the bold line represents the median of each data set. The tables of results for
E:T 10:1 and 5:1 are in appendix A5 (table A5.2 and A5.3).
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Autologous LCL lysis in modified 4-hour chromium release
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Figure 5.4: Autologous LCL lysis in modified 4-hour chromium release cytotoxicity
assay (E:T 10:1). n=9 CTLs.
Autologous LCL lysis in modified 4-hour chromium release

















10nM CMA 40uM BFA 3mM EGTA
Figure 5.5: Autologous LCL lysis in modified 4-hour chromium release cytotoxicity
assay (E:T 5:1). n=9 CTLs.
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5.2.2.2 Result analysis
The Mann-Whitney test was used to analyse the results of the modified 4-hour
chromium release cytotoxicity assays at E:T 20:1, 10:1 and 5:1. The results of the
Mann-Whitney tests carried out are summarised in table 5.2.
% autologous LCL lysis E:T 20:1 E:T 10:1 E:T 5:1
No inhibitor vs lOnM CMA p = 0.0007* p < 0.0001* p< 0.0001*
No inhibitor vs 40jaM BFA p = 0.2855 p = 0.2581 p = 0.2581
No inhibitor vs 3mM EGTA p< 0.0001* p < 0.0001* p< 0.0001*
Table 5.2: Results of Mann-Whitney tests on modified 4-hour chromium release
cytotoxicity assays at E:T 20:1, 10:1 and 5:1. * significant at p <0.05.
These results show that both CMA and EGTA significantly inhibited autologous
LCL lysis in comparison to the control without inhibitor, whereas BFA did not. This
indicates that the principal cytotoxic pathway in the CTLs tested is mediated by
calcium-mediated granule-exocytosis and not by Golgi-mediated transport of
cytolytic proteins.
5.2.2.3 Reduction in cytotoxicity in the presence of inhibitors
The percentage reduction in cytotoxicity achieved by the inhibitors was determined
using the results of the modified 4-hour chromium release cytotoxicity assays given
in figures 5.3, 5.4 and 5.5. The results are given in table 5.3 for E:T 20:1. The mean
and median percentage reduction in cytotoxicity induced by the inhibitors at E:T
20:1 remained similar at E:T 10:1 and 5:1, as shown in table 5.4. The full tables of
results for percentage reduction in cytotoxicity induced by the inhibitors at E:T 10:1
and 5:1 are given in appendix A5 (tables A5.4 and A5.5).
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% reduction in autologous LCL lysis at E:T 20:1
Induced by CMA Induced by BFA Induced by EGTA
CTL 5 71.2% 0% 98.4%
CTL 7 34.1% 34.4% 81.7%
CTL 9 67.7% 7.0% 90.7%
CTL 15 96.2% 20.4% 94.4%
CTL 16 96.4% 24.1% 97.5%
CTL 17 99.1% 15.6% 99.6%
CTL 19 99.8% 33.0% 99.7%
CTL 20 100% 30.3% 100%
CTL 21 100% 0.6% 96.7%
CTL 22 89.1% 15.8% 95.8%
CTL 23 93.6% 16.3% 91.0%









Table 5.3: Percentage reduction in autologous LCL lysis induced by CMA, BFA and
EGTA at E:T 20:1. n=12 CTLs.
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Table 5.4: Mean and median percentage reduction in autologous LCL lysis induced
by CMA, BFA and EGTA at E:T 10:1 and 5:1. n=9 CTLs.
These results support the results of the Mann-Whitney tests shown in table 5.2,
which indicate that both CMA and EGTA have significant inhibitory effect on the
cytotoxicity of the CTLs whereas BFA does not. The potential cytolytic proteins
involved in these pathways were investigated next.
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5.3 Detection of mRNA transcripts for perforin,
granzyme B. granulysin and FasL in the CTLs
5.3.1 Perforin, granzyme B. granulysin and FasL RT-PCR
As mentioned in chapter 2 section 2.3, the primers used to detect perforin, granzyme
B, granulysin and FasL mRNA transcripts were designed using Primer 3 software.
Cells expressing the CD56 cell-surface marker (an NK cell marker) were used as a
positive control as cells expressing this marker have been shown to express perforin,
granzyme B, granulysin and FasL (Lieberman, 2003). TK-143B cells (adherent
human bone osteosarcoma cells) were used as a negative control. The TK-143B cells
were growing in tissue culture and were therefore readily available. However, the
CD56-expressing cells had to be positively selected from a CTL that had been
previously found to be rich in CD56 cells. PBMCs from two healthy laboratory
volunteers were also used a positive control as up to 10% of PBMC are CD56-
expressing NK cells (Williams et al, 2005).
5.3.2 RT-PCR positive and negative controls
In addition to the PBMCs another positive control was generated using a CTL rich in
CD56-expressing cells. 64% of the cells in that CTL expressed the CD56 marker as
determined by FACS analysis. These CD56-expressing cells were enriched by
EasySep positive selection (this was carried out as described in chapter 2 section
2.2). Following the positive selection, the CD56 enriched fraction was made up of
80% of cells expressing CD56 as shown in figure 5.6. Peaks in the area below the
marker, shown in figure 5.6, were considered as positive (peaks left of the marker









Figure 5.6: Enriched CD56 fraction following EasySep positive selection.
RNA extraction, cDNA synthesis and control (3-actin RT-PCR were thereafter
carried out on these cells. Figure 5.7 a) shows an agarose gel of p-actin RT-PCR
using RNA extracted from CD56-expressing cells (two samples), which shows that
the RNA was free of DNA contamination. Figure 5.7 b) shows an agarose gel of p-
actin RT-PCR using cDNA synthesised from the RNA (extracted from CD56-




























Figure 5.7: p-actin RT-PCR using a) RNA from CD56-expressing and b) cDNA from
CD56-expressng cells.
Figure 5.8 a) to d) shows that PBMCs (from two healthy laboratory volunteers)
expressed mRNA transcripts for perforin, granzyme B, granulysin and FasL and that
CD56-expressing cells also expressed mRNA transcripts for granzyme B, granulysin
and FasL, as RT-PCR products of the appropriate size can be seen on the agarose
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5.3.3 Perforin, qranzyme B. aranulysin and FasL RT-PCR on CTLs
The RT-PCRs for perforin, granzyme B, granulysin and FasL were carried as
previously described in chapter 2 section 2.3 and these were carried out on the CTLs
and at all stimulations given in table 5.5, as well as on CTLs 15 to 24 which were in
phase 2 of growth (at stimulations ranging from S7 to SI6).
CTLs
Stimulations at which RT-PCR was carried out
Phase 1 of growth (S1-S4) Phase 2 of growth (S5-onwards)
CTL 5 SI, S2, S3, S4 S5, S6
CTL 7 SI, S2, S3, S4 S5, S6, S7
CTL 9 SI, S2, S3, S4 S5, S6
Table 5.5: CTLs and weekly stimulation of CTLs for which perforin, granzyme B,
granulysin and FasL RT-PCR were carried out.
Figures 5.9 a) to d) represent typical agarose gels obtained following RT-PCRs for
perforin, granzyme B, granulysin and FasL. Figure 5.9 shows that CTL 20, 21, 22,
23 and 24 expressed mRNA transcripts for perforin, granzyme B, granulysin and
FasL in phase 2 of growth, as RT-PCR products of the appropriate size were detected
for each reaction. CTLs 15, 16, 17, 18 and 19 also expressed mRNA transcripts for
perforin, granzyme B, granulysin and FasL in phase 2 of growth. The RT-PCR




















































Figure 5.9: Agarose gels of a) perforin, b) granzyme B, c) granulysin and d) FasL
RT-PCR on CTL 20, 21, 22, 23 and 24.
175
CHAPTER 5 CYTOTOXIC PATHWAYS AND CYTOLYTIC PROTEINS
The results of all RT-PCRs carried out on CTLs 5, 7 and 9 (listed in table 5.5) are
summarised in table 5.6 a) to d).
a) Perforin SI S2 S3 S4 S5 S6 S7
CTL 5 + + + + + + X
CTL 7 + + + + + + +
CTL 9 + + + + + + X
b) Granzyme B SI S2 S3 S4 S5 S6 S7
CTL 5 + + + + + + X
CTL 7 + + + + + + +
CTL 9 + + + + + + X
c) Granulysin SI S2 S3 S4 S5 S6 S7
CTL 5 + + + + + + X
CTL 7 + + + + + + +
CTL 9 + + + + + + X
d) FasL SI S2 S3 S4 S5 S6 S7
CTL 5 + + + + + + X
CTL 7 - + + + + + +
CTL 9 X
Table 5.6: Summary of RT-PCRs carried out on CTLs (listed in table 5.5). a)
perforin, b) granzyme B, c) granulysin L and d) FasL.+: positive result, negative
result, x: no sample available.
5.3.4 Perforin, granzyme B, granulysin and FasL RT-PCR on LCLs
As LCLs were used to stimulate the CTLs weekly during the course of in vitro
culture and their prescence in the CTLs could not be entirely excluded, RT-PCRs
were carried out on LCLs.
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Figure 5.10 represents the agarose gels obtained following RT-PCRs for perforin,
granzyme B, granulysin and FasL on LCLs. Some LCLs were used to stimulate
multiple CTLs generated from the same PBMC donor. The numbers given to the
LCLs correspond to the CTLs generated using these LCLs.
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Figures 5.10: Agarose gels of a) perforin, b) granzyme B, c) granulysin and d) FasL
RT-PCR on LCLs.
The results of all of the RT-PCR carried out on the LCLs are summarised in table
5.7, where "+" indicates a positive reaction and indicates a negative reaction.
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Perforin Granzyme B Granulysin Fas L
LCL 15 - .
LCL 16 + +
LCL 17 + +
LCL 5 & 18 + -
LCL 7 & 19 - +
LCL 9 & 20 + +
LCL 21 - -
LCL 22 - -
LCL 23 - +
LCL 24 - _
Table 5.7: Summary of RT-PCR results for LCLs.
5.3.5 Results summary
Perforin, granzyme B and granulysin mRNA transcripts were detectable throughout
phases 1 and 2 of growth in CTLs 5, 7 and 9. However, FasL mRNA was not
consistently detected throughout phases 1 and 2 of growth in CTLs 5 and 7 and it
was not detected in phases 1 or 2 of growth in CTLs 9. mRNA transcripts for
perforin, granzyme B, granulysin and FasL were detected in CTLs 15 to 24.
Perforin mRNA transcripts were detected in four of the seven LCLs tested and
granulysin mRNA transcripts were detected in five of the seven LCLs tested (16, 17,
7 & 19, 9 & 20, 23). No mRNA transcripts for granzyme B and FasL were detected.
This means that the mRNA transcripts detected in the CTLs may be of LCL origin
and not of CTL origin. To overcome this, the expression of the cytolytic proteins was
assessed next.
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5.4 Expression of cytolytic proteins in the CTLs
Based on the results obtained above, where mRNA transcripts were detected in
LCLs, further experiments were carried out to detect the cytolytic molecules at the
protein level in the CTLs. Detection of cytolytic proteins was carried out in phase 2
of growth.
Perforin, granzyme B and FasL were all detected by intracellular FACS staining as
described in chapter 2 section 2.4. Granulysin was detected by western blotting as
described in chapter 2 section 2.5.
5.4.1 Expression of perforin, granzyme B and FasL in CTLs
5.4.1.1 Expression of perforin, granzyme B and FasL in CTLs
The expression of perforin, granzyme B and FasL in the CTLs was investigated by
determining the mean fluorescence intensity (MFI) of each cytolytic molecule. The
MFI is determined by taking the geometric mean of the perforin, granzyme B and
FasL expressing cells and subtracting from that the MFI of unstained control cells.
The geometric mean is the antilog of the mean of the logarithm of the values and it is
less likely to be affected by outliers than the mean (Swinscow and Campbell, 2002).
The MFI is expressed as an arbitrary unit (AU). Representative histograms used to
determine the MFI of each cytolytic molecule in one CTL are shown in figure 5.11.
This was done for all CTLs and the results are given in table A5.6 in appendix A5.
The data in table A5.6 is graphically represented in figure 5.12.
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a) Control-MFI: 2.98 AU
b) Perforin test MFI =
4.51 (Perforin MFI)
- 2.98 (Control MFI)
1.53 AU
c) Granzyme B test MFI =
42.13 (Granzyme B MFI)
- 2.98 (Control MFI)
39.95 AU
d) FasL test MFI =
8.24 (FasL MFI)
- 2.98 (Control MFI)
5.26 AU
Figure 5.11: Histograms used to determine the MFI of cytolytic molecules in one
CTL (CTL 17). Histograms a) unstained control b) perforin MFI, c) granzyme B MFI
and d) FasL MFI.
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Figure 5.12: MFI of perforin, granzyme B and FasL in CTLs. AU: arbitrary units.
n=12 (except for granzyme B n=11). The bold horizontal bar represents the median.
Result analysis
The results in table A5.6 and figure 5.12 show that there was considerably more
granzyme B than FasL and perforin in the CTLs. There was also marginally more
FasL than perforin in the CTLs.
5.4.1.2 Expression of perforin, granzvme B and FasL in the CD4+ T-cells and
CD8+ T-cells of the CTLs
The expression of each cytolytic protein within the CD4+ T-cells and the CD8+ T-
cells within the CTLs was next investigated. In order to do this "gates" were set
around the CD4+ T-cell population (named R3 in figure 5.13) and around the CD8+
T-cell population (named R2 in figure 5.13), as shown in figure 5.13. The proportion
of CD4+ T-cells and CD8+ T-cells in each of the CTLs was determined using this
method and the results are in appendix A5 (table 5.10).
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Figure 5.13: CD4+ T-cell and CD8+ T-cell gating in one CTL. R2 = upper left part of
the quadrant (green cells) = CD8+ T-cells and R3 = lower right part of the quadrant
(pink cells) = CD4+ T-cells. The values given in the quadrant are averages of three
separate tests. This gating process was repeated for the data analysis of all CTLs.
Once these gates were set, the expression of cytolytic proteins within the CD4+ and
CD8+ T-cell populations was determined.
Figure 5.14 shows representative histograms of a) unstained control b) the granzyme
B MFI in CD8+ T-cells c) the granzyme B MFI in CD4+ T-cells for one CTF. This
figure also shows how the MFI of granzyme B in CD8+ T-cells and CD4+ T-cells
was determined. This was done for all other CTFs and the MFI (for all cytolytic
molecules) for the all of the CTFs are given in table A5.7 in appendix A5.
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a) Control
b) Granzyme B in CD8+ T-cells
Test MFI =
44.28 (Granzyme B MFI)
2.98 (Control MFI)
41.3












10' 10L 1ft-1 10"
Test MFI =
35.81 (Granzyme B MFI)
- 2.98 (Control MFI)
32.83
Figure 5.14: Histograms used to determine the geometric mean of granzyme B in
CD4+ T-cells and CD8+ T-cells in one CTL. a) control, b) granzyme B in CD8+ T-
cells and c) granzyme B in CD4+ T-cells.
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Figures 5.15 a) and b) represent the data in table A5.7.
a) Mean fluorescence intensity of perforin, granzyme B









Perforin Granzyme B FasL
b) Mean fluorescence intensity of perforin, granzyme B















Perforin Granzyme B FasL
Figure 5.15: MFI of perforin, granzyme B and FasL in a) CD4+ T-cells and b) CD8+
T-cells. AU: arbitrary unit. n=12 (except for granzyme B n=11). The bold horizontal
bar represents the median.
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Result analysis
The results in table A5.7 and figure 5.15 parallel those found for the whole CTLs.
They show that granzyme is most abundant in both CD4+ T-cells and CD8+ T-cells,
followed by FasL and perforin.
The MFI of perforin, granzyme B and FasL were compared between CD4+ T-cells
and CD8+ T-cells using the Mann-Whitney test. The results are given in table 5.8.
Perforin MFI Granzyme B MFI FasL MFI
CD4+ T-cells vs CD8+ T-cells p = 0.17 p< 0.0016* p = 0.26
Table 5.8: Results of Mann-Whitney tests for perforin, granzyme B and FasL MFI
between CD4+ T-cells and CD8+ T-cells in CTLs. * significant at p < 0.05.
These results show that there was no significant difference in the levels of perforin
and FasL in CD4+ T-cells and CD8+ T-cells in the CTLs. However, there was
significantly more granzyme B in CD8+ T-cells than in CD4+ T-cells in the CTLs.
5.4.1.3 Proportion of cytotoxic T-cells expressing perforin, granzvme B and
FasL in the CTLs
The proportion of cells in the CTLs expressing perforin, granzyme B and FasL was
determined next. This was done by defining a marker, based on the unstained
control, where cells to left of this marker are negative and cells to the right of this
marker are positive, as shown in figure 5.16 a) to d) for one CTLs. This was repeated










Figure 5.16: Proportion of cells expressing perforin, granzyme B and FasL in one
CTL. a) control, b) perforin, c) granzyme and d) FasL.
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This was done for all cytolytic molecules in all other CTLs and the proportion of
cells expressing each cytolytic molecule is given in table A5.8 in appendix A5.
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Perforin Granzyme B FasL
Figure 5.17: Proportion of cells expressing perforin, granzyme B and FasL in CTLs.
n=12 (except for granzyme B n=11). The bold horizontal bar represents the median.
Result analysis
The results in table A5.8 and figure 5.17 show that a considerably greater proportion
of the cells in CTLs expressed granzyme B than FasL or perforin. There was also a
greater proportion of the cells in the CTLs expressing FasL and perforin.
5.4.1.4 Proportion of CD4+ T-cells and CD8+ T-cells expressing perforin,
granzvme B and FasL in the CTLs
The proportion of CD4+ T-cells and CD8+ T-cells expressing cytolytic molecules
was determined by using the same gating process as described in section 5.4.1.2 a)
(see figure 5.13). The proportion of CD4+ T-cells and CD8+ T-cells expressing
perforin, granzyme B and FasL in one CTL was determined by using the histograms
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shown in figure 5.18 below (using the marker defined in figure 5.16). This was
repeated for all CTLs and the results are given in table A5.9 in appendix A5. The
data in table A5.9 is graphically represented in figure 5.19.
a) Proportion of granzyme B positive cells CD4+ T-cells and CD8+ T-cells
M-r
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b) Proportion of perforin positive cells CD4+ T-cells and CD8+ T-cells
Gated on CD8+ T-cells
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c) Proportion of FasL positive cells CD4+ T-cells and CD8+ T-cells
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Figure 5.18: Proportion of CD4+ T-cells and CD8+ T-cells from CTL 3 expressing a)
granzyme B, b) perforin and c) FasL.
a) Proportion of CD4+ T-cells positive for perforin,











0 f ■ T I i












b) Proportion of CD8+ T-cells positive for perforin,
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Perforin Granzyme B FasL
Figure 5.19: Proportion of a) CD4+ T-ceiis and b) CD8+ T-cells expressing perforin,
granzyme B and FasL in all CTLs. n=12 (except for granzyme B n=11). The bold
horizontal bar represents the median.
Result analysis
The results in table A5.9 and figure 5.19 parallel those found for the whole CTL.
There was a considerably greater proportion of both CD4+ and CD8+ T-cells
expressing granzyme B than FasL and perforin. In turn there was a greater proportion
of CD4+ and CD8+ T-cells expressing FasL than perforin.
Mann-Whitney tests were carried out to compare whether there was a difference in
the proportion of CD4+ T-cells and CD8+ T-cells expressing perforin, granzyme B
and FasL in the CTLs. The results of the Mann-Whitney tests are given in table 5.9.
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Perforin Granzyme B FasL
CD4+ T-cells vs CD8+ T-cells p = 0.19 p = 0.0023* p = 0.93
Table 5.9: Results of Mann-Whitney tests between the proportions of CD4+ T-cells
and CD8+ T-cells expressing perforin, granzyme B and FasL. * significant at p <
0.05.
These results show that there was no significant difference in the proportion of CD4+
T-cells and CD8+ T-cells expressing perforin or FasL. However, they show that
there was a significantly greater proportion of CD8+ T-cells expressing granzyme B
than there were CD4+ T-cells expressing granzyme B in the CTLs.
5.4.2 Detection of granulysin in CTLs
5.4.2.1 Western blots for granulvsin in LCLs
As LCLs 7, 9, 16, 17 and 23 tested positive by RT-PCR for granulysin mRNA
transcripts, all the LCLs used to stimulate the CTLs were tested for the expression of
granulysin protein. CD56-expressing cells were used as a positive control. This
experiment was carried out as described in section 2.5. Figure 5.20 shows a
representative western blot for granulysin carried out on four LCLs.
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1. Rainbow ladder 4. LCL 17
2. LCL 15 5. LCL 7& 19
3. LCL 16 6. Positive control
Figure 5.20: Western blot of LCLs 15,16, 17 and 7 & 19 for granulysin detection.
This figure shows that there is a clear and strong band at 9kDa for the positive
control, which corresponds to the granulysin protein. The other band for the positive
control at 27kDa is likely to be a complex of three granulysin proteins, as these can
cluster (Krensky and Clayberger, 2005). There is no band at 9kDa for any of the
LCLs indicating that no granulysin could be detected within these cells. No
granulysin was detected by western blotting in LCLs 9 & 20, 21, 22, 23 and 24.
5.4.2.2 Western blots for granulvsin in CTLs
As granulysin could not be detected in the LCLs, all the CTLs were tested. CD56-
expressing cells were used as a positive control. Figure 5.21 is a representative
western blot of seven of the CTLs tested.
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1. Rainbow ladder 4. CTL 22 7. CTL 5
2. Positive control 5. CTL 23 8. CTL 7
3. CTL 21 6. CTL 24 9. CTL 9
Figure 5.21: Western blot of CTLs 5, 7, 9, 21, 22, 23 and 24 for granulysin
detection.
This figure again shows that there was a clear and strong band at 9kDa for the
positive control, which corresponds to granulysin, as well as bands at 18kDa and
27kDa corresponding to granulysin complexes. No granulysin could be detected in
CTLs 5, 9, 21 and 22, however a 9kDa band was detected for CTL 7, 23 and 24.
Granulysin was also detected in CTL 19 but it was not detected in CTLs 15, 16, 17
and 20.
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5.4.3 Results summary for cytolytic protein detection in CTLs
There was considerably more granzyme B than FasL and in turn there was more
FasL than perforin in the CTLs. This was also the case in the CD4+ T-cells and the
CD8+ T-cells within the CTLs. There was significantly more granzyme B in CD8+
T-cells than in CD4+ T-cells but there was no significant difference in the amount of
perforin and FasL between the two cell types. There was also a considerably greater
proportion of cells in the CTLs, which were expressing granzyme B than FasL and in
turn there were more cells expressing FasL than perforin. This was also seen in
CD4+ T-cells and CD8+ T-cells within the CTLs. There was a significantly greater
proportion of CD8+ T-cells than CD4+ T-cells expressing granzyme B but there was
no significant difference in the proportion of CD4+ T-cells than CD8+ T-cells
expressing perforin or FasL. Granulysin was detected in four CTLs (33% of CTLs).
It was not detected in LCLs.
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5.5 Discussion
5.5.1 Cytotoxic pathways
The standard 4-hour cytotoxicity assays showed that the CTLs were all specific for
their autologous LCLs, with comparatively low killing of the HLA-mismatched
LCLs and K562 cells. Haque et al (2002) set cut-off values to determine whether a
CTL was sufficiently specific for infusion in PTLD patients. These were >30% of
autologous LCL lysis, <10% HLA-mismatched LCL and K562 cells. The results of
the standard cytotoxicity assays given in table 5.1 and figure 5.1 show that 10 (77%)
of the 13 CTLs tested exhibited >30% autologous LCL lysis and that three did not
(CTLs 16, 21 and 22) at E:T 20:1. Their autologous LCL lysis though was >20%.
Nine (70%) of the CTLs exhibited <10% HLA-mismatched LCL lysis. All CTLs,
with the exception of one, exhibited <10% K562 cell lysis. Whilst the cytotoxicity
results for some of the CTLs tested might not fulfil the strict criteria set up by Haque
et al (2002), they do demonstrate that all of the CTLs exhibit greatest lysis towards
their autologous LCL, which would be indicative of target specificity. Hence, the
cytotoxic pathway(s) employed by these CTLs were investigated using the modified
4-hour chromium release cytotoxicity assay.
The modified 4-hour cytotoxicity assays showed that cytotoxicity was significantly
inhibited by EGTA (p=0.0007 at E:T 20:1) and CMA (p<0.0001 at E:T 20:1) at all
three E:T ratios. (Both inhibitors are known to be non toxic to cells (Yasukawa et al,
2000)). On the other hand BFA did not significantly reduce cytotoxicity (p=0.2855 at
E:T 20:1). These findings indicate that the cytotoxic pathway(s) of the CTLs is
calcium-dependent as EGTA, a calcium-chelating agent, significantly inhibited
cytotoxicity in all CTLs tested. CMA also significantly inhibited cytotoxicity in all
CTLs tested. CMA is a specific inhibitor of perforin that acts by preventing the
acidification of vacuoles containing perforin, which leads to its degradation (Kataoka
et al, 1996; Kataoka et al, 1994). This suggests that perforin and also granzyme B,
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which is found in conjunction with perforin, are key cytotoxic proteins in the CTLs.
BFA did not significantly reduce cytotoxicity, indicating that Golgi-mediated
transport of cytolytic proteins did not significantly contribute to cytotoxicity of the
CTLs. Whilst these cytotoxicity assays provide strong indications of which pathways
are employed by the CTLs experiments were carried out to determine whether
perforin, granzyme B and FasL were present in the CTLs. In addition to these,
granulysin was also studied, as it has been suggested that it may add to the activity of
perforin (not in a synergistic fashion) (Kaspar et al, 2001).
5.5.2 Cytolytic proteins
RT-PCR results showed that all but one of the CTLs expressed mRNA transcripts for
all four cytolytic proteins (CTL 9 did not express FasL mRNA at any of the
stimulations tested). FACS and western blotting were used to complement the RT-
PCR results, not only in order to detect the proteins themselves but also because
mRNA transcripts of the cytolytic molecules were detected in LCLs.
The proposed models of differentiation of EBV-specific CD4+ and CD8+ T-cells
indicate that, along with the downregulation in CD27 and CD28 expression, both cell
types acquired perforin expression (Appay et al, 2002a; Appay et al, 2002b).
However, FACS analysis of the CTLs showed that granzyme B was the most
abundant cytolytic molecule, with FasL and perforin being considerably less
abundant (Figure 5.12). So, whilst both cell types showed downregulation in CD27
and CD28 expression, as shown in chapter 3, there was no concomitant increase in
perforin expression. In healthy blood donors the average proportion of CD4+ T-cell
expressing perforin was 2.2±0.6% (Appay et al, 2002b). The average proportion of
CD4+ T-cell expressing perforin in the CTLs was 3.6% and the average proportion
of CD8+ T-cells was lower at 3.4%. This suggests that small amounts of perforin are
sufficient for cytotoxicity to take place.
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The modified 4-hour cytotoxicity assays showed that effector functions of the CTLs
were calcium-mediated and perforin-mediated as EGTA and CMA both inhibited
cytotoxicity. This shows that perforin is pivotal in CTL cytotoxicity, as has
previously been shown (Trapani and Sutton, 2003). This suggests that granzyme B is
responsible for the cytotoxicity exhibited by the CTLs and that a small amount of
perforin is both necessary and sufficient for target cell killing to occur. On the other
hand it appears that FasL plays only a minor role in CTL cytotoxicity. BFA did not
inhibit cytotoxicity indicating that transcriptional upregulation and subsequent Golgi-
mediated transport of FasL did not significantly contribute to the cytotoxicity
achieved by the CTLs. However, FasL expression, at very low levels, can be induced
by rapid transport and degranulation of pre-formed stores found in cytotoxic granules
along with perforin and granzyme B (Bossi and Griffiths, 1999). It follows that pre¬
formed FasL is released/expressed in a calcium-dependent dependent fashion, but,
due to the very small amounts found in these stores, this mechanism is unlikely to
contribute greatly to cytotoxicity comparatively to granzyme B.
In summary, granzyme B is the cytolytic molecule found most abundantly in the
CTLs and clearly plays a key role in their killing of autologous LCLs. Perforin also
has a key role in LCL lysis, as demonstrated by the significant inhibition effected by
CMA. The function of perforin may be as a permissive factor - its presence in small
amounts being required for granzyme B activity. The importance of FasL is less
clear, as inhibition of its upregulation had no significant effect on cytotoxicity
suggesting that it plays at most a minor part in the process. The presence of CD4+ T-
cells expressing cytolytic proteins, in particular granzyme B, indicate that these cells
have the potential to contribute to the overall cytotoxicity of the CTLs, the bulk of
which will be associated with the CD8+ T-cells. Supporting this finding is that
PTLD patients treated with allogenic CTLs containing a higher mean percentage of
CD4+ T-cells responded better than those treated with CTLs that contained fewer
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This project set out to investigate the growth and phenotypic development of EBV-
specific CTLs, as well as their TCR repertoire diversity. Additionally, the presence
of cytolytic molecules and the pathways by which the CTLs effect their cytotoxic
activity were also investigated. This was carried out in order to appreciate and
understand how EBV-specific CTLs, which are in use in the clinical setting, evolve
in culture in response to weekly autologous LCL stimulations. Basic characterisation
ofCTLs may enhance understanding of potentially essential features of CTLs, which
may need to be taken into consideration for the generation of clinically effective
CTLs.
Adoptive T-cell immunotherapy for the successful treatment of PTLD using EBV-
specific CTLs was pioneered by Rooney et al (1995). Following the same principle,
other investigators used autologous and allogeneic CTL therapy to treat PTLD,
although this was achieved on a small scale in terms of CTL numbers. Wilkie et al
(2004) established a CTL bank, using the same method as Rooney et al (1995),
consisting of over 100 CTLs covering the majority of HLA-types found in the local
population. The establishment of this bank aimed to overcome the time required to
generate autologous CTLs in order to provide prompt PTLD treatment. CTL
generation time however, remains a critical issue, as it may take in excess of three
months to generate antigen specific CTLs.
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6.2 Growth, phenotype. genotype and cytotoxicity of
CTLs
6.2.1 Phenotype and growth of CTLs
Phenotypic analysis of the CTLs during the course of their development showed that
the basic phenotype of the CTLs, based around CD4 and CD8 expression, was
determined in the first three to four weeks of culture. Concurrently, the CTLs also
progressed towards an antigen-experienced phenotype characterised by an increase
in CD45RO and CD69 expression and a decrease in CD27, CD28, CD45RA and
CD62L. These phenotypic changes remained apparent later on in culture. In these
further differentiated CTLs (including both CD4+ T-cells and CD8+ T-cells)
granzyme B and perforin were detected in CTLs, with granzyme B detected at high
level in CD8+ T-cells and lower level in CD4+ T-cells and perforin detected at low
level in both cell types. FasL expression was low in both cell types. This shows that
the culture system used, efficiently induced phenotypic changes typical of an
antigen-experienced/effector phenotype in the early part of culture. This system also
promoted the maintenance of these changes in the CTLs but that this was not
accompanied by a pronounced increase in perforin levels, unlike CD4+ and CD8+ T-
cells specific for EBV in vivo (Appay, 2004; Appay and Rowland-Jones, 2004).
The phenotypic development of the CTLs was clearly a dynamic process. Such
dynamics were also seen in the proportional growth pattern and viability of the
CTLs. There was an increase in proportional growth between S2 and S4, following a
comparative decrease week on week, with CTLs no longer reaching the lxl06
cells/ml benchmark after 10 weeks in culture. This pattern of proportional growth
conforms to that previously reported by Wilkie et al (2004). The viability of the
CTLs decreased from S2 onwards and decreased more rapidly after S4. Collectively,
these results indicate that there is a limit to the potential growth that the CTLs could
achieve. This may be related to the expression of pl6INK4, a protein essential in the
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control of cell proliferation, the expression of which is associated with cells exiting
the cell proliferation cycle (Migliaccio et al, 2005). Another potential factor in the
limited growth of the CTLs in vitro may be related replicative senescence, which
occurs when telomere shortening becomes critical that it is no longer possible for the
cell to divide appropriately, at which point cell cycle arrest occurs. Transduction of
CTLs with telomerase reverse transcriptase may be a way of overcoming replicative
senescence, although this has been associated with genetic aberrations in particular
cell lines and where abnormalities were absent. However, immunological senescence
occurred following 12 months of culture (Schreurs et al, 2005).
Whilst the CTLs could not be cultured indefinitely, the culture system used for the
generation of the CTLs induced their appropriate phenotypic and functional
development, as discussed above and in section 6.2.3.
6.2.2 TCR repertoire of CTLs
Antigenic stimulation of the TCR underlies the phenotypic changes occurring in the
CTLs discussed above. The TCR repertoire of the CTLs investigated remained
diverse both in terms of V|3 family usage (i.e. the number of families in use) and in
terms of Y|3 family clonality, as there was no discernible pattern either in reduction
of V(3 family usage or in emergence of clonal V(3 families during the course of
culture. The development and maintenance of the TCR repertoire appears to differ
from what is seen in IM. In IM, the primary response to EBV, there is an expansion
of clonal and oligoclonal populations of CD8+ T-cells, which may be essential in the
control of the infection (Callan et al, 1996). This is unlike the TCR development of
the CTLs cultured here, which did not appear to clonally expand in the initial phase
of culture, although the addition of IL-2 to maintain T-cell proliferation may have
obscured the emergence of clonal or oligoclonal populations. Although, individuals
undergoing silent seroconversion maintained TCR repertoire diversity without the
detection of clonal/oligoclonal expansions (Silins et al, 2001). This suggests that
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primary EBV response may not always be associated with specific TCR repertoire
expansions.
T-cell repertoire diversity maintenance may be due to LCLs exhibiting prominent
peptide-MHC features, the absence of which has been shown to limit repertoire
diversity in virus-specific CD8+ T-cells (Turner et al, 2005). In addition, the TCR
can recognise different peptides presented by the same MHC molecule (Reiser et al,
2003), which may result in the CTLs recognising a greater number of peptides in an
allogeneic context. This would be a beneficial feature of allogeneic CTLs used for
the treatment of PTLD, increasing the likelihood of an antigenic peptide being
recognised by the CTLs. This shows that autologous LCL stimulations maintained
TCR diversity, which strongly supports the establishment and use of a CTL bank
covering many HLA types (Wilkie et al, 2004), as one CTL may therefore be used
for multiple patients in an allogeneic setting.
6.2.3 Cytotoxicity of the CTLs
The phenotypic changes observed in the first four weeks of culture, as well as in
subsequent weeks, were associated with differentiation of the CTLs towards an
antigen-experienced/mature phenotype with the acquisition of cytolytic effectors.
The results of the standard 4-hour cytotoxicity chromium release assays confirmed
that the CTLs were cytotoxic and specific following at least five weeks of culture.
This occurred without any apparent restrictions in the TCR repertoire of the CTLs.
Having established that the CTLs were cytotoxic and specific towards autologous
LCLs, preliminary experiments were carried out to determine the antigen specificity
of the CTLs. This was done using dendritic cells infected with recombinant vaccinia
vectors encoding EBV antigens, as antigen presenting cells. These antigen presenting
cells were used as target cells in a 4-hour cytotoxicity assay. The percentage of cell
lysis was used as a measure of antigen specificity. This assay was carried out as
described in section 2.2. Three CTLs were tested: CTL 7, CTL 19 and CTL 20.
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CTLs 19 and 20 were tested by Karen McAulay. Figure 6.1 represents the results of
a vaccinia 4-hour chromium release cytotoxicity assay carried out using CTL 7.
CTL 7 - EBV antigen specificity cytotoxicity assay
Figure 6.1: Results from 4-hour vaccinia chromium release cytotoxicity assay using
CTL 7.
This figure shows that the CTL was cytotoxic and therefore specific towards EBNA-
1, EBNA-2, EBNA-3A and 3B. The CTL was not cytotoxic towards the uninfected
dendritic cells or the vaccinia control. The cytotoxicity results for the three CTLs
tested are summarised in table 6.1.
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CTL 7 CTL 19 CTL 20
Dendritic cells 0% 2.2% 0.4%
Vaccinia control 0% 0% 0%
EBNA-1 27.3% 4.8% 0.1%
EBNA-2 40.3% 0% 0%
EBNA-3A 32.5% 0% 0%
EBNA-3B 18.6% 55.9% 0%
EBNA-3C 0% 0% 20.1%
EBNA-LP 0% 17.3% 11.5%
LMP-1 0% 19% 0.1%
LMP-2 0% 22.7% 0%
MA 0% 0% 0%
Autologous LCL 54.1% 25.2% 24%
Table 6.1: CTL antigen specificity.
These preliminary results show that the three CTLs tested were distinctly specific to
particular antigens, whilst not being specific to others. All three CTLs were specific
towards one or two of the three EBNA-3 antigens known to be immunodominant
among the EBV latent proteins. The CTLs 19 and 20 were also specific towards
EBNA-LP.
Characterising the antigen specificity of CTLs may enable more targeted treatment
of PTLD by matching tumour antigen expression and CTL antigenic specificity.
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6.3 CTL proteins and cytolytic pathways
The effector functions gained by the CTLs during the course of culture appeared to
be centred on perforin, found to be essential and necessary to cytotoxicity, and
granzyme B, the most abundant of the three cytolytic molecules investigated by
intracellular FACS staining in both CD4+ and CD8+ T-cells. In healthy blood donors
the average proportion of CD4+ T-cell expressing perforin was 2.2±0.6% (Appay et
al, 2002b). The average proportion of CD4+ T-cell expressing perforin in the CTLs
was 3.6% and the average proportion of CD8+ T-cells was lower at 3.4%.
Furthermore, the relative paucity of perforin in comparison to granzyme B was
surprising as chronic EBV antigenic stimulation in vivo (in EBV carriers) results in
increased expression of perforin in both CD4+ T-cells and CD8+ T-cells analysed ex
vivo (Appay et al, 2002a; Appay et al, 2002b). This suggests that prolonged in vitro
culture with autologous LCL stimulation does not induce an increase in the
proportion of cells expressing perforin (or perforin expression) but rather an increase
in the proportion of cells expressing granzyme B (0.6% CD4+ T-cells and 10.4%
CD8+ T-cells expressed granzyme B in PBMC (Grossman et al, 2004)). Low level
perforin expression however, did not to translate into reduced target cell cytotoxicity
as target cell lysis still occurred in chromium release cytotoxic assays, indicating that
granzyme B was still able to effect its pro-apoptotic role in the target cells (as
granzyme B is essential in CTL cytotoxicity (Heusel et al, 1994)). A number of
mechanisms by which granzyme B reaches the target cells have been proposed, all of
which crucially remain dependent on perforin and are not mutually exclusive. The
initial mechanism put forward involved perforin creating pores in the cell membrane
allowing granzyme B to diffuse passively through to the target cells and induce
apoptosis (Trapani and Smyth, 2002). Subsequently, a pathway was proposed
involving the internalisation of perforin pores (to which granzyme B was bound)
from the target cell surface into an endosome where the pores would facilitate the
release of granzyme B in the target cell (Browne et al, 1999). However, the same
group subsequently proposed a model in which many granzyme B molecules were
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delivered to the target cell bound to serglycin (a proteoglycan) with perforin either
bound to the serglycin/granzyme B complex or in a monomeric form. In this model,
the target cell became apoptotic in the absence of plasma membrane pores
(suggesting that perforin was present at sub-permeabilising amounts), indicating that
the serglycin/granzyme B complex was internalised by the target cell (Metkar et al,
2002). A recent publication proposed a further model in which granzyme B, as well
as other cytolytic/cationic proteins (including granulysin), dissociated from serglycin
at the surface of the target cell, and entered the target cell by pinocytosis or
endocytosis mediated by binding to cell surface proteoglycan, subsequently leading
to lysis of the endosome and apoptosis (Raja et al, 2005). Aside from the initial
model described, these models suggested that perforin is not required in high
concentrations (sub-permeablising) to facilitate the entry of many granzyme B
(complexed or not to serglycin) into a target. This may be why the CTLs investigated
in this project were cytotoxic even though perforin was only present at low level and
granzyme B was considerably more abundant.
Granulysin, a saposin-like molecule found in cytolytic granules (Krensky and
Clayberger, 2005), was detected in 33% of CTLs tested by western blotting.
Research by Kaspar et al (2001) indicated that granulysin may act in a summative
fashion with perforin, leading to increased membrane damage and ultimately to
mitochondrial damage and apoptosis. This suggests that the granulysin found in the
CTLs may be contributing to their cytotoxicity towards autologous LCLs. Raja et al
(2002) hypothesised that granulysin may be bound to serglycin along with granzyme
B and perforin in which case the role and function of granulysin may be perforin-
dependent.
FasL on the other hand, did not appear to contribute greatly to cytotoxicity in the
context of a 4-hour standard chromium release assay, not only because inhibition of
its upregulation did not significantly affect cytotoxicity but also because there was
considerably less FasL than granzyme B present in the CTLs. The possibility that
FasL may be synthesised de novo and transported to the cell surface thereafter,
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cannot be excluded, although this may be beyond the scope of the 4-hour chromium
release cytotoxicity assays carried out here. However, a role for FasL/Fas in CTLs
cytotoxicity remains unlikely as CD4+ CTLs and CD8+ CTLs (generated using
allogeneic Fas deficient EBV-infected LCLs) not only efficiently lysed Fas-deficient
target cells but their cytotoxicity was completely abrogated by CMA and EGTA
(Yasukawa et al, 2000), in the same way as the CTLs described here.
Considerations of granzyme B and potentially granulysin delivery methods into
target cells aside, it is clear that weekly stimulations with LCLs generated CTLs
capable of specific cytotoxicity towards autologous LCLs. It is plausible that
increased perforin expression by the CTLs may lead to increased cytotoxicity by




6.4 CD4+ and CD8+ T-cells in the CTLs
The majority of CTLs generated in this project were predominantly CD8+ (82%),
similar to those generated by Wilkie et al (2004), indicating that the stimulation of
the CTLs with LCLs favoured their development over predominantly CD4+ CTLs.
There was, however, always a small proportion of CD4+ T-cells present in CD8+
CTLs. This persistence may be intrinsically linked with the essential need for CD4+
T-cells by CD8+ T-cells to achieve a recall response following primary antigen
exposure (Bevan, 2004). Whilst, CD8+ T-cells could effect a primary response in the
absence of CD4+ T-cells, they could not respond to a second round of antigen
exposure. As the CTLs generated here not only underwent primary and secondary
antigen exposures but multiple weekly antigen exposures it is likely that the
contribution of the CD4+ T-cells to the maintenance of the CTLs was critical.
Furthermore CD4+ T-cells in the CTLs were also shown to express cytolytic
molecules, indicating that they may play a dual "helper/killer" role in the CTLs. A
critical role ofCD4+ T-cells in CTLs is supported by observations made by Wilkie et
al (2004), indicating that CTLs with a higher mean percentage of CD4+ T-cells did
not have reduced cytotoxicity and in fact, these CTLs induced a better response in




This study shows that important phenotypic changes occur in the CTL cultures
within the first four weeks and these changes persist later on in culture. This
complements findings by Wilkie et al (2004), which show that the phenotype in
terms of CD4+ and CD8+ was acquired within three to four weeks of culture. TCR
spectratyping of the CTLs indicates that diversity of the repertoire was maintained
over time. Further antigen specificity experiments would need to be carried out to
assess how TCR repertoire diversity and usage might relate to antigen specificity and
what the implications of TCR diversity versus uniformity are. Preliminary
experiments carried out in this study show that CTLs are certainly specific for some
antigens and not others. Characterising the antigen specificity of the CTLs may allow
better matching of CTLs to PTLD tumours (based on antigen expression by the
tumour). Finally, this study demonstrated that CTL cytotoxicity in vitro, and
potentially in vivo (in CTLs which are already in clinical use), was perforin-
dependent and that granzyme B was the most abundant cytolytic molecule. The
CTLs may be effecting their role following a recently proposed mode of delivery
whereby granzyme B and perforin dissociate from serglycin at the surface of the
target cell, and enter the target cell by pinocytosis or endocytosis (mediated by
binding to cell surface proteoglycan) subsequently leading to lysis of the endosome
and apoptosis (Raja et al, 2005). This study also demonstrated that prolonged
stimulation generated CTLs in which CD4+ T-cells and CD8+ T-cells differed from
those found in vivo in terms of perforin expression but that this did not detrimentally
affect cytotoxicity. Additionally, the CD4+ T-cells found in the CTLs were highly
differentiated and expressed cytolytic molecules, albeit at significantly lower level
than CD8+ T-cells (granzyme B only), indicating that CD4+ T-cells must play an
active role in CTL-mediated cytotoxicity.
This study aimed to characterise CTLs in order to identify and increase
understanding of features that may be adapted for improved clinical efficacy.
Features which merit further investigation include modified culture methods that
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could prolong culture period or enable specificity of the CTLs to be established
before their viability is affected; the potential for manipulation of perforin expression
to assess whether increased perforin levels may improve CTL cytotoxicity and also
the question of the nature of the role of CD4+ T-cells during the course of the CTL
culture - are they perhaps helper cells during phase 1 of growth and cytotoxic cells




Since the beginning of this project, the generation of CTLs has progressed towards
the development of CTLs specific to individual EBV antigens expressed in particular
diseases, such as LMP-1 in HD and LMP-2 in both NPC and HD. Different methods
have been used for the generation of CTLs. In one study autologous LCLs and
PBMCs from NPC patients were used to generate CTLs (Straathof et al, 2005). In
another study PBMCs were transduced with TCRs from LMP-2-specific clones
giving rise to cytotoxic T-cells capable of lysing LCLs expressing LMP-2 (Jurgens et
al, 2006).
Current investigations, in our laboratory, are concentrating on the generation of
engineered T-cells. In these engineered T-cells, the parts of the a and (3 chains of the
TCR which come in contact with the MHC/peptide complex are replaced with the
Fab fragment of antibodies specific to EBV antigens. This system, overcomes HLA
restriction, therefore considerably increasing the number of patients that may be






Adapted from data sheet provided by Amersham Biosciences.
Days before -16 -15 -14 -13 -12 -11 -10 -9
reference 1.492 1.456 1.420 1.384 1.350 1.317 1.284 1.253
-8 -7 -6 -5 -4 -3 -2 -1
1.22 1.191 1.162 1.133 1.133 1.105 1.078 1.025
Days from 0 1 2 3 4 5 6 7
reference 1.000 0.975 0.951 0.928 0.905 0.882 0.861 0.839
8 9 10 11 12 13 14 15
0.819 0.798 0.779 0.759 0.741 0.722 0.704 0.687
16 17 18 19 20 21 22 23
0.670 0.654 0.637 0.622 0.606 0.591 0.577 0.562
24 25 26 27 28 29 30 31
0.549 0.535 0.522 0.509 0.496 0.484 0.472 0.460
Table A2.1: Decay of 51Cr
The volume of chromium required was calculated as follows:
Activity required (pCi)
= volume of31Cr required
Activity factor given in the table above (pCi/ml)
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CD3 CD4 CD8 CD19 CD56
Figure A3.1: Basic phenotype of CTL 5.



























Figure A3.2: Phenotype of cells co-expressing CD4 and CD45RA, CD45RO,
CD62L, CD69, CD27 and CD28 in CTL 5.
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Figure A3.3: Phenotype of cells co-expressing CD8 and CD45RA, CD45RO,
CD62L, CD69, CD27 and CD28 in CTL 5.


























Figure A3.4: Proportion of CD4+ T-cells expressing CD45RA, CD45RO, CD62L,
CD69, CD27 and CD28 in CTL 5.
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Proportion of CD8+ T-cells expressing ceil surface markers in CTL 5
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Figure A3.5: Proportion of CD8+ T-cells expressing CD45RA, CD45RO, CD62L,
CD69, CD27 and CD28 in CTL 5.
Basic phenotype - CTL 7
CD3 CD4 CD8 CD19 CD56 CD4/CD8
Figure A3.6: Basic phenotype of CTL 7.
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Figure A3.7: Phenotype of cells co-expressing CD4 and CD45RA, CD45RO,
CD62L, CD69, CD27 and CD28 in CTL 7.
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Figure A3.8: Phenotype of cells co-expressing CD8 and CD45RA, CD45RO,
CD62L, CD69, CD27 and CD28 in CTL 7.
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Figure A3.9: Proportion of CD4+ T-cells expressing CD45RA, CD45RO, CD62L,
CD69, CD27 and CD28 in CTL 7.
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Figure A3.10: Proportion of CD8+ T-cells expressing CD45RA, CD45RO, CD62L,













18.25 All families were used.
Table A4.1: V|3 families used by CTL 2 during five weeks of culture with weekly
stimulations with LCLs. Nb: number.





Average nb of 13
families used
All families were used except families V|3-18, -20, -
24 and -25.
Table A4.2: V(3 families used by CTL 3 during five weeks of culture with weekly
stimulations with LCLs. Nb: number.
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16.25 All families were used except family V(3-25.
Table A4.3: V|1 families used by CTL 13 during eight weeks of culture with weekly
stimulations with LCLs. Nb: number.












16 All families were used except families V|3-20 and
VP-25.
Table A4.4: Vp families used by CTL 4 during nine weeks of culture with weekly
stimulations with LCLs. Nb: number.
220
CHAPTER 7 APPENDICES












14.7 All families were used except family Vp-20.
Table A4.5: Vp families used by CTL 5 during six weeks of culture with weekly
stimulations with LCLs. Nb: number.
















18 All families were used.
Table A4.6: Vp families used by CTL 7 during 15 weeks of culture with weekly











Average nb 17.4 All families were used.
of families
used
Table A4.7: V(5 families used by CTL 12 during seven weeks of culture with weekly





E:T 20:1 No inhibitor lOnM CMA 40ftM BFA 3mM EGTA
CTL5 65.7% 18.9% 78.6% 1.0%
CTL 7 77.1% 50.9% 50.6% 14.2%
CTL 9 56.7% 18.3% 52.7% 5.3%
CTL 15 29.0% 1.1% 20.4% 1.6%
CTL 16 46.5% 1.7% 35.3% 1.2%
CTL 17 50.8% 0.4% 42.9% 0.2%
CTL 19 40.9% 0.1% 27.4% 0.1%
CTL 20 33.3% 0% 23.2% 0%
CTL 21 25.9% 0% 25.8% 0.9%
CTL 22 18.1% 2.0% 15.3% 0.8%
CTL 23 16.8% 1.1% 14.1% 1.5%
CTL 24 24.5% 0.3% 13.8% 2.7%
Mean % 40.5% 7.5% 33.3% 2.4%
cytotoxicity
Median % 37.1% 1.1% 26.6% 1.1%
cytotoxicity
Table A5.1: Percentage of autologous LCL lysis without inhibitor, with CMA, BFA
and EGTA at E:T 20:1. n=12 CTLs.
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E:T 10:1 No inhibitor lOnM CMA 40^M BFA 3mM EGTA
CTL 15 29.4% 1.8% 15.2% 0.1%
CTL 16 36.6% 0% 29.9% 0.6%
CTL 17 39.8% 0% 34.4% 0%
CTL 19 34.3% 0% 25.4% 0%
CTL 20 29.3% 0% 16.3% 0%
CTL 21 21.9% 0% 24.0% 0%
CTL 22 12.3% 1.4% 11.7% 0%
CTL 23 13.4% 0.3% 9.8% 0.5%
CTL 24 12.9% 0.8% 8.3% 0%
Mean % 25.6% 0.5% 19.5% 0.1%
cytotoxicity
Median % 29.3% 0.0% 16.3% 0%
cytotoxicity
Table A5.2: Percentage of autologous LCL lysis without inhibitor, with CMA, BFA
and EGTA at E:T 10:1. n=9 CTLs.
224
CHAPTER 7 APPENDICES
E:T 5:1 No inhibitor lOnM CMA 40piM BFA 3mM EGTA
CTL 15 20.3% 1.6% 7.2% 0.4%
CTL 16 29.6% 1.8% 24.6% 0%
CTL 17 32% 0% 25% 0%
CTL 19 33% 0.9% 24.1% 0.7%
CTL 20 23.4% 0% 15% 0%
CTL 21 15.1% 0% 15.4% 2.1%
CTL 22 11.2% 0.4% 8.9% 0%
CTL 23 8.8% 0.6% 6.9% 0%
CTL 24 8.8% 0.2% 2.5% 0.8%
Mean % 20.2% 0.6% 14.4% 0.4%
cytotoxicity
Median % 20.3% 0.4% 15% 0%
cytotoxicity
Table A5.3: Percentage of autologous LCL lysis without inhibitor, with CMA, BFA













CTL 15 93.8% 15.2% 99.8%
CTL 16 100% 18.4% 98.5%
CTL 17 100% 13.8% 100%
CTL 19 100% 26.0% 100%
CTL 20 100% 44.3% 100%
CTL 21 100% 0% 100%
CTL 22 88.9% 4.7% 100%
CTL 23 97.6% 26.7% 96.5%
CTL 24 93.9% 35.4% 100%










Table A5.4: Percentage reduction in autologous LCL lysis induced by the CMA,
BFA and EGTA at E:T 10:1. n=9 CTLs.
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CTL 15 92% 7.2% 98%
CTL 16 94.1% 17.1% 100%
CTL 17 100% 21.8% 100%
CTL 19 97.3% 26.8% 98%
CTL 20 100% 36.1% 100%
CTL 21 100% 0% 100%
CTL 22 96.2% 19.9% 100%
CTL 23 93.3% 21.1% 100%
CTL 24 97.5% 71.6% 90.9%










Table A5.5: Percentage reduction in autologous LCL lysis induced by the CMA,
BFA and EGTA at E:T 5:1. n=9 CTLs.
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CTLs Perforin MFI (AU) Granzyme B MFI (AU) FasL MFI (AU)
CTL 5 0.18 31.44 1.32
CTL 7 0.16 30.95 1.68
CTL 9 0.07 83.7 1.05
CTL 15 2.34 46.91 8.7
CTL 16 1.8 23.87 4.75
CTL 17 1.53 39.95 5.26
CTL 19 1.6 45.46 6.57
CTL 20 3.33 69.43 8.65
CTL 21 2.07 59.3 5.27
CTL 22 1.23 30.33 5.37
CTL 23 1.24 58.02 5.36
CTL 24 1.46 NA 4.64





CD4+ T-cells (MFI in AU) CD8+ T-cells (MFI in AU)
Perforin Granzyme B FasL Perforin Granzyme B FasL
CTL 5 0.19 7.32 1.17 0.39 30.80 2.01
CTL 7 0 16.52 0.52 0.17 45.15 1.26
CTL 9 0.42 38.24 2.15 0 43.29 0.74
CTL 15 1.12 25.23 6.52 2.41 48.56 8.84
CTL 16 0.54 10.54 3.26 1.92 25.4 3.26
CTL 17 0.73 32.83 3.9 1.67 41.3 5.59
CTL 19 0.49 11.8 4.61 1.7 48.91 6.74
CTL 20 3.78 40.04 6.38 3.35 69.79 8.71
CTL 21 1.27 36.64 3.8 2.15 60.53 5.44
CTL 22 0.92 9.77 4.72 1.2 32.4 5.43
CTL 23 1.22 22.76 4.74 1.23 60.3 5.4
CTL 24 1.55 NA 4.64 1.45 NA 4.64
Median MFI 0.66 22.76 4.68 1.22 48.91 5.52
Mean MFI 1.35 22.91 5.59 1.11 68.23 5.76
Table A5.7: MFI of perforin, granzyme B and FasL in CD4+ T-cells and CD8+ T-
cells. AU: arbitrary units. NA: not available.
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CTLs % of perforin
positive cells




CTL 5 0.7% 68.2% 0.5%
CTL 7 1.1% 71.6% 2.9%
CTL 9 1.1% 84.7% 1.5%
CTL 15 2.1% 89.6% 27.8%
CTL 16 0.1% 81.3% 2.9%
CTL 17 0.3% 96.7% 5.9%
CTL 19 0.2% 92% 8.2%
CTL 20 3.1% 99.2% 26.5%
CTL 21 3.3% 93.3% 27.4%
CTL 22 0.5% 87.1% 11.8%
CTL 23 0.4% 98.4% 9.8%
CTL 24 0.4% NA 5.8%





CD4+ T-cells CD8+ T-cells
% Per % GrB % FasL % Per % GrB % FasL
CTL 5 3.9% 23.9% 2.6% 0.4% 72.0% 1.7%
CTL 7 0.7% 50.8% 2.9% 2% 73.2% 3.6%
CTL 9 11.3% 65.6% 13.2% 1.3% 80.1% 1.8%
CTL 15 1.5% 70.8% 7.5% 2.5% 89.3% 15.0%
CTL 16 0.4% 33.5% 3.3% 0.1% 85.1% 4.3%
CTL 17 0.8% 91.5% 2.2% 0.1% 91.5% 6.5%
CTL 19 0.7% 15.1% 5.2% 0.1% 78.2% 8.3%
CTL 20 13.9% 69.6% 14.7% 3.5% 97.7% 14.4%
CTL 21 3.3% 87.3% 16.1% 3.4% 93.5% 28.5%
CTL 22 1.5% 22.5% 9.1% 0.3% 77.4% 11.5%
CTL 23 5.4% 69.2% 18.5% 0.1% 96.2% 9.7%
CTL 24 0.2% NA 10.2% 15% NA 5.6%
Table A5.9: Percentage of CD4+ T-cells and CD8+ T-cells in all CTLs expressing
perforin, granzyme B and FasL. Per: perforin and GrB: granzyme B. NA: not
available.
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CTL 5 20.3% 77% ND ND
CTL 7 51.8% 45.5% ND ND
CTL 9 9.5% 89.7% ND ND
CTL 15 2.6% 94.3% 2.2% 0.9%
CTL 16 6.5% 91.8% 0.9% 0.8%
CTL 17 13.5% 83.7% 2.3% 0.5%
CTL 19 5.6% 91.7% 2% 0.7%
CTL 20 0.4% 98.1% 1.4% 0.1%
CTL 21 2.5% 92% 4.9% 0.6%
CTL 22 5.1% 90.4% 3.1% 1.4%
CTL 23 3.2% 94.8% 1.3% 0.7%
CTL 24 1.3% 96.2% 1.6% 0.9%
Table A5.10: Proportion of CD4+ T-cells and CD8+ T-cells in the CTLs.
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